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Abstract
This work describes the development o f a systematic methodology to overcome two o f 
the difficulties commonly encountered when expressing eukaryotic domains in bacterial 
hosts, namely the failure to obtain folded protein in vivo and the low solubility o f the 
expression product. This methodology made possible the production o f samples o f the 
first scavenger receptor cysteine rich (SRCR) domain o f human CD5, /zCD5dl, with 
properties suitable for multidimensional NMR studies.
The SRCR domains o f hCD5 express in bacteria as insoluble aggregates. The aggregates 
were purified in order to perform the folding in vitro. Optimal conditions for folding 
were found using a novel systematic screen based on a fractional factorial design. In vitro 
folding yields were assessed using RP-HPLC and non-denaturing PAGE.
The attainment o f /zCD5dl protein samples o f sufficiently high concentration to perform 
multidimensional NMR was achieved by performing rational apolar-to-polar mutations 
selected by analysis o f a multiple sequence alignment. Eight single residue mutants were 
engineered and expressed. Four o f them had better in vitro folding yields than the wild 
type and a double mutant was constructed by combination o f the best behaved single 
mutations. This double mutant was used to determine the structure o f the domain.
NMR experiments at 298 K showed that some regions o f /zCD5dl undergo 
conformational exchange on a microsecond to millisecond timescale, hampering the 
assignment o f the resonance signals. Increasing the temperature to 318 K was found to 
greatly enhance the quality o f the NMR spectra and enabled the assignment o f more than 
95% o f the resonances. The solution structure o f /zCD5dl was determined using standard 
interproton distance and dihedral angle-restrained molecular dynamics protocols. Forty 
percent o f the residues were found to be in structurally well-defined regions, including all 
o f the regular secondary structure features found for other members o f SRCR 
superfamily. The remaining residues o f the polypeptide appear to be distinctly less well 
ordered.
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_____________________________Chapter One
CD5, an enigmatic modulator of lymphocyte activation
Abstract
CD5 is a 67-kDa monomeric transmembrane protein expressed constitutively on T cells 
and a subset o f B cells, although its expression can be upregulated on all B cells by 
various stimuli. CD5 influences lymphocyte activation by modifying the strength o f the 
intracellular response initiated by antigen engagement. Activation o f CD5 can both 
amplify and reduce the strength o f the cellular response. It is not understood how this 
dual modulation is achieved, but a critical factor appears to be the concentration o f CD5 
on the cell membrane. The hyper-reactive phenotype o f CD5-negative cells suggests that 
the primary role o f CD5 is to dampen the signal o f the antigen receptor, therefore raising 
the threshold for leukocyte response, in order to avoid activation by self-antigens. A few 
ligands for CD5 have been proposed but all are poorly characterised. CD5 appears to be 
able to bind C-type lectins and immunoglobulin domains, among others. Soluble CD5 is 
able to activate B cells, possibly by binding a transmembrane protein involved in T cell- 
mediated cell activation. CD5 is in close contact with two other important coreceptors: 
CD2 and CD6; these associations have only recently been reported, and whether they 
have any biological significance is yet to be elucidated. Finally, the origin, aims and 
scope o f this thesis are summarised.
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Chapter abbreviations and acronyms
A gR  antigen receptor
AP-1 activation promoting 1
A PC  antigen presenting cell
B C R  B cell receptor
Bcl-2 B cell lymphoma protein 2
B -C LL chronic lymphocytic leukaemia B cells
CD 5cyt cytoplasmic region o f  CD5
CD 5ext extracellular region o f  CD5
C D R  complementarity determining region
DAG 1,2 diacylglycerol
F R E T  fluorescence resonance energy transfer
G T P  guanine tri-phosphate
Ig immunoglobulin
IL  interleukin
IP  inositol phosphate
IS immunological synapse
IT  AM  im m unoreceptor tyrosine-based
activation m otif
KO knock out
m A b monoclonal antibody
M A P mitogen-activated protein
M H C  m ajor histocompatibility complex
pM H C  MHC bound to peptide
spM H C  MHC bound to self peptide
N FA T nuclear factor o f  activated T cells
P I3K  phosphoinositide-3 kinase
PIP2 phosphoinositol 4,5-biphosphate
P LC  phospholipase C
P T K  protein tyrosine kinases
T C R  T cell receptor
tg transgenic
ZA P <^-chain associated protein
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Background
Vertebrates possess a group o f cells capable o f specifically recognising an enormous 
variety o f molecules derived from other 'foreign' organisms. Each one o f these cells is 
stimulated by exposure to a different antigenic agent and their activation initiates a series 
o f defence mechanisms that have evolved in order to eliminate that specific pathogen 
(Figure 1.1). This phenomenon is known as adaptive or acquired immunity. The specific 
recognition o f molecular components o f  pathogens is achieved via transmembrane 
glycoproteins generally referred to as antigen-specific receptors (AgRs). Cells that 
express AgRs are known as lymphocytes, o f which there are three classes: B cells, T 
cells and natural killer cells (natural killer cells do not need to recognise a specific 
individual antigen to be activated, therefore they are considered as a distinct category). B 
and T cells are activated by binding to antigen and also receive additional stimuli from 
receptor-mediated interactions with signalling proteins secreted by other immune cells 
(cytokines). Once activated, the lymphocytes initiate protein synthesis and undergo 
mitotic division, a process known as clonal expansion. Clones differentiate into effector 
cells, whose function is the elimination o f the antigen, and memory cells that are able to 
initiate a rapid response upon a subsequent exposure to the same antigen.
The B cell receptor fo r  antigen
The B cell receptor (BCR) is a transmembrane anchored antibody (Ab). Abs are 
disulphide-bonded glycosylated tetramers o f two identical light chains and two identical 
heavy chains (Figure I.2A). Light chains, are classified in two groups, k  and X, and are 
formed by two immunoglobulin domains, each o f which consist o f -110  amino acid 
residues in a disulphide bonded all-p fold. The amino acid sequence o f the N-terminal 
immunoglobulin domain o f the light chains varies from one B cell clone to another, and 
it is called V l, the C-terminal domain is relatively constant and called Cl. There are five 
types o f heavy chain or isotypes: a , 5, e, y and p. Each has an N-terminal variable 
immunoglobulin domain (Vh) and three (a , 5, y) or four (e and p) immunoglobulin 
domains that do not vary within the same isotype (Ch 1-4). Only Ab isotypes 8 and p, 
commonly known as IgD and IgM, are found in the membrane bound form that 
constitutes the BCR. The cytoplasmic tail o f the BCR is not involved in down-stream 
signalling. Rather, signal transduction through the BCR is accomplished by CD79, a
19
N>O
Macrophage
K A ^ a Y
Helper T cell 2
B cell Plasma cell
Helper T cell 1
B
Infected 
target cell
+  Antigen
*  Antigen peptide (Ag)
■ Cytokine
Y B cell receptor/ Antibody (BCR/Ab)
Major histocompatibility complex (MHC) class II 
n  Major histocompatibility complex (MHC) class I
Y  T cell receptor (TCR)
Figure 1.1 Overview o f the main events in the adaptative immune response.
Monocytes (macrophages) and other antigen presenting cells (APC) bind and phagocytise pathogens. Pathogen peptide fragments are then displayed on the APC cell surface bound to MHC 
class II molecules; the MHC-peptide complex is denoted (pMHC-II). APCs secrete cytokines to induce local inflamation leading to increased cellular adhesion and attraction o f  leukocytes. 
CD4POS (helper) T cells recognise pMHC-II and become active. CD4,,os cells secrete cytokines and undergo clonal expansion. Different types of activated CD4POS cells are involved in 
subsequent stages o f the immune response:
(A) Type 2 helper (Th2) T cells secrete cytokines to promote B cells to divide and differentiate into antibody secreting plasma cells.
(B) Type 1 helper (Th 1 or inflammatory) cells signal macrophages to fuse lysosomes and phagocytic vesicles for more efficient pathogen destruction.
(C) Helper T cells may also stimulate CDS1”055 (cytotoxic) cells. CD8POi> cells recognise the MHC-class I molecule, that is expressed on the surface o f almost any nucleated cell when it has been 
infected by intracellular pathogen. Upon recognition o f the target antigen, CD8POS T cells become cytotoxic effector cells and induce the infected cell to undergo apoptosis.
Cytotoxic effector cell
disulphide bonded heterodimer whose monomer chains are also referred to as Ig -a  and
ig-p1-
The Vl and V h domains determine ligand specificity and the antigen binding site is 
located in a cleft or surface between the two domains. There are three loops in any given 
Vl or Vh domain that present higher amino acid variability than the rest o f the sequence, 
these loops are called complementarity determining regions (CDR) or hypervariable 
regions (Figure I.2B). The rest o f the domain is known as the framework region. 
Framework regions vary in considerably less extent that the CDR, but may also influence 
ligand specificity.
Structure o f  the T cell receptor fo r  antigen and its mechanism o f  antigen recognition 
The T cell receptor (TCR) is a disulphide-bonded glycosylated heterodimer (Figure 
I.2C). Each o f the chains (a  and P) is formed by two immunoglobulin-like domains. The 
N-terminal domain o f both chains is the variable antigen binding region (V a and Vp). 
Signal transduction through the TCR is achieved by the transmembrane glycoprotein 
complex CD3, which is always co-expressed with the TCR. The CD3 complex is formed 
by a combination o f five subunits (y, 5, e, £ and r|). These subunits arrange in three 
dimers, two o f these are always the heterodimers ye and 5e, the third can either be Qt\ or
Compared to the BCR that can bind several different types o f free antigens (e.g. lipids, 
carbohydrates, nucleic acids, proteins, peptides, second messengers), the TCR/CD3 
complex is restricted to bind oligopeptides displayed on the surface membrane o f  an 
antigen presenting cell (APC). The antigen presenting complex on the membrane o f the 
APC is known as the major histocompatibility complex (MHC) gene product. There are 
two classes o f antigen presenting MHC proteins each o f which has a different subunit 
composition. Class I MHC proteins are expressed by almost any type o f cell when the 
cell is infected by virus, bacteria or protozoa. The proteins from the intracellular 
pathogen are processed by proteasomes into short peptides and the class I MHC proteins 
fold around the peptides in the endoplasmic reticulum prior to transport to the cell 
surface. Class II MHC proteins are only expressed by professional APCs and they 
display peptides from a pathogen that has been phagocyted and proteolysed. Productive 
binding o f the TCR to the MHC molecule requires other accessory proteins, including
21
toK)
Figure 1.2 Schematic representation o f the major immune receptors for antigens.
(A) The B cell receptor is a tetramer o f two identical polypeptide heavy chains and two identical light chains. The heavy chains comprise five immunoglobulin (Ig) domains and the light chains 
two Ig domains. The heavy chains are joined to each other by two disulphide bonds and each heavy chain shares one disulphide with one o f the light chains. Signal transduction is accomplished 
via CD79. The cytoplasmic domains o f CD79 contain an amino acid m otif with two tyrosines that is phosphorylated by src-family kinases on antigen recognition.
(B) Detail o f an X-ray structure o f the N-terminal variable Ig domains o f both the light and the heavy chains in complex with their corresponding antigen (PDB: la2y). The regions which 
contribute the most to antibody specificity, /. e. the complementarity determining regions (CDRs) are highlighted.
(C)The T cell receptor is a disulphide bonded heterodimer. The TCR recognises peptides bound to the major histocompatibility complex (MHC) proteins. Productive binding o f the TCR 
requires the intervention o f CD4 (or CD8 in cytotoxic T cells). CD4 binds the C-terminal Ig domain o f the (3 chain o f the MHC class II proteins. Signal transduction is accomplished by CD3, 
which has several cytoplasmic chains having one or three activation motifs that are phosphorylated upon antigen recognition. The src-family tyrosine kinase Lck is associated with the 
cytoplasmic domain o f CD4 (or CD8). The extracellular regions o f the BCR, TCR, CD 3y, C D 3e, CD4 and CD79 are formed of Ig domains. The extracellular region o f CD35 is predicted to be 
highly homologous to an Ig domain, but is not detected as such in databases (PFAM, SMART). MHC class-II is a heterodimer, and each polypeptide is formed by one Ig domain (a2  and 02) and 
a peptide-binding domain ( a  1 and 01).
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either CD4 or CD8. Each o f these binds a different class o f MHC proteins and their 
expression defines the function o f the T cell. Helper T cells are CD4-positive (CD4P0S) 
and bind peptide-loaded MHC class II; upon TCR engagement these cells secrete 
cytokines to activate other cells to respond to the pathogen. CD8P0S cells bind MHC 
class I proteins and become cytotoxic cells upon TCR engagement; these cells induce 
apoptosis o f infected cells by a variety o f different mechanisms.
Thymocyte maturation
T cell precursors develop from haematopoietic stem cells in the bone marrow and 
migrate to the thymus where the maturation process occurs. T cell progenitor cells 
express neither CD8 nor CD4 and are called double negative (DN) thymocytes. DN cells 
undergo extensive random rearrangement o f the gene that encodes the p chain o f the 
TCR in order to generate different antigen binding regions. The p-chain, which is 
associated with a pseudo-a-chain and CD3 at this stage, is transported into the cell 
membrane where, if  functional, it induces expression o f both CD4 and CD8, and genetic 
rearrangement o f the a-chain locus. CD4POSCD8POS (double positive cells), now with a 
functional TCR/CD3 complex, undergo two selection processes that depend on the 
avidity o f the TCR/CD3 for self-peptides presented by MHC molecules (spMHC). Cells 
with a strong avidity for spMHC undergo negative selection and are deleted. Cells with a 
very low avidity for the spMHC complex are also deleted in a positive selection stage. At 
the end, the only cells to survive are those which are able to interact with spMHC with 
moderate avidity. As a consequence o f positive selection, in a process that is not well 
understood, thymocytes differentiate into either CD4pos or CD8P0S (single positive) cells 
and finally leave the thymus and enter circulation2'4.
Signal transduction by the antigen receptors
Antigen engagement results in the tyrosine phosphorylation o f CD3 in the case o f T cells 
or CD79 in the case o f B cells. Initial phosphorylation is performed by src-family 
kinases, mainly Lck and Fyn in T cells and Fyn, Blk and Lyn in B cells5. 
Phosphorylation o f CD3 or CD79 occurs within the specific motifs with the consensus 
amino acid sequence D/E-X 2 -Y-X2 -L-X6-8-Y-X 2-L (where X is any residue), known as 
immunoreceptor tyrosine-based activation motifs (ITAM). Phosphorylated ITAMs 
recruit syk-family tyrosine kinases, i.e. zeta chain-associated protein (ZAP-70) in the 
case o f T cells and Syk in the case o f B cells, which in turn are activated by trans­
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autophosphorylation and by the src-family kinases6. Syk-family kinases activate 
phosphatidylinositol-3 kinase (PI3K) and Tec family tyrosine kinases. Tyrosine kinase 
activation triggers at least two signal cascades (Figure 1.3). One o f the cascades involves 
the activation o f phospholipase C (PLC) and the other the activation o f small GTPase 
proteins. PLC hydrolyses phosphatidylinositol bisphosphate (PIP2) into diacylglicerol 
(DAG) and inositol trisphosphate (IP3). Diffusion o f IP3 through the cytoplasm leads to 
Ca2+ release from the endoplasmic reticulum and activation o f calmodulin, whist DAG 
activates protein kinase C (PKC). Small GTPases, such as Ras and Rac, activate the 
mitogen activated protein (MAP) kinases, including ERK, JNK and p38. The final 
outcome o f the signalling events is the regulation o f the cytoskeleton and the activation 
o f various families o f transcription factors relevant for lymphocyte proliferation and 
differentiation. The best known o f these transcription factors are: activating protein 1 
(AP-1), a heterodimer formed by different combinations o f fo s  and ju n  gene products; 
nuclear factor o f activated T cells (NFAT), activated by an increase in the concentration 
o f cytoplasmic Ca2+; Rel/NFKB proteins that migrate to the nucleus when their inhibitor 
is phosphorylated; and the erythroblast transformation specific (ETS)-domain protein 
Elk-1 activated by phosphorylation by different MAP kinases5 ,7 ' 9 (Figure 1.3).
Lymphocyte surface glycoprotein CD5
The precise nature o f the lymphocyte response to an activating APC is not controlled by 
antigen engagement alone, but by the orchestrated response o f several accessory 
transmembrane co-activators and inhibitory molecules. Co-activators stabilise the 
interaction interface between the APC and the lymphocyte that takes place in a complex 
structure that has come to be known as the immunological synapse (IS). Within the IS, 
co-activators amplify and sustain the AgR signal or activate pathways that synergise with 
the AgR signalling cascade. The degree o f activation is regulated by inhibitory molecules 
that recruit phosphatases, degradation promoting ligases or inhibitory adaptors to the 
IS 10. The protein labelled as cluster o f differentiation 5 (CD5) is one o f many different 
proteins that participate in the modulation o f the AgR response.
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Figure 1.3 T cell antigen receptor signalling 
cascade.
TCR/CD4 engagement with pMHC brings Lck in 
contact with CD3. Lck phosphorylates CD3, Fyn, 
and SHP-1. Phosphorylated (^-chain recruits ZAP- 
70, which becomes active via phosphorylation by 
Lck followed by autophosphorylation. ZAP-70 
phosphorylates different adapter proteins such as 
LAT and  SL P -76 . P h o sp h o ry la te d  LAT 
activatesVAV1 and PLCyl. Activation o f PLCyl 
leads to mobilisation o f intracellular Ca: * and 
activation o f PKC and calmodulin. Activation of 
VAV1 activates small GTPases and the MAP 
kinases. The final outcome is the expression and 
activation o f transcription factors that promote 
lymphocyte mitosis and differentiation.
All T cells express CD5 from an early stage in their maturation. Expression levels o f 
CD5 increase progressively as T cells mature and finally decrease slightly at full 
maturation11. Among B cells CD5 expression levels vary with precise cell type and 
species origin. For human and mouse B cells, it is considered that CD5 is expressed 
constitutively only on a subpopulation o f cells known as B 1. However, novel techniques 
with increased sensitivity have detected the presence o f CD5 on all human and murine B 
cells12. For rabbits13 and chickens14, it appears that all B cells express CD5.
The surface levels o f CD5 change during thymocyte development and following AgR 
engagement15' 18. The level o f expression o f CD5 depends on the level o f expression o f 
the AgR and the strength o f the interaction o f the AgR with its ligand19. CD5 up-
regulation is thought to be mainly controlled at a transcriptional level, because the CD5
20mRNA level correlates with the surface level o f the receptor at the cell surface .
The transfection o f green fluorescent protein fusion constructs o f CD5 into CD5-negative 
(CD5neg) cells show that CD5 co-localises with CD3 in the IS21. Fluorescence resonance
energy transfer (FRET) experiments have further shown that CD5 is in close proximity to
00the TCR/CD3 complex under physiological conditions . Co-immunoprecipitation and 
co-capping experiments had previously suggested that CD5 was in proximity with the 
CD3 subunits23,24 and with the BCR in B1 and chronic lymphocytic leukaemia B cells 
(B-CLL)25,26.
CD5 has been conserved throughout vertebrate evolution (Figure 1.4). Homologues have 
been found in mammals, birds14 and amphibians27. Evolutionary conservation indicates 
that its presence is an important selective advantage. However, CD5 gene knockout (KO) 
mice show no gross alterations in T cell development and are capable o f mediating 
several types o f immune responses28. CD5 may be dispensable because it has 
overlapping roles with other molecules which are able to compensate for the absence o f 
CD5, or perhaps the loss o f CD5 only represents a survival risk in certain conditions yet 
to be determined. The absence o f a distinctive phenotype o f the KO mice is perhaps not 
altogether surprising as recent experiments have provided evidence that thymic selection 
is a highly flexible process, able to create a T cell repertoire o f essentially normal 
reactivity even when genetic defects o f T cell activation are present, thus masking the 
effects o f a single gene deletion29.
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Figure 1.4 Amino acid sequence alignment o f human lymphocyte glycoprotein CD5 and some orthologues (continued on the next page).
(*) Predicted N- or O-linked glycosylation site; (A) Putative phosphorylation site. Red, positive; purple, negative; blue, hydrophobic; green, aliphatic & polar; 
pink, cysteine; yellow, proline; orange, glycine.
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CD5 protein structure
CD5 is a type I monomeric transmembrane glycoprotein o f 67 kDa formed by a single 
polypeptide chain o f 492 residues (in human). The 348-residue extracellular region 
contains three ~110-residue domains (CD 5dl, CD5d2 and CD5d3) that belong to the 
scavenger receptor cysteine-rich superfamily (SRCR). The 92-residue cytoplasmic 
domain has a highly conserved sequence but no discernible 3D fold type. The 
cytoplasmic domain is predicted to have little regular secondary structure, except for two 
regions that could form p-strands and an a-helix30.
CD5dl and CD5d2 both possess potential N-linked glycosylation sites and are separated 
by a 25-residue proline and threonine-rich region containing 9 potential O-linked 
glycosylation sites31. O-glycosylation o f peptides produces extended structures that are 
rigid, and it is thought that the CD5dl-CD5d2 spacer region acts as a stalk that helps 
project CD5dl away from the cell membrane32,33. When expressed as a recombinant 
protein in Chinese hamster ovary cells, the N-glycan attached to CD5dl is almost 
exclusively a fucosylated biantennary glycan (A2G2F) with zero, one or two covalently 
bound molecules o f sialic acid33 (Figure 1.5). It is known that most anti-CD5 antibodies 
bind to CD 5dl, presumably because it is the domain with the highest sequence 
divergence among species34'36 (Figure 1.4)
CD5 regulation in lymphocyte activation
The nature o f the modulation o f AgR signalling by CD5 has been a matter o f controversy 
for many years. At this time there is a fragile consensus that it is primarily a negative 
modulator, but a good deal o f the available data indicate that it can also act as an 
activation enhancer o f leukocyte function. Research groups active in the field appear to 
be coming to terms with the concept that CD5 is able to both augment and inhibit the 
responses o f the AgR37 depending on the type o f B or T cell, the cellular differentiation 
state and the nature o f the induced stimulus38,39.
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Experimental methodology can alter the cellular response to CD5 stimulation. CD5 is 
generally activated by addition o f anti-CD5 mAbs. The precise effect observed appears to 
depend on the specific antibody used40,41 and the method o f stimulation42, e.g. cross- 
linking o f anti-CD5 mAbs alone, cross-linking o f anti-CD5 mAbs with anti-CD3 mAbs, 
use o f mAbs bound to a solid support. There is also a possibility that some anti-CD5 
mAbs might be able to block the interaction o f CD5 with its ligand or sequester CD5 
away from the antigen receptor complex (as has been done deliberately on some 
occasions43,44), leading to an erroneous interpretation o f results39.
Recent studies have revealed that the level o f CD5 on the cell surface has an influence 
upon the strength o f the TCR-mediated response. This observation has turned out to be 
fundamental to the comprehension o f the variable effects o f CD5. Thus, it is reported that 
the concentration o f CD5 on the cell surface is inversely correlated with the cell's 
responsiveness to TCR engagement18,45. In turn, CD5 expression level affects the T cell 
threshold to activation, since low levels o f CD5 expression appears to render T cells 
hyper-responsive39.
Cell surface levels o f CD5 are affected by the avidity o f the binding o f the TCR to the 
complex o f the corresponding antigenic peptide with the MHC protein (pMHC). TCRs 
that bind their pMHC with high avidity trigger a strong activating response that increases 
the expression levels o f CD5. Hence, the outcome o f direct CD5 stimulation with anti- 
CD5 mAbs in any particular experimental system would appear to depend on, among 
other factors, the degree o f activation o f the cells. The concentration o f CD5 on the cell 
surface is also actively maintained by APCs presenting self-peptides (spMHC)45"48. 
These self-antigens play an important role in the long-term survival and homeostasis o f 
peripheral B and T cells, they have been described as 'ticklers' that maintain a healthy 
lymphocyte population49. Both the frequency o f contact and the binding avidity for the 
spMHCs are reported to influence the expression levels o f CD5 in T cells. High avidity 
and/or a high number o f contacts sustain high CD5 expression levels that, in turn, 
decrease the responsiveness o f T cells after pMHC engagement45.
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(A) Schematic representation o f the general features o f the CDS glycoprotein.
(B) The structure o f A2G2F, the predominant glycoform found attached to Asn 116 in CD5dl expressed in CHO cells. The identity o f the other CDS glycans has not been determined. 
The greek letter ( a  or P ) refers to the configuration o f the anomeric hydroxyl group in the first monosacharide and the number refers to the position o f the carbon attached to the 
hydroxyl group in the second monosaccharide. All glycosidic linkages represented here originate from the C l hydroxyl group, e.g. an a ( l-6 )  glycosydic linkage is represented as a6 .
CDS stimulation can enhance the activation signals o f  the TCR in mature T cells 
Early studies o f the function o f CD5 led to the conclusion that CD5 co-activates T 
cells50’51, and this was the dogma until recently. In agreement with this co-activator 
hypothesis, it has been reported that simultaneous costimulation o f CD3/CD5/CD28 
using three mAbs generates the most complete activation o f T cells52. Additionally, it has
been found that cross-linking o f anti-CD5 on T cells and suboptimal doses o f anti-CD3
2 _|_
results in activation o f PLC-y, increase in intracellular Ca levels and expression o f 
interleukin-2 (IL-2), the most important stimulation cytokine required for full activation 
o f T cells53’56.
Under certain circumstances CD5 can even induce transcription o f genes related to 
lymphocyte activation (IL-2, ITF-y and transferrin receptor) and cause T cell 
proliferation without the need to simultaneously stimulate the TCR. Examples include 
ligation with the anti-CD5 mAbs C risl40, F145GF340 or TS4341, and simultaneous 
ligation of CD5 and CD28 using the corresponding immobilised mAbs57. The activation 
pathway triggered was reported to be independent from the TCR-dependent cascade. The 
alternative pathway involves DAG release58 and PKC40,57 but is not associated with PLC- 
y activation, increase in intracellular Ca2+ concentration or release o f IPs40, which are key 
events in the activation o f T cells via the TCR.
CD5 stimulation is able to inhibit the activation o fT  cells
The availability o f CD5NEG cells and knockout mice has given rise to a reassessment o f 
the role o f CD5 in T cell activation28,59. CD5NEG mice have hyper-responsive T cells and 
show increased tyrosine phosphorylation o f TCR/CD3 components59. In CD5NEG cells, 
transfection with vectors encoding CD5 reduces Ca2+ mobilisation and Tyr 
phosphorylation at the IS21, and suppresses the TCR response to antigen or anti-CD3 
stimulation60, showing consistently that CD5 behaves as a negative regulator. Moreover, 
it has been reported that co-cross-linking o f  CD3 and CD5 in Jurkat cells (a human T cell 
line) decreases the phosphorylation o f the CD3 £ chain, ZAP-70, Syk and PLC-y and 
reduces Ca2+ mobilisation61.
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Dendritic cells (DC) are APCs which are able to suppress peripheral T cell activity 
against self-antigens by several distinct mechanisms62. Recently, it was reported that one 
o f these mechanisms involves inducing T cells to up-regulate CD5 expression and that 
this process renders T cells anergic in vivo, i.e. unable to respond to antigen. Despite 
their unresponsive state in vivo, these DC-exposed CD5H1GH T cells could be activated in 
vitro. T cells that had not been exposed to DC (CD5L0W) exhibited enhanced activation 
upon co-cross-linking o f CD3, CD28 and CD5 compared to co-cross-linking o f only 
CD3 and CD28, supporting the idea that CD5 acts as a co-activator. However DC- 
exposed T cells (CD5high) showed the opposite behaviour, suggesting that high levels of 
CD5 down-regulate T cell activation through a pathway independent o f the TCR 
signalling cascade .
CDS increases the threshold fo r  TCR stimulation during T cell maturation
The expression o f CD5 starts in very early stages o f thymocyte maturation and is
16 17dynamically up-regulated during thymocyte development ’ . Thymocytes are also more 
responsive to CD5 stimulation than mature T cells11. Most studies support the hypothesis 
that CD5 is involved in raising the threshold for negative selection in thymocytes. 
Thymocytes o f CD5NEG mice show increased proliferation, increased tyrosine 
phosphorylation o f PLC-y and Vav and increased Ca2+ influx59. Furthermore, the level of 
negative selection following stimulation with anti-CD3 mAbs is much higher in CD5NEG 
mice than in wild type mice39,59. All these results suggest that the presence o f CD5 
dampens the activation responses in thymocytes.
Experiments using transgenic mice that have a particular TCR (tg-TCR) expressed in 
large numbers o f T cells have been very informative as to the effect o f CD5 on the 
outcome o f thymic maturation. Thymocytes bearing a tg-TCR that is known to normally 
undergo severe negative selection can be rescued by activation o f CD5 with anti-CD5 
mAbs39. Conversely, CD5NEG mice show increased negative selection o f thymocytes 
expressing the tg-TCR DO 11.10, which in normal mice is expressed in virtually all 
CD4P0S T cells60. Both o f these results show that very reactive TCRs avoid apoptosis in 
the thymus if  CD5 is active, but otherwise would experience an inadmissible level of 
activation and would be deleted. Therefore, it seems that CD5 activity reduces the 
number o f thymocytes undergoing apoptosis because o f their extremely high levels of
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activation (negative selection), but also increases the number o f thymocytes that undergo 
apoptosis because o f their unacceptable low levels o f activation (positive selection).
A chimeric construct consisting o f the extracellular domain o f the human receptor Tac, 
that has no ligand in mice, and the cytoplasmic region o f CD5 has been reported to be 
able to inhibit TCR signalling in CD5NEG thymocytes. This observation suggests that the 
function o f CD5 in the thymus does not require engagement o f any ligand64. The authors 
o f this study proposed that CD5 acts constitutively as a negative regulator that can switch 
to being a co-stimulator upon ligand binding in mature T cells. However, these results 
may simply indicate that there are other receptors in the thymocyte surface able to 
counteract the effect o f CD5's inability to bind its ligand.
Despite the foregoing evidence, there is a degree o f controversy concerning the negative 
regulator role o f CD5 in thymocytes. A few reports have suggested that CD5 together 
with other receptors such as CD28, the main T cell co-stimulator, are responsible for 
TCR activation in thymocytes and, in this manner, CD5 enhances, rather than reduces, 
negative selection65,66. Two explanations for this apparent inconsistency have been 
suggested. It could either be that the effect o f CD5 is different at different stages of 
thymocyte maturation, or that the particular mAbs used in order to stimulate CD5 in 
these experiments are actually having unanticipated effects and acting in the opposite 
sense to that supposed39.
CDS inhibits the signalling events activated by BCR engagement and promotes the 
production o f  a cell survival cytokine
B cells from humans and mice are classified according to the presence o f  CD5 on their 
surface: B1 cells are CD5P0S and B2 cells are CD5NEG. B1 cells are able to produce Abs 
(mainly IgM and IgA) in the absence o f any given antigen stimulation67. These, so-called 
natural, Abs have low affinity and broad specificity, and are able to recognise bacterial 
antigens, DNA, multicellular parasites and autoantigens38’68'70. The role o f B 1 cells is not 
well characterised, but they are known to be involved in the defence against bacteria and 
parasites71'73, and in modulating the Ab repertoire by establishing the idiotypic network74 
(an interconnecting series o f self-Abs able to recognise the variable regions o f the 
organism's own BCRs). B1 cells are also associated with autoimmune diseases and 
malignant transformations. Thus, B1 cell-count increases in some autoimmune
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conditions such as rheumatoid arthritis, Sjogren's syndrome and lupus70. Several B cell 
malignancies, e.g. chronic lymphocytic leukaemia and mantle-cell lymphoma, are 
characterised by cells that express CD5 at high levels75,76.
The behaviour o f B 1 cells is in agreement with a role for CD5 as an inhibitor o f the 
signalling events triggered by the BCR. For example, CD5NEG cells become active and 
begin to differentiate upon BCR engagement, in contrast the response o f CD5P0S cells to 
BCR engagement is poor: cells do not proliferate and instead show enhanced apoptosis77. 
Moreover, CD5pos cells have reduced PLC activation, delayed or absent triggering o f 
MAP kinase cascades and are unable to activate NF-kB transcription factors78,79. B1 cells 
o f CD5-deficient mice are resistant to apoptosis after BCR engagement and undergo 
proliferation43. Additional findings consistent with a role for CD5 in negative regulation 
o f the BCR have been obtained by expression o f a tg-BCR that renders B cells 
functionally impaired. In contrast to the tg-BCR/CD5P0S anergic phenotype, tg- 
BCR/CD5neg cells are hyper-responsive in vitro*0, suggesting that CD5 plays a key role 
in the impaired activity o f the tg-BCR cells.
Down-regulation o f the BCR response is not the sole function o f CD5 in B cells. B1 cells 
are long-lived and self-renewing because they are able to produce interleukin-10 (IL-10), 
a potent immunosuppressive cell-survival cytokine81. CD5NEG cells transfected with a 
vector containing CD5 produce more IL-10 than the control mock transfected cells. CD5 
was found to activate the promoter o f the IL-10 gene without requiring BCR 
stimulation .
New evidence suggests that B2 cells do express CD5 in very low quantities12. Moreover, 
the expression o f CD5 in B2 cells can be up-regulated using different stimuli such as 
anti-IgM antibodies, T cell-independent antigens such as bacterial polysaccharides, 
expression o f retroviral GTPases, and BCR cross-linking83'85. These observations have 
led to the hypothesis that B1 cells are simply an anergic state o f B cells caused by 
chronic stimulation, rather than a separate cell lineage86. In mice unable to express the 
SHP-1 phosphatase (the so-called 'motheaten' mutation) not only are most o f B cells 
CD5pos but macrophages are also found to be CD5P0S 87, leading to support another 
ongoing hypothesis that B1 cells and macrophages develop from a common progenitor 
cell88.
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To summarise, it is clear that alteration o f the activation state and the cell surface 
concentration o f CD5 modifies the strength and the nature o f the intracellular response 
initiated by the antigen receptor o f T and B cells. Unfortunately, the precise mechanism 
of this modification is still far from transparent. The reports from different laboratories, 
using distinct methods to manipulate CD5, are not obviously consistent and seem to be 
susceptible to a variety o f interpretations.
CD5 signal transduction
The 92-residue cytoplasmic domain o f CD5 (CD5cyt) does not possess intrinsic catalytic 
activity, but it contains 11 serine residues, 4 threonines and 3 tyrosines, and of these, 10 
are predicted to be phosphorylation sites89: Ser404, Thr412, Ser415, Ser423, Tyr429, 
Ser439, Ser458, Ser459, Ser461 and Tyr463* (Figure 1.4). Experiments have shown that 
CD5 recruits both protein kinases and phosphatases and undergoes phosphorylation on 
serine90, threonine91 and tyrosine23,92,93 residues either constitutively or following 
stimulation o f the AgR and/or stimulation with anti-CD5 Abs92. Although current 
knowledge o f the signalling events triggered by CD5 stimulation is very fragmented, it 
appears that CD5 is able to alter the molecular signals generated as a result o f AgR 
engagement, and it is also involved in AgR-independent signalling pathways.
Casein kinase 2 phosphorylates S459 and S461
Casein kinase 2 (CK2) has been found by co-immunoprecipitation and yeast two-hybrid 
assays to interact with the cytoplasmic domain o f CD5. CK2 phosphorylates S459 and 
S461 upon stimulation with anti-CD5 Abs94,95. CK2 is probably the most pleiotropic 
individual protein kinase96 and the final consequence o f this activation is not yet known. 
However, there has been some speculation that this pathway could lead to the activation 
o f the AP2 adapter complex that mediates receptor-dependent endocytosis97.
* Note: Authors that have published on signal transduction involving CD5 do not include the signal peptide 
(M etl to Gly24) in their residue numbering. I have followed this convention only in this Chapter o f the 
thesis.
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Figure 1.6 A summary o f current reports o f the protein-protein interactions and signalling pathways involving 
CD5 inT  cells.
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Protein kinase C phosphorylates T410 and T412
Purified peripheral blood mononuclear cells (PBMCs) and T cells treated with phorbol 
ester, a protein kinase C (PKC) activator, display increased cell surface expression levels 
o f both CD5 and CD2 898,99. Activation o f PKC is also able to counteract the ability o f 
some anti-CD5 mAbs to lower the cell surface levels o f CD5, by a mechanism involving 
actin polymerisation100. Co-immunoprecipitation studies have shown that PKC interacts 
with CD5 in vivo and this kinase has been found to phosphorylate T410 and T412 both in 
vitro and in Jurkat cells after treatment with phorbol ester91. Phosphorylation o f CD5 by 
PKC triggers the production o f DAG in the absence o f Ca2+ mobilisation40 and it also 
inhibits the internalisation o f CD5 in Jurkat cells91.
CD5cyt associates with serine/threonine kinase CAMK2S
The unphosphorylated cytoplasmic domain o f CD5 is reported to bind 
calcium/calmodulin-dependent kinase 25 (CAMK25) in yeast two-hybrid experiments 
and in affinity chromatography101 assays. The precise consequence o f this interaction in 
vivo has not been defined, but most likely involves the regulation o f transcription factor 
activity102’103.
Src-family kinases phosphorylate Y429 and Y463
The activation o f the src-family tyrosine kinases p56Lck (Lck) and p59fyn (Fyn) is one of 
the first events in T cell activation after TCR engagement. These kinases phosphorylate 
CD3, PLC and several other kinases and adapter proteins104. Lck is deeply implicated in 
the CD5 signalling pathway. It not only phosphorylates CD5cyt, but subsequent binding 
to phosphorylated CD5cyt increases Lck kinase activity by 10-fold105. The two predicted 
tyrosine phosphorylation sites in the cytoplasmic domain o f CD5, Y429 and Y463, are 
both phosphorylated in activated T cells by Lck93,106.
Phosphorylation o f Y429 is known to play a central role in the inhibition of Ca2+ 
mobilisation and production o f IL-2 in CD5P0S B cells107,108. However, there is some 
disagreement about the identity o f kinase responsible for CD5cyt tyrosine 
phosphorylation in B cells. Lyn kinase was the first to be reported to phosphorylate CD5 
in B cells109. In contrast to Fyn and Lck, which are mainly considered stimulatory 
kinases, Lyn is usually implicated in the down-regulation o f B cell activation110,111.
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Along with CD5, Lyn has been co-immunoprecipitated with anti-CD5 mAbs from 
purified B1 cells after stimulation with anti-IgM. Whilst in wild-type B1 cells CD5cyt 
was found to be tyrosine phosphorylated after anti-IgM stimulation, tyrosine 
phosphorylation could not be detected in LynNEG B1 cells109.
A recent publication has challenged the function o f Lyn as the kinase involved in the 
phosphorylation o f CD5cyt in B cells. The authors o f this study propose that this role is 
fulfilled by Lck, as co-expression of Lck and CD5 was found to confer the hypo- 
responsive phenotype o f B1 cells68. CD5NEG B cells do not express Lck112, but in CD5P0S 
B cells Lck is an important signalling molecule, as Lck activity appears to be necessary 
for the activation o f the MAP kinase cascade triggered by BCR engagement113.
CD5cyt associates with tyrosine kinase ZAP-70 via the chain
The syk-family kinase ZAP-70 plays an essential role in the activation o f T cells. It is 
recruited to the phosphorylated £ chain o f CD3 where in turn it is phosphorylated by Lck. 
Phosphorylated ZAP-70 then phosphorylates downstream adapter proteins such as the 
linker for activation o f T cells (LAT) and SH2 domain-containing leukocyte protein 
(SLP76) (Figure 1.3). ZAP-70 has been found by co-immunoprecipitation to be 
associated with CD5 in freshly isolated thymocytes24. However, the interaction does not 
appear to be direct, as a peptide containing the Tyr phosphorylated CD5cyt region does 
not bind ZAP-70114. The authors suggest that the interaction is via the ^-chain, because 
phosphorylated <^-chain immunoprecipitates, which are able to bind to ZAP-70, also 
contain CD524.
Phosphorylated CD5cyt could recruit SHP-1
Phosphatases counter-balance the tyrosine phosphorylation cascade triggered by AgR 
engagement. One o f the most studied phosphatases in AgR signalling is the SH2 domain- 
bearing protein tyrosine phosphatase 1 (SHP-1). SHP-1 is recruited to the cell membrane 
following the phosphorylation o f specific tyrosine-based motifs in inhibitory receptors. It 
is phosphorylated and subsequently engages in the dephosphorylation o f a plethora o f 
substrates including kinases, adapter proteins and transmembrane receptors. As CD5 is 
able to dampen lymphocyte activation, it was hypothesised that CD5cyt would recruit 
SHP-1 and/or other phosphatases in order to initiate down-regulation o f AgR signalling.
39
An association between SHP-1 and phosphorylated CD5 has been detected by co- 
immunoprecipitation in purified B1 cells26, mature T cells61,115 and thymocytes116. The 
phosphotyrosine residue that binds to the SH2 domain o f SHP-1 was proposed to be 
Y378, based on experiments performed in Jurkat T cells with a chimeric construct o f the 
cytoplasmic domain o f CD5 and the extracellular domain o f CD661. However, this 
tyrosine is predicted to be at the C-terminal end o f the transmembrane region, and other 
groups have concluded that Y378 is not phosphorylated93,106. In B1 cells, the association 
between SHP-1 and the BCR appears to stabilised by the presence o f CD526, and there is 
also evidence that CD5 binding to SHP-1 is mediated by Lyn109.
The validity o f the recruitment o f SHP-1 is still debated, as other groups have not been 
able to detect SHP-1 in association with CD5. It has been reported that in CD5NEG Jurkat 
T cells expressing a recombinant CD5 transgene, no SHP-1 was detected after 
stimulation with pervanadate (a tyrosine phosphatase inhibitor) or co-cross-linking with 
anti-CD3 and anti-CD5 mAbs93. In experiments in a B cell line using a chimera o f 
CD5cyt with the extracellular domain o f the inhibitory receptor FCyRIIBl, no SHP-1 
activity could be found in the anti-FCyRIIBl immunoprecipitates. However, this chimera 
was able to antagonise both Ca2+ mobilisation and the MAPK pathway, and its inhibitory 
properties depended on the presence o f the CD5cyt region comprising Y429107.
The role o f CD5 in relation with SHP-1 has also been investigated in animal models. 
SHP-1NEG mice ('motheaten' mutation, me) have severe autoimmune disease and die at 
three weeks o f age o f autoimmune pneumonitis. A less severe mutation, SHP-1LOW 
(viable motheaten, mev) is usually used to study the effects o f the absence o f SHP-1 
because mev mice live longer than me m ice117. Both CD5NEG and SHP-1L0W B cells are 
hyper-reactive consistent with the hypothesis that CD5 inhibits the AgR signalling 
pathway by recruitment o f SHP-1. According to this premise, CD5NEG mev B cells should 
show even higher hyper-responsiveness than mev B cells. Surprisingly however, CD5NEG
p y - v o  i  i  n
mev mice have increased lifespan and less severe phenotype than CD5 mev mice . 
The phenotype o f CD5NEG mev mice illustrates the complexity o f the events triggered by 
gene deletion in the immune system, and perhaps suggest that CD5 is also part o f an 
alternative pathway that is not o f an inhibitory nature and does not necessary require 
SHP-1. This pathway does not have to involve CD5cyt, but could be activated by the 
extracellular region of CD5 (CD5ext) upon binding to its ligand. Consistent with this
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hypothesis, different groups have reported that the application o f recombinant CD5ext is 
able to activate B cells118' 120. In the absence o f SHP-1 CD5cyt would be unable to down- 
modulate the AgR, which would render cells hyper-reactive, but CD5ext would still be 
capable o f promoting activation via its putative counter-receptor, this would further 
enhance cell reactivity. Within this model, he loss o f CD5 in the absence o f SHP-1 would 
additionally influence the activation pathway triggered by the counter-receptor, thus the 
cancellation o f these positive and negative effects would eliminate the contribution of 
CD5 to cell reactivity.
Phosphoinositide 3 kinase binds to phosphorylated CDS
PI3K is recruited to the membrane once CD3 is phosphorylated upon antigen 
engagement. Being held close to its substrates, i.e. membrane phospholipids, PI3K starts 
active generation o f phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 in turn
191facilitates recruitment o f PLC-y 1 and activates several downstream protein kinases .
Association between PI3K and phosphorylated CD5cyt has been documented in activated 
thymocytes114, in Jurkat T cells93 and in purified T cells122. The interaction was found to 
be direct and mediated by the SH2 domains o f the p85 adaptor subunit o f PI3K. Whilst 
the C-terminal SH2 domain showed preferential binding to a PY4 6 3DLH peptide, the N- 
terminal SH2 domain bound preferentially to a peptide containing pY429 and pY441, 
indicating that PI3K could potentially bind CD5cyt with both SH2 domains.
The pathway that leads to the activation o f  IL-2 gene transcription after CDS stimulation 
is different from  the pathway triggered by TCR engagement
Ca2+/Calmodulin dependent kinase IV (CaMK IV) is a serine/theonine kinase involved in 
the up-regulation o f the expression o f proteins that form the AP-1 transcription factor123. 
CaMK IV also appears to be implicated in decreasing the threshold for positive selection 
in thymocytes124. CaMK IV has been reported to be involved in the expression o f IL-2 by 
purified T cells stimulated with anti-CD5, anti-CD28 and phytohemagglutinin125. This 
pathway o f IL-2 expression was reported to involve the phosphorylation o f PI3K, Vav, 
R acl and CaMK IV (in that order), and to cause an increase in the DNA binding activity 
o f AP-1 transcription factor, while leaving other transcription factors unchanged122. 
These results suggest that CD5 stimulation is able to trigger an AgR-independent signal 
transduction cascade that activates one o f the most important genes for T cell activation.
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The CD5 signalling cascade in thymocytes might be different to that in mature T cells 
Both cellular-Cbl and the GTPase-activating protein for Ras GTPase (RasGAP), are 
considered negative regulators o f the TCR signalling cascade. The oncoprotein c-Cbl 
recognises tyrosine kinase substrates and promotes their ligation to ubiquitin marking 
them for degradation110,126. Disruption o f the c-Cbl gene causes enhanced T cell 
responsiveness upon anti-CD3 mAh stimulation127. RasGAP is the down-regulator o f the 
small GTPase Ras128. Ras activity is necessary for the activation o f T cells, as it is up­
stream of both the Rac and R af pathways. In isolated thymocytes stimulated with 
pervanadate and cross-linked with anti-CD5 Abs, CD5cyt associates with both c-Cbl and 
rasGAP129. However, none o f these associations was found in mature T cells93, 
suggesting that this could be a reason for the different effects o f CD5 in T cells and 
thymocytes.
It has been reported that in DP thymocytes, cross-linking o f CD5 and CD3 causes a 
reduction in the levels o f intracellular Ca2+, as expected for an inhibitor o f the TCR, but 
an increased level o f activity for the MAP kinase cascade component ERK56. This 
increased ERK activity stimulates the production o f B cell lymphoma protein 2 (Bcl-2)56, 
an oncoprotein that promotes cell survival by inhibiting apoptosis130.
An undetermined ceramide-mediatedpathway becomes active after CD5 ligation 
CD5 has been found to be involved in an undefined pathway that uses ceramide as a 
second messenger. Stimulation o f T cells with anti-CD5, anti-CD3 and anti-CD28 mAbs 
activates two phosphoric diester hydrolases: acidic sphingomyelinase (aSMase)131 and 
phosphatidylcholine-specific phospholipase C (PC-PLC)58. These enzymes catalyse the 
formation o f ceramide and 1,2-diacyl-glycerols (DAG) from the cell membrane 
components sphingomyelin and phosphatidylcholine respectively132' 134. Activation o f 
aSMase was severely compromised by mutation o f the Ser residues phosphorylated by 
CK2131, which could mean that CK2 is also implicated in this pathway. The group also 
found that other components o f this signalling cascade are the ceramide-activated protein 
kinase C-C, (PKC-Q, mitogen activated protein kinase kinase (MEK) and c-Jun NH 2 - 
terminal kinase (JNK), but the final outcome o f the pathway is yet to be elucidated.
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Interactions with other extracellular proteins
As well as being in close contact with the AgRs and CD4 or CD8135, CD5 has been 
reported to be in physical proximity with three other leukocyte cell surface 
transmembrane proteins, CD2, CD6 and CD9. The interaction between CD5 and CD9 in 
T cells was discovered in co-immunoprecipitation and capping experiments. CD9 does 
not have a cytoplasmic domain for signal transduction, and it is thought to function in
136association with other molecules . CD9 belongs to a family o f transmembrane proteins 
that function as 'molecular facilitators' and its interaction is most likely to assist the 
distribution o f  CD5 on the cell surface137.
CD2 is a lymphocyte receptor involved in the stabilisation o f the IS and in signal
100
transduction . The binding o f CD2 with its ligand (CD58 in humans and CD48 in rats) 
aids T cell activation139 and contributes to the adhesion to the A PC140. The direct 
interaction o f CD2 with CD5 was detected by co-immunoprecipitation and co-capping in 
T cells and thymocytes141. Both the extracellular and the cytoplasmic domain of CD2 
appear to be involved in the association141. Stimulation o f CD2 with anti-CD2 Abs was 
reported to induce dephosphorylation o f CD5 in T cells, presumably by recruitment of 
SHP-1115. CD5neg and CD2NEG mice have similar phenotypes, in that CD2NEG mice seem 
healthy and able to mount a strong immune response142. As CD5NEG thymocytes, CD2NEG 
thymocytes have enhanced negative and positive selection143, indicating that CD2 is 
inhibiting TCR signalling events in thymocytes, the opposite effect than observed in 
mature T cells stimulated with anti-CD2 mAbs144.
CD5 and CD6 are thought to have evolved from a gene duplication event145,146. They 
have very similar domain organisation and are expressed by the same cell types147. The 
function o f CD6 in lymphocyte activation is not well established but, as with CD5, it is 
known to be involved in the modulation o f lymphocyte activation and thymocyte 
development. CD6 is thought to be an enhancer o f the AgR148 and to favour positive 
selection in thymocytes149. Antibodies anti-CD6 are able to activate resting T cells150' 152. 
It has also been reported that CD6 is able to rescue B-CLL cells from apoptosis by up- 
regulating the expression of the oncoprotein Bcl-2153 and that it enhances T cell adhesion 
to the APC154. FRET, co-immunoprecipitation and co-capping experiments have shown 
that CD6, the same as CD5, associates with the TCR154. CD6 and CD5 are able to co- 
immunoprecipitate155 in T cells, and their physical proximity in resting and activated T
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cells has been detected by FRET156. Stimulation o f CD6 with anti-CD6 Abs has been 
reported to increase the tyrosine phosphorylation level o f CD5155. CD6 is able to recruit 
Lck and also the IL-2 inducible T cell kinase (Itk). Itk is critical for PLC-y 1 activation 
and it does not appear to be associated with CD5 or the TCR155. A combination o f Lck 
and Itk is able to efficiently phosphorylate a CD5cyt peptide containing Tyr 429 and 
Tyr441, suggesting that Itk may also be a part o f the signalling pathway o f CD5155.
The reported interactions with CD6 and CD2 show that the nature o f the effects o f CD5 
on the modulation o f  lymphocyte activation is more complex than has been foreseen. 
These observations raise the possibility that the activation o f CD2 and/or CD6 is able 
influence the outcome o f the transduction pathways associated with CD5. Perhaps these 
receptors have redundant functions, which would explain why CD5NEG and CD2NEG mice 
do not possess a very distinctive phenotype, and why the extracellular domain o f CD5 
appears to be dispensable for thymocyte development.
The extracellular ligand of CD5
The identification o f the molecular ligand(s) for extracellular region o f CD5 has been 
controversial as reported interactions have proved difficult to reproduce. Furthermore, 
there have not been any recent publications concerning most o f the proposed ligands, 
possibly indicating that the target molecules remain elusive. Most o f the identified 
potential ligands (see below) are able to activate B cells118,120,157' 159. Although there is 
always a possibility that CD5 might not have a ligand, the fact that the administration o f 
soluble forms o f CD5 ameliorates certain experimental autoimmune diseases in 
vivo159,160, that soluble CD5 can promote B cell proliferation120, and the very existence of 
a natural soluble form o f CD5161, suggest that there is a lymphocyte-derived molecule 
capable o f binding CD5ext.
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The first proposed ligand for CD5 was CD72162, a B cell C-type lectin (a Ca2+-dependent 
carbohydrate recognition receptor). The interaction was discovered by incubating 
purified biotinylated CD5 with several cell lineages. Subsequently, it was also reported 
that purified CD5 binds immobilised recombinant CD72 in an enzyme-linked 
immunosorbent assay (ELISA)118. In both cases the binding o f CD5 to the target could 
only be prevented by addition o f anti-CD72163. However, no independent research has 
been able to reproduce these findings120,159,164,165.
Two inducible unidentified glycoproteins, present in both activated B and T cells, have 
been reported to be able to bind soluble recombinant constructs o f CD5. Glycoproteins 
gp40120,159 and gp80120 were pulled-down from activated lymphocyte cell lysates using 
recombinant CD5 as a bait120,159. This interaction was found to be divalent metal cation- 
dependent and to depend on the glycosylation o f CD5, which suggests that the ligand is a 
C-type lectin, but it was actively confirmed that the receptor was not CD72159 in this 
case. A similar association was reported independently: a soluble recombinant construct 
o f bovine CD5 was found to interact with a 200 kDa protein in activated B cells158.
A broadly-distributed constitutively-expressed glycoprotein, gpl50, has also been 
proposed to be a ligand for CD5. As opposed to the putative C-lectin ligands, the binding 
o f gp 150 to a recombinant form o f CD5 was independent o f divalent metal cations and 
was only disrupted at high concentrations o f monosaccharides165. The interaction was 
discovered by incubating several cell lines with a recombinant soluble CD5. G pl50 
could not be cross-linked with CD5 under the conditions that were attempted, but could 
be isolated by co-immunoprecipitation with anti-CD5 m Abs165.
CD5 has been reported to bind the immunoglobulin domain that constitutes the variable 
region o f the heavy chain (V h ) o f the BCR. The binding has been mapped to the second 
SRCR domain o f CD5 (CD5d2) and framework region o f the Vh119,166 (the face o f the 
domain that presents lower variability within different Vh domains compared to the 
CDRs). Purified recombinant CD5, and CD5 from lysates o f several kinds o f B cells can 
be immunoprecipitated using purified immobilised Ig or Ab fragments. The binding is 
not specific to the kind o f Ab used, arguing that it does not depend on Ab specificity119. 
I f  this is true, all experiments on lymphocytes involving the use o f antibodies could 
influence the status of CD5. It was proposed that this interaction is involved in the long­
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term survival o f peripheral B cells by delivering mild stimulatory signals, just as is
167claimed for low-affinity self-antigens .
Origin and scope of the thesis
The interest in determining the 3D structure o f the extracellular domains o f CD5 arose 
more than 8 years ago from a collaboration with Prof Neil Barclay and Dr Marion Brown 
at the Sir William Dunn School o f Pathology in Oxford. There were two strong 
motivations for attempting to obtain the structure o f the SRCR domains o f CD5: to 
enable a structure-fimction analysis o f CD5; and to establish if  SRCR domains were 
members o f the immunoglobulin superfamily or not, as was debated at that time. The N- 
terminal domain o f CD5 (CD 5dl) was chosen as the primary target for structural 
investigation because it was thought most likely to contain the ligand-binding site as it is 
the most distant from the cell surface. Furthermore, the presence o f the stalk region 
between CD5dl and CD5d2 suggested that it was unlikely to require the other domains 
to achieve its native fold.
CD5dl was expressed in Chinese hamster ovary cells in sufficient quantities to establish 
by ]H-NMR that the domain was folded and globular. Because NMR structure
15 13determination o f a 15 kDa protein requires several milligrams o f N and C isotope- 
labelled protein, efforts were made to develop a yeast expression system. However, the 
levels o f expression in the yeast Pichia pastoris were always low and labelling with 13C 
proved prohibitively expensive. Using glycosydase-treated 15N single-labelled samples, it 
was possible to assign ca. 85% of the backbone amide resonances, but further progress 
was hampered by substantial peak overlap.
Inspired by the successes o f other laboratories in expressing unglycosylated versions o f 
glycoproteins in Escherichia coli, the bacterial expression o f  CD5dl was then pursued. 
The bacterial CD5dl was found to be expressed in an insoluble form in inclusion bodies. 
In vitro folding by dilution was attempted with very limited yields and poor 
reproducibility. However, sufficient 15N-labelled sample was produced to confirm that 
the unglycosylated construct was folded and that the NMR spectra o f the bacterial 
CD 5dl were similar to those o f the yeast and mammalian versions, implying that the N- 
glycan was not essential for proper folding. Such was the state o f affairs when I took
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over the project.
In order to proceed with the resonance assignment and progress towards the 
determination o f the 3D solution structure o f CD 5dl, further optimisation o f the in vitro 
folding methodology and improvement of protein solubility were essential. This thesis 
describes the strategies that I developed to produce correctly folded double isotope- 
labelled CD5dl at suitable concentrations for three-dimensional NMR experiments. The 
NMR data recorded with these samples has enabled us to determine the long-sought 
solution structure o f CD 5dl. The NMR structure o f CD5dl presented here provides a 
framework for analysis o f the structure-function characteristics o f both CD5 in particular 
and SRCR domain-containing proteins in general.
The approaches that I have developed to optimise in vitro folding conditions and improve 
solubility are not only applicable to CD 5dl, but are general methods that could be 
applied, straightforwardly, to other proteins. In particular, the application of these 
methods will allow the future 3D structure determination o f the other SRCR domains o f 
CD5 and CD6, which will provide additional information for the future understanding o f 
the interactions o f CD5 and CD6 with their putative ligands.
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____________________________ Chapter Two
Renaturation of two extracellular domains from human 
CD5 expressed in Escherichia coli: Optimisation of in 
vitro oxidative folding conditions using a fractional 
factorial screen
Abstract
Constructs o f the first (/*CD5dl) and third (/7CD5d3) scavenger receptor cysteine-rich 
(SRCR) domains o f human CD5 were overexpressed in Escherichia coli BL21(DE3) 
cells. Both constructs expressed at high levels as inclusion bodies. Initial efforts to fold 
the domains in vitro by dialysis or dilution were not successful, due to substantial 
precipitation. The purification o f the reduced unfolded monomers using size-exclusion 
chromatography prior to in vitro folding improved the yield, but still, yields were low. 
Published protein folding screens were applied but without success. However, these 
results inspire the design o f a new protein folding screen optimised for proteins having 
disulphide bonds in their native conformation. Reversed phase HPLC was found to be 
useful as a rapid assay to detect disulphide formation, because a protein containing intra­
molecular disulphide bonds is usually more hydrophilic in denaturing conditions than its 
reduced counterpart. Non-denaturing polyacrylamide gel electrophoresis was also found 
to be valuable for detecting the change in protein shape due to folding. This new 
oxidative folding screen was tested with lysozyme and RNase A, and proved successful 
in finding conditions to fold /zCD5dl and /*CD5d3 with good yields. ID and 2D NMR 
showed that both o f these constructs have a good dispersion o f resonances, which is 
characteristic o f folded proteins.
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Chapter abbreviations and acronyms 
ID  one-dimensional 
2D two-dimensional 
e molar extinction coefficient 
CV column volume
EDTA ethylene diamine tetra acetic acid, di­
sodium salt
DsbA periplasmic protein thiokdisulphide 
oxidoreductase from Escherichia coli 
D sbC periplasmic protein thiokdisulphide 
isomerase from Escherichia coli 
G dnH C l guanidine hydrochloride 
G SH  L-gamma-glutamyl-L-cysteinylglycine 
(glutathione, reduced form)
G SSG  glutathione, oxidised form 
/iC D 5dl N-terminal SRCR domain o f  CD5
hCD5d3 C-terminal SRCR domain o f CD5
H PL C  high performance liquid chromatography
H IC  hydrophobic interaction chromatography
IDA iminodiacetic acid
IPT G  isopropy 1-P-D-thiogalactopyranoside
N M R  nuclear magnetic resonance
PDB Protein Data Bank
PDI protein disulphide isomerase
RN ase A bovine pancreatic ribonuclease A
R PC  reversed phase chromatography
R T room temperature
s standard deviation
s2 variance
SEC size-exclusion chromatography
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Introduction
The remarkable process o f transforming inactive and water insoluble, heat or acid- 
denatured protein into its biologically active form was first reported by Mortimer Anson
1 7and Alfred Mirsky in the early 1930s ’ . Nobel laureate crystallographer Max Perutz, then 
a graduate student, wrote a famous note 'Unboiling an Egg'3, a title that illustrates how 
striking this revolutionary discovery was. From the early 1980s, with the development o f 
the technology to over-express heterologous proteins in Escherichia coli, the techniques 
originally used to study the mechanisms o f protein renaturation found a new application: 
the in vitro 'activation' o f recombinant polypeptide chains that did not express in vivo in 
their biologically active, native, form. Over-expression products that do not attain their 
native conformation in the cytoplasm often self-aggregate forming insoluble dense 
particles called inclusion bodies. The inclusion bodies can be isolated by centrifugation 
o f the cell lysate, solubilised using chaotropes (urea, guanidine hydrochloride) or 
detergents (sarkosyl, Triton X-100, sodium deoxycholate) and folded in vitro. The 
folding is promoted by reducing the concentration o f the solubilising agent significantly, 
so that the denatured polypeptide can rearrange and establish native intramolecular 
interactions. This process can be accomplished by direct rapid dilution, by dialysis or 
exchanging buffers using a chromatography matrix (size-exclusion, metal ion affinity). In 
vitro folding is used routinely to prepare proteins for functional and structural studies as 
well as in large-scale commercial production. Some examples o f folded proteins 
produced in an industrial scale are human insulin4 for the treatment o f diabetes (Humulin, 
Eli Lilly), bovine chymosin5 for the production o f cheese (Chymax, CHR Hansen), 
interleukin-26 for the treatment o f cancer (Proleukin, Chiron) and human interferon-a27 
for leukaemia, hepatitis B and C and AIDS-related Kaposi’s sarcoma (Roferon-A, Roche; 
Intron-A, Shering-Plough).
Inhibition o f  aggregation during in vitro protein folding
When the denaturing conditions are withdrawn, most proteins undergo irreversible 
aggregation as well as folding. Inhibiting protein aggregation is fundamental to achieving 
a good folding yield. The most straightforward way o f doing so is to keep the protein 
concentration low. However, working at low protein concentrations is often not practical 
because large volumes o f folding buffer are needed and extensive concentration is 
required afterwards. Several methods have been developed in order to reduce aggregation 
while keeping the protein concentration relatively high, such strategies include:
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i. Using aggregation inhibitors in the folding buffer. Some common examples are 
arginine8, low concentrations o f chaotropes9' 13, polyethylene glycol (PEG)14'17, 
detergents (CHAPS18, Tween19, Triton20 and SDS21) and antibodies22,23.
ii. Folding in the presence o f a mixture o f protein chaperones and/or isomerases. 
Examples are immobilised GroEL, DsbA and prolyl isomerase24,25 and DsbA and 
DsbC26.
iii. Mimicking chaperone activity by adding detergent to the unfolded protein and then 
initiating folding using cyclodextrins27'30.
iv. Augmenting the total charge o f the polypeptide chains by site-directed mutagenesis
or, in the case o f proteins with cysteines, forming mixed disulphide bonds with
1
polar thiols like glutathione .
v. Folding on a solid support to prevent individual polypeptides from interacting with
17each other. This has been achieved using size-exclusion chromatography and
33 37NTA-agarose for poly-histidine tagged proteins ' .
vi. Applying high pressure to reverse aggregation38'40.
The greatest drawback o f in vitro protein folding is that suitable folding conditions seem 
to be unpredictably different for every protein. Variables such as optimal temperature, 
redox potential, pH, and ionic strength and the efficacy o f any o f the above outlined 
methodologies to inhibit aggregation, have to be found empirically. This process is 
usually a very slow and labour intensive task, hence systematic screens that can rapidly 
assess different conditions are very valuable.
In vitro protein folding screens
The first attempt to systematise the search for in vitro folding conditions was published 
by Hofmann and co-workers41. They used a matrix o f 50 buffers for protein 
crystallisation to find suitable folding conditions for 9 enzymes using activity assays to 
quantify the folding yield. Some years latter, Chen and Gouaux42 designed a protein 
folding screen based on a fractional factorial design, which was further improved43 and 
made commercially available from Hampton Research, under the name o f Foldlt. 
Recently, Klein and co-workers published a modification o f the Gouaux screen44. Instead 
o f screening for the variables suggested in the original in vitro folding protocol, they 
screened variables they knew from experience to be significant for the folding o f the 
target protein; this flexibility is a general feature o f factorial screens and makes them 
very versatile. Tobbell and co-workers also published a slight modification of the
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Gouaux screen45, their major innovation being that they carried out a first round o f 
screening to detect the important variables, and a second round to optimise the values for 
such variables.
The Gouaux screen tests the importance for folding o f 12 variables (pH, protein 
concentration, redox potential, ionic strength and the presence o f several additives) at 
two different values for each variable (e.g. pH 6.2 and pH 8.2). The screen consists o f 16 
parallel in vitro folding experiments each one with a different combination o f values of 
the 12 variables. I f  the experimenter has some knowledge o f the characteristics and 
behaviour o f the target protein, using a large set o f fixed variables that may be beneficial, 
detrimental or neutral for the folding o f their particular protein is not an efficient strategy. 
Instead, the experimenter could select the particular variables that are expected to 
promote folding, exclude those that are known to be unfavourable and design a 
customised smaller parameter set. By doing so, fewer experiments will need to be 
performed and the probability o f achieving good yields will be higher. Recently, Pierce 
launched a fractional factorial folding screen called Pro-matrix. Pierce made explicit this 
potential o f choosing factors to screen, what they called the 'adjustable matrix'. Pro­
matrix screens the effect o f only four variables, but two o f them are chosen by the 
experimenter to suit the particular requirements o f their target protein. By running 9 
experiments, Pro-matrix screens these four variables at three different values, instead of 
only two, which provides a finer sampling o f folding conditions.
In vitro protein folding with concomitant disulphide bond formation  
Proteins that require disulphide bond formation to fold need an environment that allows 
thiol oxidation. Oxidation can utilise ambient oxygen in the air46'48, or more frequently, 
by using catalytic mixtures o f low molecular weight thiols in both their reduced and 
oxidised form49. Such a mixture is known as an oxido-shuffling system. The most 
popular oxido-shuffling reagents are oxidised and reduced glutathione (GSSG/GSH). 
Other pairs are cysteine/cystine and 2-mercaptoethanol/2-hydroxyethyldisulphide. Little 
has been reported using other redox couples. However, some more efficient reagents 
have been developed recently, including l,2-bis(mercaptoacetamido)cyclohexane 
(Vectrase-P)50 and aromatic thiols such as 4-mercaptobenzeneacetate51. These new 
molecules are able to increase both the rate o f the folding reaction and the final yield of 
folded protein. The superior performance appears to be the result o f having similar thiol 
pKa and redox potential to that of the eukaryotic protein disulphide isomerase (PDI)50’51,
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and in the case o f Vectrase-P also to the presence o f two thiol groups in the same 
molecule, which is another characteristic o f P D I52.
All oxido-shuffling reagents undergo an extensive thiol/disulphide exchange process 
with the cysteines o f the protein. First a mixed disulphide bond is formed between the 
oxido-shuffling reagent and one o f the free cysteines in the protein. Then another o f the 
protein’s cysteines displaces the oxido-shuffling reagent to form an intramolecular 
disulphide bond53,54 (Figure II. 1). The thiol/disulphide exchange is a classical 
bimolecular nucleophilic substitution ( S n 2 ) ,  where the active species is the thiolate ion 
(S')54,55. Therefore the reaction rate is favoured at basic pH values, above the pKa o f the 
sulphydryl group. The involved thiols have to be good nucleophiles to attack other thiols, 
but they also have to be good leaving groups so that they can, in turn, be displaced by 
another thiol. For this reason, the optimal pH for the reaction is close to the pKa o f the 
thiols involved52,56. Both the reduced and the oxidised forms are needed because the 
formation o f native disulphide bonds requires extensive rearrangement, so that a 
continuous cycle o f reduction and oxidation takes place until the native disulphide bonds 
are formed53. This situation has been observed not only with oxido-shuffling reagents, 
but also with the oxido-reductase chaperone machinery in bacteria57 and eukaryotes58. In 
bacteria, the oxidation o f free cysteines is performed by DsbA, while the isomerisation o f 
non-native disulphide bonds is facilitated by DsbC. Both in vivo and in vitro, the 
presence o f DsbC but not DsbA enhances the efficiency o f folding26.
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SH + H ,0
S" + RS-SR
S-SR + HX>
S-SR
RS'
+ h 3o
S-SR + RS
S-SR + K O
+ h 3ct ^  RSH
S' + RS
+ H20
F ig u re  I I . 1 R e p re s e n ta tio n  o f  th e  re a c tio n s  in v o lv e d  in  th e  fo rm a tio n  o f  p ro te in  
d is u lp h id e  b o n d s  in  th e  p r e s e n c e  o f  an  o x id o - s h u f f l i n g  p a i r  (R S H / R S S R ). 
The reaction rate is favoured at basic pH values, above the pKa o f  the involved thiol groups.
64
Choice o f  variables to screen fo r  protein folding with disulphide bondformation  
Important variables that any folding screen should include are protein concentration, 
temperature and the presence of arginine and guanidine hydrochloride (GdnHCl), which 
have been shown to be by far the most successful folding additives. Given the industrial 
and basic research importance o f in vitro protein folding, the literature describing in vitro 
folding methodologies is vast. Several reviews have been published gathering tens o f 
different conditions that have been successful for folding proteins with concomitant 
disulphide bond formation59'63. All this information is extremely valuable in choosing 
variables to screen and the values for those variables. By reviewing the literature the 
following guidelines can be established:
i. The folding buffer pH has to be basic, usually between pH 8.0 and 10.0.
ii. Substrate protein concentration ranges mainly between 10 pg/ml and 100 pg/ml.
iii. The ratio o f reduced to oxidised oxido-shuffling thiol reagent is between 10:1 and
1:1 with a reduced thiol concentration between 1 mM and 10 mM.
iv. Widely used low molecular weight folding enhancers are:
a. Arginine, at 0.4 M to 1.0 M concentration
b. Urea or GdnHCl, at 1 M to 2 M concentration
c. Polyethylene glycol (PEG)
d. Glycerol
e. Detergents (e.g. CHAPS and Triton X-100)
f. There are no general trends in folding temperature or time. These parameters 
range from 4°C to 37°C and from 1 hr to 150 hrs.
General techniques to characterise protein folding
In the quest for a folding screen that would be widely applicable, a general method to 
assess the amount o f native folded protein is a fundamental requirement. The ideal 
method to measure folding yields has to be straightforward, fast, preferably quantitative, 
and as insensitive to methodological variations as possible. These requirements rule out 
the traditional methods to quantify in vitro folding yield because they rely on substrate- 
specific methods such as catalytic activity41,43,45 or conformation-dependent antibody or 
ligand binding43,64. Heiring and Muller65 demonstrated the use o f limited proteolysis 
followed by SDS PAGE and silver staining as a universal method to distinguish between 
folded and unfolded protein, however, this method is not quantitative and requires a great 
deal o f sample manipulation, which increases the possibility o f experimental error.
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Alternatively, spectroscopic techniques such as intrinsic fluorescence66 could be used if 
readily available. In other circumstances chromatographic techniques are the method of 
choice. Armstrong and co-workers43 introduced analytical size-exclusion (SEC) 
chromatography to quantify folding yield. However, SEC is very restricted in terms of 
the sample volume size, as the elution peaks start to broaden with sample volumes larger 
that 2% the volume o f the column. Therefore, the protein concentration o f the loaded 
sample has to be fairly high in order to detect the eluted protein. As this is often not the 
case after a protein folding screen, the volume limitation is a major drawback to this 
method. Another contribution was made recently by Scheich and co-workers66, who 
quantified folding yields using hydrophobic interaction chromatography (HIC), thereby 
making use o f the fact that folded proteins are less hydrophobic than their unfolded 
counterparts. In HIC there is no restriction on the sample volume, if  the protein 
concentration is very low, it is possible to load a greater volume in order to be able to 
detect it. This enrichment aspect o f HIC is an enormous advantage over SEC.
Screening variables using factorial designs
Knowledge o f experimental design and statistical analysis is very valuable in the process 
of solving problems and interpreting the results o f experiments involving many variables. 
Among the experimental problems that can be approached using statistics, two are 
particularly relevant to the field o f recombinant protein expression and purification:
a. The selection o f conditions to maximise yields, e.g. protein solubility or protein 
expression levels, by systematic identification o f those variables that are 
important for the outcome o f a process.
b. The evaluation o f the magnitude and sources of variation in measurements with 
the aim to determine whether the data obtained truly provide information about 
the system or simply reflect experimental or measurement errors.
In screening for suitable protein folding conditions, the experimenter needs to assess the 
effect o f many variables, individually or jointly, on the final folding yield. One o f the 
ways that experimental design can address this kind o f problem is with a factorial 
experiment. A factorial strategy consists o f systematically testing the influence on the 
experimental outcome o f every possible combination o f the variables to be studied, and 
by doing so, determine which variables have an statistically significant positive or 
negative influence. Published examples o f systems that have been optimised using some 
form o f factorial screen include: protein crystallisation67,68, recombinant and endogenous
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protein expression ' , protein chromatography , cell growth ’ , and cDNA microarray
l f \signal-to-noise ratio .
As discussed above, there are many variables (termed factors1 in the experimental design 
field), that may or may not improve folding yields. These factors include protein 
concentration, temperature, time, pH, nature, ratio and concentration o f oxido-shuffling 
agents, and the presence o f folding enhancers. Despite the justifiable desire to test all 
these variables at once, when conducting a factorial screen it is important to keep the 
number o f factors low because the number o f combinations or runs needed to screen 
these factors increases rapidly, from only 4 runs for 2 factors to 256 runs for 8 factors. 
Once the factors have been chosen, two or more values (levels) for each factor have to be 
selected. The simplest factorial experiments use only two levels, usually represented by 
the signs + and -  for the extreme high and low levels o f each factor respectively. In this 
project, six factors at two levels, as shown in Table II. 1, were chosen for the factorial 
folding screen.
Illustration o f  the factorial design methodology
Table II.2 shows a set o f hypothetical results obtained for a full-factorial folding screen 
of six factors at two levels. The response, the outcome of the experiment that is to be 
measured, is the area under the peak corresponding to the oxidised, folded, protein in the 
imaginary chromatogram. The units o f the response in this case are arbitrary units o f area 
(AU). Each one o f the 64 factor-level combinations is called a run or treatment. It is an 
important requisite that runs are assayed randomly, in order to average out potential 
unaccounted influences on the experiments.
Calculation o f  main effects
The effect o f the presence of, for example, arginine (factor A) can be calculated from the 
difference in the response for run 1 and 2. The only difference between these two runs is 
that in run 2 the arginine concentration is high (A+; 0.6 M) and in run 1 its concentration 
is low (A-; 0.0 M); all of the other factors remain constant. In a similar manner, one 
could also calculate the effect o f arginine in different backgrounds by subtracting the 
response o f run 3 from 4, run 5 from 6, run 7 from 8 and so on. The main effect o f 
arginine is the average for all 32 individual effects. A simpler way o f calculating the
1 Italics will be used to introduce experimental design term inology for the first time
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same main effect is to subtract the average yield of all runs in which arginine was at its 
higher level from the average yield o f all runs in which arginine was at its lower level. 
Taking n as the number o f runs:
A rg in ine effect = y ie ld (A + ) - y ie ld ( A - )
~  64 (3595) -  624 (3247)
= 10.9 AU
In this instance, interpretation is that the presence o f arginine, at a concentration of 0.6 
M, has an average positive effect o f  10.9 AU on the yield o f folded protein. The other 
main effects can be derived in a similar manner, and their values appear in Table II.3. In 
this example, arginine, and glycerol have a positive effect on the folded protein yield and 
GdnHCl, high temperature, high pH and high protein concentration have a negative 
effect.
Calculation o f  interaction effects
If instead o f a factorial design, the experimenter used a 'change-one-factor-at-a-time' 
strategy, it would not be possible to tell whether the observed effect o f a particular factor 
depends at all on the fixed levels for all the other factors. In this example, the averaged 
main effect o f temperature (D) is slightly negative -1.9, meaning that folding at room 
temperature (RT) instead of 4°C would reduce the yield by 1.9 AU. However, the 
average effect o f temperature when the protein concentration is low is 6.1 AU, and the 
average effect o f temperature when the protein concentration is high is -10.0 AU. At high 
protein concentration, the effect o f temperature is to dramatically decrease the yield, but 
at low protein concentration, the yield actually increases if  the experiment is performed 
at room temperature. The effects o f temperature and protein concentration depend on 
each other; they are said to be interacting. H alf the difference between the average 
temperature effect with high protein concentration and the average temperature effect 
with low protein concentration is called the 'temperature by protein concentration 
interaction ' (denoted DF using the symbols from Table II. 1). In this case DF has a value 
o f -8.1 AU. As can be seen in Table II.3, there are no other important two-factor 
interaction effects.
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Table 11.1 Factors and levels for the in vitro folding screen
Factor Level+ -
A [Arginine] 0.6 M 0.0 M
B [Guanidine HC1] 0.5 M 0.0 M
C [Glycerol] (w/v) 20% 0%
D Temperature Room temp 4°C
E pH 9.0 8.0
F Protein concentration 0.2 mg/ml 0.1 mg/ml
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Table II.2 Design matrix for a 2 6 full-factorial in vitro folding screen and hypothetical experimental results
Run
Factor* Area**
2
S Run
Factor Area
2
SA B C D E F Order* R1 R2 Average A B C D E F Order * R1 R2 Average
1 14 108 112 110 8 33 + 19 100 104 102 8
2 + 61 127 123 125 8 34 + - - - - + 6 111 105 108 18
3 - + - - - - 60 112 112 112 0 35 - + - - + 10 90 94 92 8
4 + + - - - - 38 120 124 122 8 36 + + - - - + 1 108 102 105 18
5 - - + - - - 33 121 113 117 32 37 - - + - - + 43 93 85 89 32
6 + - + - - - 55 121 127 124 18 38 + - + - - + 27 96 104 100 32
7 - + + - - - 13 116 108 112 32 39 - + + - - + 59 86 96 91 50
8 + + + - - - 8 125 129 127 8 40 + + + - - + 62 106 100 103 18
9 - - - + - - 16 110 120 115 50 41 - - - + - + 31 88 82 85 18
10 + - - + - - 50 135 125 130 50 42 + - - + - + 11 87 89 88 2
11 - + - + - - 56 112 124 118 72 43 - + - + - + 28 73 85 79 72
12 + + - + - - 48 141 125 133 128 44 + + - + - + 58 91 87 89 8
13 - - + + - - 51 117 121 119 8 45 - - + + - + 35 89 85 87 8
14 + - + + - - 29 137 127 132 50 46 + - + + - + 20 93 85 89 32
15 - + + + - - 37 114 128 121 98 47 - + + + - + 17 82 88 85 18
16 + + + + - - 30 128 130 129 2 48 + + + + - + 42 90 86 88 8
17 - - - - + - 45 110 116 113 18 49 - - - - + + 4 93 87 90 18
18 + - - - + - 40 124 120 122 8 50 + - - - + + 7 106 102 104 8
19 - + - - + - 3 110 102 106 32 51 - + - - + + 12 86 98 92 72
20 + + - - + - 47 121 125 123 8 52 + + - - + + 32 100 104 102 8
21 - - + - + - 24 111 117 114 18 53 - - + - + + 25 99 91 95 32
22 + - + - + - 9 120 124 122 8 54 + - + - + + 23 107 101 104 18
23 - + + - + - 21 103 111 107 32 55 - + + - + + 53 99 93 96 18
24 + + + - + - 18 126 120 123 18 56 + + + - + + 22 105 95 100 50
25 - - - + + - 5 117 115 116 2 57 - - - + + + 49 80 90 85 50
26 + - - + + - 52 124 130 127 18 58 + - - + + + 26 95 89 92 18
27 - + - + + - 57 117 111 114 18 59 - + - + + + 34 86 82 84 8
28 + + - + + - 36 131 127 129 8 60 + + - + + + 46 98 90 94 32
29 - - + + + - 2 124 112 118 72 61 - - + + + + 39 80 84 82 8
30 + - + + + - 44 124 132 128 32 62 + - + + + + 63 96 90 93 18
31 - + + + + - 15 120 116 118 8 63 - + + + + + 54 80 86 83 18
32 + + + + + - 64 127 133 130 18 64 + + + + + + 41 105 115 110 50
* Factors as given in Table II. 1
** A rea under the elution peak o f  the UV absoption curve used as a measure o f  protein quantity. Given in arbitrary units, 
t  Random ised order in w hich to perform the experiments 
R1 and R2 are repeats o f  the experiment; f  is the sample variance
A quick method to calculate two and higher-factor effects is to use the table of signs that 
is shown in Table II.2. To calculate the effect o f DF, for example, one multiplies the 
signs in column D by the signs in column F by the output response value for each run. 
These results are added and finally divided by half the number o f rum.
+ 110 +  125 +  112 +  122 +  117 +  124 +  112 +  1 2 7 - 1 1 5 - 1 3 0 - 1 1 8 - . . .  _  - 2 5 8  _
^ e f f e c t  -    3 2  -  3 2  ~  '
In total, a six-factor factorial experiment has 64 effects: the average response, 6 main 
effects, and 57 interaction effects: 15 two-factor, 20 three-factor, 15 four-factor, 6 five- 
factor and 1 six-factor. However, as can be seen in Table II.3, high-order interactions, i.e. 
those involving three or more factors, are seldom significant. It is a fundamental 
empirical principle that lower order effects are more likely to be important than higher
77order effects, a feature o f these systems known as hierarchical ordering . In this manner, 
main effects tend to be more significant than two-factor interactions, which in turn tend 
to be more important than three-factor interactions, and so on.
Measuring experimental error
The standard deviation (5 ) for the effects in a factorial screen can be estimated in 
different ways. One o f them is to perform two or more complete independent 
experiments containing the full set o f runs, each one o f these complete experiments is 
known as a replicate. If  two replicates are performed, the variance (s2) for each run (i) is 
the square o f the difference (d) between the duplicate observations divided by two:
s 2 = d 2 / 2
The variance o f each effect is equal to four times the pooled run variance (the sum of the 
individual run variances divided by the number o f runs in each replicate, n) divided by 
the total number o f runs performed (N= n x number o f replicates):
4  p *
S  effects — ~
N  n
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Table II.3 Calculated effects for the 2 full-factorial in vitro folding screen
Effect (AU) Effect (AU)
1 [Arginine] (A) 10.9 + 0.9 33 BCE 0.1 + 0.9
2 [GdnHCl] (B) -0.3 ± 0.9 34 BCF 1.3 ± 0.9
3 [Glycerol] (C) 0.9 ± 0.9 35 BDE 0.9 + 0.9
4 Tem perature (D) -1.9 ± 0.9 36 BDF 0.0 + 0.9
5 pH (E) -0.3 ± 0.9 37 DEF 1.4 ± 0.9
6 [Protein] (F) ■27.2 ± 0.9 38 CDE -0.4 ± 0.9
7 AB 1.4 ± 0.9 39 CDF 1.2 ± 0.9
8 AC -0.4 ± 0.9 40 CEF 1.3 ± 0.9
9 AD -0.1 + 0.9 41 DEF 1.2 ± 0.9
10 AE 1.0 ± 0.9 42 ABCD -0.2 ± 0.9
11 AF -1.4 ± 0.9 43 ABCE 0.4 ± 0.9
12 BC 0.9 ± 0.9 44 ABCF -0.2 ± 0.9
13 BD 1.4 ± 0.9 45 ABDE 0.8 ± 0.9
14 BE 0.6 ± 0.9 46 ABDF 1.4 ± 0.9
15 BF 0.3 ± 0.9 47 ABEF -0.9 ± 0.9
16 CD 1.2 ± 0.9 48 ACDE 1.5 ± 0.9
17 CE 0.9 ± 0.9 49 ACDF 0.9 ± 0.9
18 CF -0.7 ± 0.9 50 ACEF 0.3 ± 0.9
19 DE 1.3 ± 0.9 51 ADEF 1.5 + 0.9
20 DF -8.1 ± 0.9 52 BCDE 1.4 ± 0.9
21 EF 1.9 ± 0.9 53 BCDF 0.3 ± 0.9
22 ABC 0.2 ± 0.9 54 BCEF -0.5 ± 0.9
23 ABD 0.3 + 0.9 55 BDEF 0.5 ± 0.9
24 ABE 0.6 ± 0.9 56 CDEF -1.2 ± 0.9
25 ABF 0.2 ± 0.9 57 ABCDE 0.9 ± 0.9
26 ACD 0.4 ± 0.9 58 ABCDF 0.9 ± 0.9
27 ACE 0.6 ± 0.9 59 ABCEF 1.1 ± 0.9
28 ACF 0.8 ± 0.9 60 ABDEF 0.9 ± 0.9
29 ADE 1.1 ± 0.9 61 ACDEF 1.3 ± 0.9
30 AD F -0.3 ± 0.9 62 BCDEF 0.9 ± 0.9
31 AEF 1.0 ± 0.9 63 ABCDEF -0.1 ± 0.9
32 BCD 0.0 ± 0.9 64 Average 106.90
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Figure II.2 Plot o f  main effects for the 26 full-factorial folding screen shown in Table II.3
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For the hypothetical folding screen,
2 4 1666
S  effects —
128 64
2
S effects 0 .8 1
Finally, the estimated standard error in this hypothetical experiment is the square root o f 
the effect variance, 0.9 in this case. Taking this value into account, it is evident that only 
arginine and protein concentration have a significant effect on the response (Table II.3 
and Figure II.2). As there is no evidence that arginine has a significant interaction with 
any other factor, the experimenter can therefore reliable conclude that the effect o f the 
presence o f arginine at its high level is to increase the folding yield and that this effect in 
not dependent on the other factors. The main effects o f both elevated temperature and 
higher protein concentration are negative. However these two parameters should be 
considered jointly, because the two-factor interaction effect DF has a significant value. It 
would be misleading to conclude that the effect o f temperature is to decrease the final 
yield, because, as discussed previously, the effect o f temperature is dependent on the 
protein concentration level.
Fractional factorial designs
The greatest drawback o f full factorial experiments is that as the number o f factors 
increase, the number o f runs rapidly becomes very large. A 8-factor experiment, for 
example, would require 256 runs. O f the 256 calculated effects 219 would be o f 
interactions involving three or more factors. As the hierarchical ordering principle 
indicates, these interactions would probably have little or no significance on the outcome 
o f the experiment and their calculated effects would be indistinguishable from the noise. 
'Fractional' factorial designs systematically disregard these high-order interactions, and 
by doing so they allow the screening o f large numbers o f factors in a relatively small 
number o f runs. Common fractional factorial design experiments require only 1/2, 1/4 or 
1/8 o f the experimental runs needed for a full factorial design.
A folding screen based on a half-fraction factorial design (26' 1=25=32 runs) is shown in 
Table II.4 together with the hypothetical set o f results that would have been obtained 
using this screen. The calculated effects for the main and two-factor interactions, 
obtained following the same methodology used for the full-factorial design are shown in 
Table II.5. The analysis of this reduced dataset also highlights that arginine and the
7 3
combination o f temperature and protein concentration are the important factors. 
Nevertheless, there is a loss of information. This deficit becomes evident when trying to 
calculate three or higher order interactions by multiplying the signs in the respective 
columns.
The sequence o f resultant signs obtained for the ABCE interaction by multiplying the 
signs in columns A, B, C and E for each run is:
ABCE= -t* —  -b —"b ~b — + —  + — + + — + + — + —  + — +  +  — + —  +
This result is identical to the sequence of signs for the DF interaction,
D F =  + —  ~b —~b -b — -b —  + — + + — H—b — +  —  + —+ + —+ —  +
It is said that the ABCE effect and DF effect are aliases o f each other. The value 
calculated for the effect o f DF in Table II.5 is in fact the sum o f the DF and the ABCE 
effects seen in the full factorial case (Table II.3).
DF +A B C E = -7.6 ± 1.1
Strictly speaking it is not possible to know whether the negative effect calculated in the 
fractional factorial design is due to the combined effect o f temperature and protein 
concentration, or to the combined effect o f the rest o f the factors under investigation, or 
to both. However, the hierarchical order principle states that two-factor interactions are 
probably more significant than four-factor interactions. Thus, it is reasonable to assume 
that the calculated effect is mainly due to the two factor interaction of temperature and 
pH. O f course, this assumption might not be true in the general case, and this is the risk 
that has to be taken in adopting the fractional factorial design to reduce the experimental 
effort, time and costs.
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Table II.4 Design matrix for a 2 6-1 half-fraction factorial in vitro folding screen and hypothetical experimental results
Run #
Factor Area
2
S Run #
Factor Area
2
SA B C D E F Order * R1 R2 Average A B C D E F Order * R1 R2 Average
1 1 30 108 112 110 8 17 34 - - - - + + 10 93 87 90 18
2 4 + - - - - + 8 111 105 108 18 18 35 + - - - + - 18 124 120 122 8
3 6 - + - - - + 7 90 94 92 8 19 37 - + - - + - 32 110 102 106 32
4 7 + + - - - - 5 120 124 122 8 20 40 + + - - + + 19 100 104 102 8
5 10 - - + - - + 25 93 85 89 32 21 41 - - + - + - 31 111 117 114 18
6 11 + - + - - - 1 121 127 124 18 22 44 + - + - + + 2 107 101 104 18
7 13 - + + - - - 11 116 108 112 32 23 46 - + + - + + 17 99 93 96 18
8 16 + + + - - + 15 106 100 103 18 24 47 + + + - + - 22 126 120 123 18
9 18 - - - + - + 14 88 82 85 18 25 49 - - - + + - 6 117 115 116 2
10 19 + - - + - - 23 135 125 130 50 26 52 + - - + + + 16 95 89 92 18
11 21 - + - + - - 9 112 124 118 72 27 54 - + - + + + 26 86 82 84 8
12 24 + + - + - + 29 91 87 89 8 28 55 + + - + + - 12 131 127 129 8
13 25 - - + + - - 3 117 121 119 8 29 58 - - + + + + 13 80 84 82 8
14 28 + - + + - + 24 93 85 89 32 30 59 + - + + + - 4 124 132 128 32
15 30 - + + + - + 21 82 88 85 18 31 61 - + + + + - 20 120 116 118 8
16 31 + + + + - - 28 128 130 129 2 32 64 + + + + + + 27 105 115 110 50
# Run number in the full-factorial design (Table II.2)
* Factors as given in Table II. 1
** Area under the elution peak o f the UV absoption curve used as a measure of protein quantity. Given in arbitrary units 
$ Randomised order in which to perform the experiments 
R1 and R2 are repeats o f the experiment; i  is the sample variance
Table II.5  C alculated  effects for the 2 61half-fraction factorial in vitro folding screen
Effect (AU) Effect (AU)
1 [Arginine] (A) + BCDEF 11.8 ± 1.1 17 CE + ABDF 2.4 ± 1.1
2 [GdnHCl] (B) +  ACDEF 1.0 ± 1.1 18 CF + ABDE 0.1 ± 1.1
3 [Glycerol] (C) + ABDEF 1.9 ± 1.1 19 DE +  ABCF 1.1 ± 1.1
4 Temperature (D) + ABCEF -0.9 ± 1.1 20 DF + ABCE -7.6 ± 1.1
5 pH (E) + ABCDF 0.8 ± 1.1 21 EF + ABCD 1.8 ± 1.1
6 [Protein] (F) + ABCDE -26.3 ± 1 .1 22 ABC + DEF 1.4 ± 1.1
7 AB + CDEF 0.3 ± 1.1 23 ABD + CEF 1.6 ± 1.1
8 AC + BDEF 0.1 ± 1.1 24 ABE + CDF 1.8 ± 1.1
9 AD + BCEF -0.6 ± 1.1 25 ABF + CDE -0.3 ± 1.1
10 AE + BCDF 1.3 ± 1.1 26 ACD + BEF 1.8 ± 1.1
11 AF + BCDE 0.0 ± 1.1 27 ACE + BDF 0.6 ± 1.1
12 BC + ADEF 2.4 ± 1.1 28 ACF + BDE 1.6 ± 1.1
13 BD + ACEF 1.6 ± 1.1 29 ADE + BCF 2.4 ± 1.1
14 BE + ACDF 1.5 ± 1.1 30 ADF + BCE -0.1 ± 1.1
15 BF + ACDE 1.8 ± 1.1 31 AEF +  BCD 1.0 ± 1.1
16 CD + ABEF 0.3 ± 1.1 32 Average + ABCDEF 106.9
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F igure II.3 Plot o f main effects for the 261 half-fraction factorial folding screen shown in Table II.5
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In a full factorial design, each column o f signs and each o f the 64 effects is unique. In a 
fractional factorial design all columns have one or more aliases. As can be seen in Table 
II.5, in a half-fraction design each effect has an alias. Main and two factor interactions 
are only aliased with three or higher factor interactions, and are therefore said to be clear. 
As fewer and fewer runs are performed to screen for the same number o f variables, the 
aliasing increases. A quarter-fraction design requires 16 runs to screen for 6 factors. In 
this design each effect has three aliases. The main effects are still clear, but the two- 
factor interactions are aliased with other two-factor interactions, and they are not clear. 
An eighth-fraction design requires only 8 runs to screen the same 6 factors (26'3= 23= 8 
runs). At this point, the design is heavily aliased. Each effect has eight aliases and the not 
all o f the main effects are clear, as some o f them are aliased with the two-factor 
interactions. Table II.7 displays the calculated effects for the eighth fraction factorial 
design o f Table II.6. Arginine and protein concentration are still the variables that show 
an important effect. However, at this degree o f aliasing, it is not possible to identify the 
interaction between the temperature and the protein concentration. As long as this 
limitation is kept in mind, an eighth-fraction design is a very attractive option for a 
folding screen. It provides sufficient information to shed light on the variables that have 
an important effect on the yield, and it is a good starting point from which one could, if 
considered necessary, optimise the conditions or study them in greater depth.
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Table 11.6 Design m atrix  for a 2 6 3 eigh th-fraction  fac to ria l in vitro folding 
screen and  hypothetical results
Factor* Area
Run # A B C D E F Order* R1 R2 Average s2
1 57 - - - + + + 5 80 90 85 50
2 34 + - - - - + 3 111 105 108 18
3 19 - + - - + - 8 110 102 106 32
4 12 + + - + - - 4 141 125 133 128
5 13 - - + + - - 7 117 121 119 8
6 22 + - + - + - 6 120 124 122 8
7 39 - + + - - + 1 86 96 91 50
8 64 + + + + + + 2 105 115 110 50
# Run number in the full-factorial design (Table II.2)
* Factors as given in Table II. 1
** Area under the elution peak o f the UV absoption curve used as a measure o f protein quantity. Given 
in arbitrary units.
$ Randomised order in which to perform the experiments 
R1 and R2 are repeats o f the experiment; S is the sample variance
Table 11.7 C alcu lated  effects for the 2 eighth- 
fraction  fac to rial in vitro folding screen
Effect (AU)
1 [Arginine] (A) 9.0 ± 3.3
2 [GdnHCl] (B) 0.8 ± 3.3
3 [Glycerol] (C) 1.3 ± 3.3
4 Temperature (D) + AB 2.5 ± 3.3
5 pH (E) + AC -3.5 ± 3.3
6 [Protein] (F) + BC -10.8 ± 
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Figure II.3. Plot o f  main effects for the 26 3 eighth-fraction factorial folding screen shown in Table II.6
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Experimental procedures2
E. coli expression plasm idfor hCD5dl
The expression plasmid for /zCD5dl was constructed by Dr Mark McAlister before I 
joined the Driscoll group. The construct (Figure II.5) comprises residues 25 to 134 of 
hCD5 inserted between the Ndel and Xhol restriction sites o f pET15b (Novagen). The 
vector incorporates an N-terminal hexa-histidine sequence to allow for immobilised 
metal affinity purification o f the expression product; following the tag there is a m otif for 
thrombin protease cleavage. In the pET expression system, transcription o f the 
recombinant gene is performed by the bacteriophage T7 RNA polymerase78. The 
expression hosts are lysogens o f bacteriophage ADE3. These lysogens have a 
chromosomal copy o f the T7 RNA polymerase gene under the control o f the lacUV5 
promoter. In the absence o f the disaccharide allolactose (P-Gal-(1,6)-Glc) or its non- 
hydrolysable analog isopropyl-p-D-thiogalactopyranoside (IPTG), the lacl repressor 
protein is bound to the lacUV5 promoter inhibiting transcription. Binding o f allolactose 
or IPTG reduces the affinity o f the lacl repressor for DNA and allows transcription to 
proceed. The transcription in the expression plasmid is also control via a lac operator. To 
further suppress recombinant protein expression in the absence o f IPTG, the pET15b 
plasmid also carries the coding sequence for the lacl repressor protein.
Construction o f  the E. coli expression p lasm idfor hCD5d3
The DNA encoding the whole extracellular domain o f hCD5 was a kind gift from Dr 
Marion H. Brown and Prof Neil A. Barclay at the MRC Cellular Immunology Unit, Sir 
William Dunn School o f Pathology, Oxford.
The system for prokaryotic expression chosen was ProEX HT (Invitrogen). The vector 
incorporates an N-terminal hexa-histidine sequence, followed by a tobacco etch virus 
(TEV) protease cleavage site. Transcription is performed by the endogenous bacterial
2 Full details o f the protocols are provided in Appendix A.
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RNA polymerase and initiated via the strong Trc promoter. The vector also carries a 
laclq repressor gene to suppress expression in the absence o f IPTG.
The section o f hCD5 comprising residues 269 to 374 was amplified by PCR (one cycle: 
94°C for 5 min; 30 cycles: 95°C for 30 s, 55°C for 45 s, 72°C for 2 min; one cycle: 72°C 
for 5 min) using Pfu polymerase (Stratagene), to introduce an Ncol restriction enzyme 
site at the 5 ’ end and a stop codon followed by an Xhol recognition site at the 3 ’ end. The 
primers used were the following:
Forward 5’-GAT GAT GAT GAT ccatgg GT TTC CAG CCC AAG GTG-3’
Reverse 5’-GAT GAT GAT GAT ctcgag CTA GCC TGC GGG GTT TGG ATC-3’
The PCR product was purified using the QIAquick PCR purification kit (Qiagen). The 
vector and the purified PCR product were digested at the same time with Ncol and Xhol 
and purified by gel extraction using the QIAquick Gel extraction kit (Qiagen). Ligation 
was performed overnight at 14°C using T4 DNA ligase (NEB). The ligation reactions 
were used to transform subcloning efficiency D H 5a competent cells (Invitrogen). 
Colonies were screened for the construct by colony PCR and restriction digestion. The 
sequence o f the construct (Figure II.5b) was confirmed by automated DNA sequencing 
using dRhodamine dye-terminator chemistry (Applied Biosciences). The sequencing 
reaction products were run on a Abi Prism 377 at the Ludwig Institute o f Cancer 
Research by Dr Athena Nikitopoulou. The calculated properties o f the protein product 
based on their amino acid sequence, as computed by Expasy’s ProtParam appear in Table 
II.8.
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ACD5dl ACD5d3
A ffinity tag
MSYYHHHHHH
rTEV cleavage site ACD5
DYDIPTTENL YFQGAMGFQP
ACD5
KVQSRLVGGS SICEGTVEVR QGAQWAALCD
hC D5
SSSARSSLRW EEVCREQQCG SVNSYRVLDA
ACD5
GDPTSRLFCP HQKLSQCHEL WERNSYCKKV
ACD5
FVTCQDPNPA G
Affinity tag
thrombin 
cleavage site hCDS
MGSSHHHHHH SSGLVPRGSH
ACD5
MRLSWYDPDF
QARLTRSNSK CQGQLEVYLK DGWHMVCSQS
hCD5
WGRSSKQWED PSQASKVCQR LNCGDPLSLG
hCD5
PFLVTYTPQS SIICYGQLGS FSNCSHSRND
hCDS
MCHSLGLTCL E
Figure II.5 Amino acid sequence o f  the constructs for the N-terminal (/iCD 5dl) and C-terminal 
(ACD5d3) SRCR domains o f  human leukocyte receptor CD5. The shaded regions correspond to 
the SRCR domain sequence.
Table II.8  P red icted  p roperties o f constructs
h  C D 5dl h  CD5d3
Number o f  residues 131 132
M olecular weight [kDa] 14.7 kDa 14.9 kDa
Extinction coefficient* at 280 nm 
(reduced) [M '1c m 1]
27880 24750
Extinction coefficient* at 280 nm 
(oxidised) [M‘1cm~l]
28360 25230
Theoretical pi 8.20 6.42
* Calculated with the Gill and von Hippel equation.
Gill,SC & von Hippel,PH (m 9 )A n a l. Biochem. 182(2):319-316
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Over expression in Luria-Bertani medium
E. coli BL21(DE3) cells were transformed with the expression construct, plated onto 
Petri dishes with LB/agar and 50 pg/ml carbenicillin, and grown overnight at 37°C. A 
single colony was used to inoculate 10 ml o f LB medium with 50 pg/ml carbenicillin, 
and the culture was incubated overnight at room temperature with shaking. Each o f two 
500 ml aliquots o f LB medium with 50 pg/ml carbenicillin in a 2-litre baffled flask was 
inoculated with 1 ml o f the overnight culture. The cultures were grown at 37°C with 
vigorous shaking until the OD60o reached 1.0. Protein expression was then induced by 
addition o f IPTG to a final concentration o f 1 mM. Cells were harvested 4-12 hours after 
induction by centrifugation at 6000 g for 20 min.
Over expression in ,sN-labelled minimal media fo r  1H /I5N  2D NMR 
A single freshly transformed BL21(DE3) colony was used to inoculate 10 ml of LB 
medium with 50pg/ml carbenicillin. The culture was incubated at 37°C with shaking for 
eight hours. One ml o f this culture was used to inoculate 100 ml o f minimal medium (6 
g/1 Na2H P04, 3 g/1 KH2P 0 4, 0.5 g/1 NaCl, 1 g/1 ( l5NH4)2S04, 2 g/1 D-glucose, metal salts 
and vitamins) with 50 pg/ml carbenicillin in a 500 ml baffled flask. The 100 ml culture 
was incubated overnight at 30°C with vigorous shaking. Cells were harvested by 
centrifugation at 4000 g for 30 min and resuspended in 50 ml o f fresh minimal medium. 
Each one o f four 2-litre baffled flasks with 500 ml o f 15N-labelled minimal medium with 
50 pg/ml carbenicillin was inoculated with 5 ml o f the cell suspension. The flasks were 
incubated at 37°C with vigorous shaking for 8-12 hrs. Cells were harvested by 
centrifugation at 6000 g for 20 min.
Cell disruption, and isolation and solubilisation o f  inclusion bodies
Cell pellets were resuspended in a 50 mM potassium phosphate buffer pH 7.0 with 0.1 M 
NaCl and disrupted using a French pressure cell hydraulic press. The lysate was then 
centrifuged for 30 minutes at 27,000 g. The resulting pellet was resuspended using a 
mortar and pestle type homogeniser in a 50 mM potassium phosphate buffer pH 7.0 with 
0.1 M NaCl and 2 M urea and incubated for 15 minutes at room temperature. The washed 
inclusion bodies were isolated by centrifugation at 27,000 g for 30 minutes. The pellet 
was resuspended, using a mortar and pestle type homogeniser, in 0.1 M potassium 
phosphate, 10 mM Tris-HCl, 6 M GdnHCl pH 8.0, and then incubated at room
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temperature for 2 hrs with gentle stirring. The suspension was clarified by centrifugation 
at 27,000 g for 60 minutes.
Purification o f  the expression product by immobilised metal ion affinity chromatography
Gravity-driven chromatography was carried out in denaturing conditions using Ni- 
imminodiacetic acid (IDA) agarose (His-Bind, Novagen). The resin was equilibrated at 
pH 8.0 with 5 column volumes (CV) o f the same buffer used to solubilise the inclusion 
bodies. The inclusion bodies obtained from a 0.5 litre o f culture were purified as a single 
load onto 5 ml o f resin. After loading the sample the column was washed with 10 CV of 
a buffer with the same composition but pH 6.0. The recombinant protein was eluted with 
4 CV of the buffer at pH 4.5.
Reduction o f  cysteines and isolation o f  the monomeric species by size exclusion 
chromatography
The eluate was adjusted to pH 8.5 by drop-wise addition o f 1 M NaOH and concentrated 
to 4 ml by centrifugal ultrafiltration (Vivaspin 20, Vivascience). Solid DTT (Melford 
Labs) was added to achieve a final concentration of 0.1 M and the solution was incubated 
overnight at RT with gentle stirring. SEC was performed on a 55 x 1.6 cm Superdex 75 
column (Amersham Biosciences). The column was equilibrated with a 0.1 M potassium 
phosphate buffer pH 4.5, 10 mM Tris-HCl, 6 M GdnHCl (Melford Labs). Fractions 
corresponding to the protein monomer were pooled and concentrated by centrifugal 
ultrafiltration to yield solutions above 10 mg/ml as measured by absorbance at 280 nm.
Preparation o f  denatured RNAase A and lysozyme
Lyophilised hen egg white lysozyme and bovine pancreatic ribonuclease A (RNase A) 
(both Sigma) were resuspended in a 0.1 M potassium phosphate, 10 mM Tris-HCl buffer 
pH 8.0 with 6 M GdnHCl to a final concentration around 10 mg/ml. Solid DTT was 
added to obtain a final concentration o f 0.1 M. Solutions were incubated overnight at 4°C 
with gentle stirring. Protein concentration was estimated by absorbance at 280 nm 
(Reduced lysozyme: 8=37980 M ^cm '1 and 14.3 kDa M.W; Reduced RNase A s=7680 M‘ 
^ m '1 andM .W . 13.6 kDa).
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Design o f  the oxidative folding screen
Based on bibliographic research and previous experience, the parameters selected for the 
screen were: temperature, pH, protein concentration and the presence o f three additives, 
arginine, GdnHCl and glycerol. Each o f these factors was assessed at two arbitrary 
values (levels). The values chosen for temperature were 4°C and RT and for pH were 8.0 
and 9.0. Arginine was screened at 0 and 0.6 M, GdnHCl at 0 and 0.5 M, and glycerol at 0 
and 20% (m/v). Final protein concentration was assessed at 0.1 mg/ml and 0.5 mg/ml for 
lysozyme and RNase A, and 0.1 mg/ml and 0.2 mg/ml for the hCDSdl and /*CD5d3 
constructs.
The experiment design is a two-level one-eighth fractional factorial that assesses six 
parameters using eight combinations o f levels for such parameters. The design was 
constructed following standard statistical procedures77,79. Briefly, the levels for the first 
three variables appear in every possible combination at two levels, i.e. 23= 8 
combinations. The levels for the fourth factor are the product o f the levels for the first 
and the second factors (e.g. In B1 the level for the first factor is - and the level for the 
second factor is -, the result of the multiplication is +, and this is the level for the fourth 
factor). In the same manner, the levels for the fifth factor are generated by multiplying 
the levels for the first and third factors, and the levels for the sixth factor are obtained by 
multiplying the levels for the second and third factors (Table II.9).
Oxidative folding screen
Denatured and reduced protein solutions were diluted to the appropriate concentration 
into 4-6 ml of degassed 0.1 M Tris HC1 buffer with 0.5 mM cystine and 5 mM cysteine 
and each o f the eight conditions listed in Table II.9. Samples were incubated with gentle 
stirring for 48 hrs. After centrifugation for 10 minutes at 4000 g, the 8 supernatants (3-5 
ml of each) were dialysed together against 3.5 1 of a 0.05 M potassium phosphate buffer 
pH 6.0 with 0.2 M NaCl and 1 mM EDTA.
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Table 11.9 Experimental conditions for the in vitro oxidative protein folding screen
Buffer
Factors* Conditions
A B C D E F
Arginine
[M]
Gdn HC1 
[M]
Glycerol
%
Temp pH
Protein
[mg/ml]
B1 - - - + + + 0 0 0 Room 9.0 0.5
B2 + - - - - + 0.6 0 0 4 °C 8.0 0.5
B3 - + - - + - 0 0.5 0 4 °C 9.0 0.1
B4 + + - + - - 0.6 0.5 0 Room 8.0 0.1
B5 - - + + - - 0 0 20 Room 8.0 0.1
B6 + - + - + - 0.6 0 20 4 °C 9.0 0.1
B7 - + + - - + 0 0.5 20 4 °C 8.0 0.5
B8 + + + + + + 0.6 0.5 20 Room 9.0 0.5
* A Arginine concentration [M];B Guanidine concentration [M];C Glycerol concentration (w/v) [%]J> Temperature; 
E pH; F Protein concentration [mg/ml]
Reversed-phase H P L C
Each protein solution (1 ml for lysozyme and RNase A; 2 ml for /zCD5d3 and 5 ml for 
/*CD5dl) was loaded onto a Sephasil Protein C4 (300 A, 5pm, 4.6 mm x 100 mm) 
column connected to an Akta Purifier chromatography system (Amersham Biosciences). 
Solvent A was 5% (v/v) acetonitrile with 0.1% (v/v) trifluoroacetic acid (TFA) and 
solvent B was 95% acetonitrile 0.1% TFA. After injection, unbound material was eluted 
with 100% Solvent A with a flow rate of 2 ml/min for 2 CV. Protein was then eluted with 
a linear gradient from 0 to 45% Solvent B within 9 CV. Protein concentration was 
monitored by measuring absorbance at 220 and 280 nm.
Peak integration
Peak area was calculated using the Unicom 4.0 software package (Amersham 
Biosciences). The elution volume range corresponding to each peak was set manually 
and was the same for all runs. Baseline calculation was performed automatically using 
the morphological algorithm implemented in the Unicom package.
Non-denaturing polyacrylamide gel electrophoresis fo r  basic proteins
The protocol used is an adaptation o f the method for non-denaturing polyacrylamide gel 
electrophoresis (PAGE) for basic proteins described by D.P. Goldenberg80. The main 
difference was that ammonium persulphate (APS) was used instead o f riboflavin to 
catalyse the polymerisation o f acrylamide. APS can potentially oxidise the loaded protein 
samples and it is important to remove it once the gel has cast. In order to remove the APS 
gels were then pre-run at 30 mA for 2 hrs. The separating gel was 15% acrylamide, 0.4% 
bisacrylamide with an acetate buffer pH 4.0, and the stacking gel was 2.5% acrylamide, 
0.3% bisacrylamide with an acetate buffer pH 5.0. Gels were 1.5 mm thick in order to 
prevent band distortion. The electrode buffer was 0.4 M P-alanine pH 4.0. After pre­
running, tracking dye (50% glycerol, 0.2% methyl green) was added to the samples 
before loading. Electrophoresis was carried out at 10 mA for 3 hrs. Gels were stained 
with Coomassie blue.
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Preparative fold ing and purification ofhC D 5dl
The inclusion bodies obtained from a 2-litre culture were purified and reduced, as 
described for the folding screen, and then diluted into 200 ml o f the buffer for run B6 
(0.1 M Tris pH 9.0 with 0.6 M arginine, 20% glycerol, 5 mM cysteine, 0.5 mM cystine at 
4°C). Unfolded and reduced protein was added to the folding buffer in up to 4 steps, one 
addition every 2 hrs81. Each of the additions increased the protein concentration by 0.05 
mg/ml. 48 hrs after the last addition, the protein solution was concentrated to an 
approximate final volume o f 30 ml using a ultrafiltration stirred cell with a membrane 
with a molecular weight cut-off o f 3kDa (Amicon, Millipore). Extensive dialysis to 
remove the arginine was performed against 0.05 M potassium phosphate buffer pH 6.0 
with 0.2 M NaCl, 1 mM EDTA and 0.1% NaN 3 . The solution was concentrated to -20  
ml using the stirred cell and then to ~1.5 ml by centrifugal ultrafiltration (Vivaspin 20, 
Vivascience), then loaded onto the Superdex 75 SEC column equilibrated in the same 
potassium phosphate buffer. Fractions containing the monomer were pooled and 
concentrated to -0 .5  ml.
Preparative folding and purification ofhCD5d3
The methodology was very similar to that used for /zCD5dl except that the folding buffer 
was that used for run B4 (0.1 M Tris pH 8.0 with 0.6 M arginine, 0.5 M Gdn HC1, 5 mM 
cysteine, 0.5 mM cystine at RT).
Nuclear magnetic resonance spectroscopy
Native and in vitro folded proteins were dissolved in 0.05M potassium phosphate buffer 
pH 6.0 with 0.2 M NaCl, 1 mM EDTA and 0.1% NaN 3 . Unfolded and reduced samples 
were dissolved in 0.05M potassium phosphate buffer pH 8.0 with 6 M Gdn HC1 and 0.1 
M DTT.
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NMR spectra were acquired by Dr Richard Harris on either a Varian UnityPlus or 
Unity INOVA spectrometer, operating at nominal ’H frequencies o f 500 MHz and 600 
MHz respectively. ID spectra were recorded with 4096 complex data points with a 
spectral width o f 10 kHz. The 2D ’H -^N  HSQC of /*CD5dl was recorded with 256 
complex points and a spectral width o f 4 kHz in the *H dimension and 242 complex 
points and a spectral width o f 1,600 Hz in the ,5N dimension. For /zCD5d3, the 2D *H- 
15N HSQC was recorded with 1024 complex points and a spectral width o f 4 kHz in the 
!H dimension and in the 15N dimension 192 complex points were recorded with a spectral 
width o f 1.6 kHz. Chemical shifts were indirectly referenced to sodium 2,2-dimethyl-2- 
silane-pentane-5-sulphonate (DSS) using absolute frequency ratios for the *H signals 82. 
NMR data were processed using NMRpipe/NMRDraw83. The figures o f the 2D
84experiments (Figure II. 12) where made with the Plot2 program o f AZARA .
Results
Analysis o f  the data obtainedfrom the folding screen
The unfolded and reduced proteins were set to fold by diluting them into the eight 
different conditions o f the screen (Table 9). After 48 hours, the samples were dialysed 
against 50 mM potassium phosphate buffer pH 6.0, 0.2 M NaCl, 1 mM EDTA, 0.1% 
NaN 3 (w/v). Some o f the folding buffers underwent considerable osmosis when dialysed 
because o f the high concentration o f arginine and/or GdnHCl, as a result, the volume of 
most o f the runs increased. Dialysed samples were injected into a C4 RP-HPLC column 
and eluted with an increasing linear gradient o f acetonitrile. Peak areas were computed 
and used as the measure for protein quantity. In order to compare folding yields among 
runs, peak areas were normalised taking into account the changes in volume (V) as well 
as the difference in nominal initial protein concentration, these normalisation factors 
appear in the tables o f results. The same volume o f protein solution for each o f the four 
proteins was always injected into the column, however if  the concentration o f protein 
was so high as to saturate the detector, dilutions o f the dialysed samples were injected in 
order to obtain accurate data. To account for deliberate dilution and changes in volume 
during dialysis, the formula to obtain the normalisation factor was:
XT . • , • r  . ^ a f te r  dialysis X ^ a f te r  dilutionNormalisation factor = ------------------ -----------------------------
V x C x Vbefore dialysis initial v before dilution
The calculation o f effects was performed as explained in the Introduction. Every factor, 
appears in its + level in four o f the eight conditions, and in the other four, it appears in its 
-  level. The value for the effect is then one quarter o f the sum of the results for the runs 
in which the factor is its + level, minus one quarter o f the sum o f the results for the runs 
in which the factor is in its -  level:
V  runs with X(+) - V  runs with X(-)
Effect o f X = — -----------------------—-------------------
4
For the model proteins, a rough estimation o f the percentage yield was also obtained. In 
order to estimate the amount o f refolded protein present, a known mass o f native protein 
was injected onto the RP-HLPC column and the area o f the elution peak was compared 
to the area o f the peaks obtained in the in vitro folding experiments.
Oxidative folding screen fo r  RNase A
Bovine pancreatic ribonuclease A (EC 3.1.27.5) is probably the best studied protein in in 
vitro folding experiments. It is a monomeric 13.7 kDa secreted enzyme with four 
disulphide bonds and a pi o f 9.4585. RNase A was able to fold in all o f the screen 
conditions with yields o f between 40% and 80%. The best conditions were in runs B3, 
B4, B6 and B8 with yields between 70% and 80%. (Figure II.6; Table 11.10). The only 
parameter that appeared to reduce the yield was high protein concentration. On the other 
hand, the presence o f both arginine and guanidine hydrochloride had a positive influence 
on the yield. There is also a slight positive effect for high pH. The influences o f glycerol 
and temperature are not distinguishable from the experimental error.
Oxidative folding screen fo r  lysozyme
Hen egg white lysozyme (EC 3.2.1.17 is a secreted 14.4 kDa monomeric protein with 
four disulphide bonds and a pi o f 1 1.086. Lysozyme refolded in buffers B3, B4, B6 and 
B8, with yields between 20% and 67%. The analysis o f the effects showed that the 
detrimental factors to folding were high protein concentration and higher temperature 
while the presence o f arginine and a pH value o f 9.0 had a positive effect on the yield, as 
did GdnHCl but to a lesser extent. The influence o f glycerol was negligible (Figure II.7; 
Table 11.11).
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Figure II.6 Results o f  oxidative refolding screen for RNase A.
(A) RP-HPLC analysis for quantifing refolding yield for different refolding conditions. Ordered 
by increasing area under the curve.
(B) Normalised area under the curve o f  the RP-HPLC chromatogram for each o f  the eight sets o f  
conditions (Table II. 10a).
(C) Main effects o f  each o f the six factors (data in Table II. 10b).
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F igu re  II.7  Results o f  oxidative refolding screen for lysozyme.
(A) RP-HPLC analysis for quantifing refolding yield for different refolding conditions. Ordered 
by increasing area under the curve.
(B) Norm alised area under the curve o f  the RP-HPLC chromatogram for each o f  the eight sets o f  
conditions (Table II. 1 la).
(C) M ain effects o f  each o f the six factors (data in Table II. 11 b).
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Table 11.10a O xidative refolding screen results for RNase A
R un1
Replicate 1 Replicate 2 Replicate 3 Average
relative
yield s*
Refolding 
yield (%)NF2 A rea3
Relative
yield4
NF
Peak
area
Relative
yield
NF
Peak
area
Relative
yield
B1 10.00 24.68 246.80 10.00 27.19 271.90 10.00 15.50 155.00 224.57 61.54 44
B2 13.00 19.00 247.00 12.50 30.16 377.00 13.00 19.09 248.17 290.72 74.72 57
B3 10.00 37.66 376.60 10.00 45.84 458.40 10.00 32.64 326.40 387.13 66.63 76
B4 13.50 31.60 426.60 13.50 32.3 436.05 13.20 27.23 359.44 407.36 41.77 80
B5 14.75 15.64 230.69 14.75 21.56 318.01 14.60 21.87 319.30 289.33 50.79 57
B6 19.00 24.66 468.54 19.50 23.25 453.38 17.00 18.64 316.88 412.93 83.53 81
B7 15.40 21.80 335.72 15.58 12.34 192.20 13.80 20.52 283.18 270.36 72.61 53
B8 20.00 21.02 420.40 20.00 21.46 429.20 20.00 18.00 360.00 403.20 37.67 79
■"Standard deviation
1 Experimental conditions for runs given in Table II.9
2 Normalization factor to account for dilution effects
3 Area under the elution peak o f the UV absorption curve used as a measure o f protein quantity
4 Relative yield is the result o f the area times the NF
Table 11.10b Estimation of main effects for RNase A
Factor
Levels
Alias Effect S- +
A Arginine [M] 0 0.6 A 85.70 ± 26
B Guadinine [M] 0 0.5 B 62.63 ± 26
C Glycerol % 0 20 C 16.51 ± 26
D Temperature [°C] 4 RT D + A B -9.17 ± 26
E pH 8.0 9.0 E + A C 42.51 ± 26
F Protein conc. [mg/ml] 0.1 0.5 F + BC -76.98 ± 26
Table 11.11 a Oxidative refolding screen results for lysozyme
Run1
Replicate 1 Replicate 2 Replicate 3 Average
relative
yield s
Refolding 
yield (%)NF2 Area3
Relative
yield4
NF
Peak
area
Relative
yield
NF
Peak
area
Relative
yield
B1 10.00 0.00 0.00 10.00 0 0.00 10.00 0.00 0.00 0.00 0.00 0
B2 13.50 20.40 275.40 35.00 7.1 248.50 14.00 7.40 103.60 209.17 92.41 12
B3 10.00 130.65 1306.50 10.00 130.38 1303.80 10.00 92.99 929.90 1180.07 216.65 67
B4 13.75 75.13 1033.04 13.75 91.74 1261.43 14.20 46.52 660.58 985.02 303.29 56
B5 15.25 0.00 0.00 15.75 0.43 6.77 15.40 0.17 2.62 3.13 3.42 0
B6 17.50 70.00 1225.00 21.00 61.16 1284.36 17.80 44.73 796.19 1101.85 266.37 63
B7 16.00 1.20 19.20 14.75 0.99 14.60 13.60 23.08 313.89 115.90 171.48 7
B8 20.50 10.51 215.46 22.50 7.09 159.53 19.60 27.41 537.24 304.07 203.85 17
* Standard deviation
1 Experimental conditions for runs given in Table II.9
2 Normalization factor to account for dilution effects
3 Area under the elution peak of the UV absorption curve used as a measure of protein quantity
4 Relative yield is the result o f the area times the NF
Table 11.11 b Estimation of main effects for lysozyme
Factor Levels
— +
Alias Effect s
A Arginine [M] 0 0.6 A 325.25 ± 78
B Guadinine [M] 0 0.5 B 317.73 ± 78
C Glycerol % 0 20 C -212.32 ± 78
D Temperature [°C] 4 RT D + A B -328.69 ± 78
E pH 8.0 9.0 E + AC 318.20 ± 78
F Protein conc. [mg/ml] 0.1 0.5 F + BC -660.23 ± 78
Expression and purification o fhC D 5dl and hCD5d3
Both /*CD5 constructs expressed at high levels in BL21(DE3) cells and accumulated 
exclusively as inclusion bodies (Figures II.8a and II.9a). The expression levels reached 
their maximum at 3-4 hrs. The inclusion bodies were solubilised using 6 M GdnHCl, the 
recombinant protein was purified using immobilised metal ion affinity chromatography 
(IMAC). Samples were reduced and the monomeric species were isolated and by size- 
exclusion chromatography (SEC). Figures II.8 and II.9 show typical purification results 
for each o f the /zCD5dl and hCD53 protein products.
Early attempts to fold these two domains were made without isolating the monomer and 
the folding yields were significantly lower than those obtained after the introduction o f 
the SEC step. The efficiency o f the protein reduction step varied from batch to batch. 
Considerable amounts o f oligomers and/or high molecular weight contaminants were 
present in some batches. These disulphide-bonded oligomers and/or contaminants may 
have been responsible for the overall low in vitro folding yields. It is generally accepted 
that the folding yields are affected by the presence o f common contaminants such as
/•>  0 7  Q A
other proteins, lypopolysaccharides and nucleic acids ’ ' . However, there is evidence 
that folding yields are not always affected by the presence o f contaminants91.
Oxidative folding screen fo r  hCD5d3 and hCDSdl
After evaluating and tuning the methodology with the model proteins RNase and 
lysozyme, the folding screen was carried out for /iCD5dl and /iCD5d3. The final protein 
concentrations after dialysis were much lower than for the model proteins. As a result, in 
the case o f /zCD5d3 twice the volume was required in order to detect protein in the RP- 
HPLC eluate and in the case o f /*CD5dl five times the volume was necessary for 
detection.
Folded /iCD5d3 was detected in all the screen conditions (Table 11.13; Figure 11.11). 
Conditions with arginine gave the highest yields, and the yield with run B4 was the best 
o f all. The presence of arginine was by far the most important effect. Arginine and 
GdnHCl had a positive effect on the folding yield. Higher protein concentration was the 
most detrimental factor, whist the effect o f glycerol and temperature was negligible.
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Figure II.8 Expression and purification o f /iCD5dl.
(A) Reducing SDS-PAGE analysis o f  expression at different time points.
Lane M: molecular weight markers (kDa). Lanes 1-6: Fraction o f the cell lysate soluble in 0.05 M phosphate, 0.2 M NaCl pH 7.0.
Lanes 7-12: Fraction soluble in 8 M urea, 0.1M phosphate, 0.01 M Tris pH 8.0.
Lanes: 1 & 7, 0 min after induction; 2 & 8, 60 min; 3 & 9, 120 min; 4 & 10, 180 min; 5 & 11, 240 min; 6 & 12, 960 min.
(B) Non-reducing SDS-PAGE analysis o f purification o f unfolded protein. Lanes: M, molecular weight markers (kDa); 1, total cell fraction; 2, soluble fraction; 3, 2 M urea wash;
4, 8 M urea soluble fraction; 5, eluate from Ni(II) IMAC; 6, reduced protein; 7, monomeric fraction from SEC.
(C) Size exclusion chromatography (SEC) in denaturing conditions in Superdex 75 matrix.
(D) Non-reducing SDS-PAGE analysis o f fractions from denaturing SEC (panel C). Lane M: molecular weight markers (kDa). Other lane numbers correspond with fraction number.
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Figure 11.9 Expression and purification of/iCD5d3.
(A) Reducing SDS-PAGE analysis o f  expression at different time points.
Lane M: molecular weight markers (kDa). Lanes 1-6: Fraction o f the cell lysate soluble in 0.05 M phosphate. 0.2 M NaCl pH 7.0. Lanes 7-12: Fractions soluble in 8 M urea, 0.1 M phosphate, 
0.01 M Tris pH 8.0. Lanes: 1 & 7,0 min after induction; 2 & 8,60 min; 3 & 9 ,1 2 0 m in ;4 & 1 0 ,180 min; 5 & 11,240 min; 6 & 12,960 min.
(B) Non-reducing SDS-PAGE analysis o f purification o f unfolded protein.
Lanes: M , molecular weight markers (kDa); 1, total cell fraction; 2, soluble fraction; 3 ,2  M urea wash; 4 ,8  M urea soluble fraction; 5,eluatefrom N i(II)IM A C; 6, reduced protein;
7, monomeric fraction from SEC.
(C) Size exclusion chromatography (SEC) in denaturing conditions in Superdex 75 matrix.
(D) Non-reducing SDS-PAGE analysis o f fractions from denaturing SEC (panel C). Lane M: molecular weight markers (kDa). Other lane numbers correspond with fraction number.
In contrast to the model proteins and /*CD5d3, /zCD5dl immediately precipitated upon 
dilution into some o f the screen buffers. This straightforward qualitative observation was 
sufficient to indicate conditions that were not suitable for folding. hCD5dl was only able 
to fold in two o f the eight conditions and then with a very poor yield. Table 11.12 and 
Figure 11.10 summarise the results obtained, the effects o f the variables were not 
calculated because o f the lack o f data.
Non-denaturing polyacrylamide gel electrophoresis
Native, or non-denaturing, gel electrophoresis is a simple method that can provide 
evidence o f a change of conformation. In native conditions, the mobility o f the 
polypeptide through the gel depends on the molecular shape and the net charge. An 
unfolded protein with an extended conformation will migrate more slowly than the
on
native, globular, conformation . As all the proteins in this study are basic, the native 
PAGE was performed using a buffer system at pH 4.0 as, under these conditions, basic 
polypeptides are positively charged. Representative gels for all the studied proteins are 
shown in Figure 11.12. In all cases, the fully reduced species migrated more slowly than 
the native and/or in vitro folded species, suggesting that the shape o f the latter is more 
compact.
ID  !H  NMR spectroscopy
Folded status o f a purified protein can be assessed by one-dimensional NMR 
spectroscopy. For a flexible, unstructured, polypeptide, the frequencies at which the ’H- 
NMR signals appear, the chemical shifts, are largely determined by the nature o f the 
chemical group to which the proton is bonded. Every chemically equivalent group, for 
example, every threonine methyl group, will have a signal at a similar frequency. In the 
case o f a folded protein, the resonance frequencies depend not only on the bonding 
electrons but also on the non-bonded electrons o f the atoms that are physically close in 
space. These neighbouring groups create a unique electronic environment for each group 
o f protons, thus the signals are typically no longer equivalent and are dispersed over a 
wider range o f resonance frequencies. The neighbouring electronic environment can 
either 'shield* a nucleus from the static magnetic field provided by the spectrometer (Bo), 
or make the nucleus experience a magnetic field higher that B0 (deshielding). If  the 
nucleus is shielded the resonance frequency is lower and the signal shifts to the right of 
the spectrum. If  it is deshielded the resonance frequency is higher and the peak appears to
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Figure 11.10 Results o f oxidative refolding screen for ZiCD5d3.
(A) RP-HPLC analysis for quantifing folding yield for different folding conditions, plotted in order o f 
increasing area under the curve.
(B) Normalised area under the curve o f the RP-HPLC chromatogram for each o f  the eight sets o f 
folding conditions (Table II. 12a).
(C) Main effects o f  each o f the six factors (Table II. 12b)
Table II.12a Oxidative folding screen results for h CD5d3
R un1 N F2 A rea3 Relative yield4
B1 25 29 733
B2 32 82 2634
B3 50 31 1526
B4 68 47 3223
B5 75 12 873
B6 94 30 2773
B7 36 32 1134
B8 45 62 2795
1 E xperim en tal c o n d itio n s  fo r ru n s  g iv en  in  T ab le  II.9
2 N orm aliza tion  fac to r to  a c co u n t fo r d ilu tio n  e ffec ts
3 A rea  u n d e r the  e lu tio n  p eak  o f  th e  U V  a b so rp tio n  c u rv e  u se d  as a 
m easu re  o f  p ro te in  q uan tity
4  R elative y ie ld  is the  resu lt o f  th e  a rea  tim e s  the N F
Table II.12b Estimation of main effects for h CD5d3
Factor
Levels
Alias Effect
+
A Arginine [M] 0 0.6 A 0
B GndHCl [M] 0 0.5 B 0
C Glycerol % 0 20 C 0
D Temperature 4°C Room D + A B -111
E pH 8.0 9.0 E +  AC -10
F Protein conc. [mg/ml] 0.1 0.5 F + BC -275
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Figure 11.11 Results o f oxidative refolding screen for ACD5d 1.
(A) RP-HPLC analysis for quantifying folding yield for different folding conditions, plotted in order o f 
increasing area under the curve.
(B) Normalised area under the curve o f the RP-HPLC chromatogram for each o f  the eight sets o f 
folding conditions (Table II. 13).
Table 11.13 Oxidative folding screen results for h CD Sdl
Run1 NF2 Area3 Relative yield'
B1 5.0 0 0
B2 13.2 69 907
B3 20.0 0 0
B4 27.6 2 62
B5 28.8 0 0
B6 36.0 47 1694
B7 14.8 0 0
B8 18.0 5 90
1 Experimental conditions for runs given in Table II.9
2 Normalization factor to account for dilution effects
3 Area under the elution peak of the UV absorption curve used as a measure 
o f protein quantity
4  Relative yield is the result o f  the area times the NF
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the left o f the spectrum. In a flexible unstructured polypeptide, amino acid methyl groups 
display resonance frequencies between 2.1 and 0.8 ppm92. Signals at the right o f 0.8 ppm 
indicate the presence o f methyl groups that are shielded from the external magnetic field 
and are generally diagnostic o f ordered, globular protein structure.
ID ’H NMR spectra were recorded for the native, unfolded and in vitro re-folded samples 
o f the model proteins RNase A and lysozyme, and for the unfolded and in vitro folded 
samples o f /iCD5dl and /?CD5d3 (Figure 11.12). In each case the reduced samples in 6 M 
GdnHCl did not have disperse NMR signals, as opposed to the native and the in vitro 
folded samples that have signals below 0.8 ppm. In the case o f the model proteins, the 
native and in vitro folded samples gave very similar spectra, confirming that the native 
structure had been regained.
Preparative folding and 2D NMR ofhC D Sdl and hCD5d3
In order to prepare suitable samples for 2D NMR, 15N-labelled protein was expressed and 
purified as described in Experimental Procedures. The buffer conditions chosen to fold 
these samples were those with the best yield in the folding screen: run B6 for /?CD5dl 
and B4 for /zCD5d3. After folding and dialysis, the proteins were concentrated by 
ultrafiltration and finally purified using SEC, in order to remove any oligomers and 
traces o f the folding buffer additives. For both constructs, there was significant 
precipitation at final protein concentrations above 200 pM, indicating that the constructs 
were not very soluble in the final NMR buffer.
The ]H -15N single quantum heteronuclear coherence (HSQC) spectrum o f a protein is 
regarded, by NMR spectroscopists, as its 'fingerprint'. The 'H -^N  HSQC spectrum 
contains a signal for every proton bound to a nitrogen atom. In the ideal case, each amino 
acid residue, except proline and the N-terminus, yields one peak corresponding to its 
backbone amide group. Additionally, side chain N-H bonds amine o f His, Trp, Arg, Gin 
and Asn also give rise to signals in the spectrum. In the ]H -15N HSQC o f an unfolded 
protein the backbone NH signals appear heavily overlapped, mainly between 8.0 and 8.5 
ppm in the ]H dimension, and between 120 and 125 ppm in the I5N dimension. The ]H- 
15N HSQC spectrum of a folded protein typically shows a wider spread o f signal 
frequencies. For /iCD5dl and /iCD5d3 the JH-15N HSQC spectrum displays a broad
99
Native 6 M GdnHCI +0.1M DTT Folded in vitro Non-denaturing PAGE
Figure 11.12 High field region of 'H 1D-NMR spectra and non-denaturing PAGE before and after in vitro folding.
(A) Lysozyme; (B) RNase A; (C) hCD 5dl; (D) hCD5d3.
Native gel lanes: I. native; II. denatured with intact disulphide bonds; III. denatured with reduced disulphide bonds; IV. after in vitro folding.
range o f NMR frequencies, indicative of the presence of a folded polypeptide chain 
(Figure 11.13).
Discussion
Recombinant protein expression in bacteria is still undergoing rapid development. New 
strategies to overcome the problems associated with production o f heterologous proteins, 
such as low yield, codon bias and low solubility, are constantly coming to light. The 
expression o f proteins with native disulphide bonds has not been the exception. Three 
solutions have had particular success in this regard: exporting the expression product to 
the periplasm using a suitable signal peptide93,94; co-expression o f oxidoreductases o f the 
Dsb family, either as tandem fusion constructs with the target sequence or on their own 
in parallel95;26 and use of a suppressor strain with mutations in thioredoxin and 
glutathione reductases, which permits disulphide bond formation in the cytoplasm96'98. 
However, none o f these strategies is a panacea and folding in vitro remains a very 
valuable and powerful technique to produce native folded protein.
Benefits o f  using a factorial screen to improve folding yields
Some proteins will spontaneously fold even without application o f an intentional folding 
procedure99,100. Other proteins, perhaps the majority, require careful optimisation of 
conditions in order to fold in vitro with acceptable yield. There are many parameters than 
can influence the success o f an in vitro folding procedure, and the nature o f these 
influences is still unpredictable. Usually, the approach that is taken to find suitable 
folding conditions is to change one parameter at a time while keeping the others 
constant13,34,66,101' 103. There are flaws with this strategy, as is well understood by 
statisticians and industrial chemists. The nature o f this problem, in the context o f in vitro 
protein folding, was highlighted many years ago by Ahn and co-workers104. They 
realised that for the folding o f the Pseudomonas fluorescences lipase, the optimal 
concentration o f GdnHCl depended on the buffer pH and the protein concentration. Often 
the most favourable value for one factor varies when the value o f another factor is 
changed. A one-factor-at-a-time strategy will probably fail if  the optimal value for any of 
the variables involved depends on the value o f another variable. The conclusions 
obtained from one-factor-at-a-time-experiments are not general, and they may not be
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Figure 11.13
(A) 'H-ISN HSQC spectrum o f /iCD5dl at 278K in 50 mM potassium phosphate pH 6.0, 0.2 M NaCl, recorded at 500 MHz
(B) 'H-ISN HSQC spectrum o f ACD5d3 at 278K in 50 mM potassium phosphate pH 8.0, 0.2 M NaCl, recorded at 600 MHz
reproduced if  any o f  the other parameters is changed77,79. A factorial design is a better 
way to screen conditions efficiently and effectively. This strategy explicitly takes into 
account the possibility that the factors studied might not be independent of each other. 
Even if  they are independent, the utility o f a factorial design is that it requires fewer 
experiments than the one-factor-at-a-time approach to achieve good precision in the 
estimation of the effects. In their original paper on their fractional factorial screen for in 
vitro folding Chen and Gouaux42 showed how time-consuming it can be to develop a 
'rational step-by-step' methodology when compared with a factorial screen. In my 
experience, trying to find suitable folding conditions using a trial-an-error approach 
instead o f a factorial screen was not only excessively time consuming but also fruitless.
Advantages and drawbacks o f  the screen
The design for the oxidative folding screen described here is a one-eighth fractional 
screen, which investigates the effect o f six variables by running only eight combinations 
o f such variables. A design like this is appealing because it provides information on 
many parameters with a relatively small effort. It is ideal for an initial screen for relevant 
factors that influence yield, when little or no information is available for a particular 
system a priori. Once the important parameters are identified, further improvements on 
the folding conditions can be achieved in a second round screen, also by factorial 
designs, but performing a more focussed analysis on a smaller set o f factors in order to 
find the values for such parameters that optimise the experimental outcome.
The screen was designed in such a way that the first three factors, the additives, were not 
aliased, i.e. their calculated effect is due to their presence and not to a combination o f the 
other parameters. However, as stated in the Introduction, the calculated effects for the 
other factors have to be treated with caution because the design is highly aliased. In the 
particular case o f the screen described here, this means that it is not possible to know for 
certain whether the calculated effect for the last three factors: temperature (D), pH (E) 
and protein concentration (F), is due to the factors themselves or due to the combination 
o f two of the first three factors: arginine (A), glutathione (B) and glycerol (C). 
Temperature is aliased with the joint effect, if any, o f arginine and GdnHCl (AB); pH is 
aliased with the joint effect o f  arginine and glycerol (AC), and protein concentration is 
aliased with the joint effect o f GdnHCl and glycerol (BC). I f  there evidence to support 
the existence o f any o f these joint effects, it should be investigated further. Heavy 
aliasing and the limited success in analysing individual effects does not negate the fact
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that by this method the experimenter is able to find a set o f conditions that produces 
natively folded protein with an acceptable yield, even if  each and every parameter is not 
completely optimised.
A factorial screen should be regarded as a very malleable methodology. If  the particular 
set o f factors described here does not give the desired results, the values or the 
parameters to screen can be simply changed. Other parameters that might be tested are 
the ratio o f redox shuffling reagents and the presence o f PEG. The proposed levels and 
factors should not be regarded as permanently fixed, what is important is to become 
familiar with the theory and methodology o f factorial designs, and use this knowledge to 
tailor the screen to suit particular needs. Once this technique has been set up and the 
experimenter has become dextrous in its implementation, it takes only one week from 
expressing a protein construct as inclusion bodies to having evidence that the construct is 
able to fold.
Importance o f  general methods to characterise folding
The efficient evaluation of different folding strategies and the ability o f a great variety o f 
additives to prevent aggregation requires a systematic method to quantify folded protein 
yields. This task is straightforward if  the protein has a quantitative biological assay, such 
as catalytic activity, ligand binding or conformation-dependent antibody binding. When 
none o f these methods exist for the target protein, or if  many different proteins need to be 
tested, it is paramount to set up a robust general technique which allows not only to 
quantify, but also to distinguish between folded and unfolded protein. Chromatography 
and spectroscopy have proven to be useful as general detection methods for protein 
folding. The former methodology might be more attractive because it is readily available 
in any protein biochemistry laboratory. Previously two different chromatographic 
methods sensitive to changes in protein conformation have been reported to be 
applicable: analytical SEC and analytical HIC. The folding o f disulphide-bonded proteins 
can also be assessed by analytical RPC. Both HIC and RPC are based on non-polar 
interactions between the matrix and the solvent-exposed groups in the protein. However, 
in RPC the interaction between the matrix and the protein is stronger than in HIC, and 
non-polar solvents are required for elution, while in HIC elution can be achieved using a 
decreasing gradient o f salt concentration105. Proteins usually unfold in RPC conditions 
due to the presence of organic solvent and the acidic pH. However, if  disulphide bonds 
hold the polypeptide chain in a compact state, the hydrophobic core is not completely
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exposed upon denaturation without reduction, and the resulting conformation is still less 
hydrophobic than the fully unfolded species without the native disulphides. Evidence 
suggests that, after RPC disulphide-bonded proteins tend to refold readily once the 
organic solvent has been removed4,106"108. RP-HPLC has been used extensively to 
monitor protein folding in kinetic experiments and to identify the presence o f the 
oxidised protein26,109,110, and at least once to quantify folding yields103. Protein samples 
from folding experiments are often highly dilute, and protein cannot be detected in small 
loading volumes without prior concentration. In both HIC and RPC the sample volume is 
not a limiting factor as protein is retained and concentrated on the column matrix before 
elution conditions are applied. This feature is a big advantage for HIC and RPC over 
SEC, which requires small sample loading volumes. This aspect was crucial in the case 
o f /*CD5dl and //CD5d3 whose folding yields using un-optimised conditions are very 
low. In order to detect any protein it was necessary to load 5-ml and 2-ml sample 
volumes, respectively, onto the analytical RP-HPLC column. In contrast, in applications 
of analytical SEC the loading volume should be limited to 200 pi.
When using chromatographic techniques for protein quantification it is important to 
ensure that the calculated peak areas truly reflect the amount o f protein present in the 
samples. Peak shapes and baseline profiles greatly affect the accuracy o f peak 
integration, and this issue was a major concern during this work, as the elution peaks 
from some runs had uneven profiles, most likely because there were intermediate folding 
species present. The problem was ameliorated by defining the elution time boundaries o f 
the peaks manually and using the same boundaries for all the runs of the same protein, 
but this is a problem that requires more attention because it is vital for accurate 
quantification. An alternative to explore is to use maximum peak height as the 
quantifying parameter instead o f peak area. The solvent gradient and the column matrix 
used could also be thoroughly optimised in order to obtain better resolution, however, 
this would probably make each measurement more time-consuming. It would also be 
valuable to ensure that there is a linear response between quantity o f protein and peak 
area/height and to apply typical analytical chemistry strategies such as using an internal 
standard to account for unanticipated variations in the injection volume.
In the folding screen described in this project, non-denaturing gel electrophoresis was a 
useful method to detect changes in protein conformation. It is a simple and inexpensive 
technique and, as with chromatography, the necessary equipment is already found in
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every biochemistry laboratory. The technique provides qualitative information on the 
degree o f compactness o f the polypeptide chain. An extended unfolded conformation will 
have reduced electrophoretic mobility compared to a folded globular entity. If  the folded 
sample does migrate further than the unfolded protein, further investigation is justified, 
e.g. preparation o f a sample for NMR experiments,
Refolding o f  lysozyme and RNase A
Model proteins provide a frame o f reference when dealing with unfamiliar problems. 
However, the characteristic response that they show should be treated with reservation 
because they often represent the best case scenario. The wide range o f conditions in 
which the two model proteins folded may correlate with the fact that they are secreted 
enzymes, evolutionary selected for their robustness, thermodynamic stability and 
solubility. RNase A was only marginally affected by the changes in the folding 
conditions and could refold to a greater or lesser extent in all buffers that were sampled 
(Figure II.6B). Lysozyme required low protein concentrations and arginine and/or 
GdnHCl to refold (Table II. 1 lb). As expected, in both cases the most detrimental effect 
was high concentration of protein. The fact that high pH seemed to improve the folding 
yield has to be taken with caution, since this factor was aliased with the two-factor effect 
o f arginine and glycerol, and arginine was the most beneficial factor (Tables 11.10 and 
11.11)
Folding o f  hCD5d l and hCD5d3
The oxidative folding screen was successful in rapidly finding suitable folding conditions 
for both hCD5dl and hCD5d3, albeit with much lower yields than for the model 
proteins. The ]H -15N HSQC spectra proved that after in vitro folding, both constructs 
have, at least at some degree, a three dimensional structure as judged by the chemical 
shift dispersion o f the NMR signals. Although the final concentration o f  protein obtained 
was enough to obtain a HSQC spectrum, at least five times higher concentration will be 
necessary to perform the NMR experiments needed for the assignment o f the signals and 
structure determination. The low concentration could be a result o f  low folding yields or 
intrinsic low protein solubility. If  the latter was the case, the composition o f the NMR 
buffer needs to be optimised. It may be o f benefit to study the use o f fractional factorial 
screens to solve this particular problem.
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To summarise, a novel screen to find suitable in vitro folding conditions for disulphide- 
bonded proteins was designed. The screen is based on a fractional factorial design that 
allows to systematically screen 6 different variables in 8 trial experiments. In each trial, 
in vitro folding is attempted by diluting the unfolded and reduced protein into a buffer 
consisting of a specific combination o f such 6 variables. Folding yield is then assessed 
using RP-HPLC and non-denaturing gel electrophoresis. The screen was tested and 
optimised with RNase A and lysozyme and then used to find suitable in vitro folding 
conditions for two o f the three extracellular domains o f human leukocyte receptor CD5 
(7zCD5dl and /*CD5d3). NMR experiments confirmed that the in vitro folded ACD5dl 
and /zCD5d3 have a compact 3D structure. However, both CD5 domains appear to have 
intrinsic low solubility in the final NMR buffer and at this point are unsuitable for 
structure determination by NMR.
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__________________________ Chapter Three
Improvement of solubility and in vitro oxidative folding 
yield of the N-terminal domain of human CD5 by site- 
directed mutagenesis
Abstract
The poor solubility o f the N-terminal domain o f human CD5 (/zCD5dl) expressed in 
Escherichia coli makes it unsuitable for structural studies. Replacing hydrophobic 
residues for polar amino acids to improve solubility has been successful in other cases 
and this approach has been adopted here. In order to find target residues for substitution, 
the amino acid sequence o f /zCD5dl was compared with orthologue sequences and with 
that o f the scavenger receptor cysteine-rich domain o f Mac-2 binding protein, the only 
homologous structure known at that time. Eight single mutations were introduced in 
positions that were occupied by non-polar residues in /iCD5dl and by polar residues in 
at least one of the other sequences. Similarly to the wild type /zCD5dl, the eight single 
mutants expressed in high yields as inclusion bodies. However, the in vitro folding yield 
o f four o f the mutants was higher than that o f the wild type. The best two variants were 
combined in a double substitution mutant: V88D/V97K /zCD5dl. The folding yield of 
this double mutant is four times higher than the wild type. Furthermore this new variant 
could be concentrated to more than 1.0 mM, making V88D/V97K /zCD5dl appropriate 
for structural studies by multidimensional NMR.
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Chapter abbreviations and acronyms 
3D three-dimensional 
e molar extinction coefficient 
p Spearman correlation coefficient 
ANOVA analysis o f variance 
GdnHCl guanidine hydrochloride 
/iC D 5dl N-terminal SRCR domain o f CD5 
HPLC high performance liquid chromatography 
HSQC heteronuclear single quantum coherence 
1PTG isopropyl-P-D-thiogalactopyranoside
M 2BP Mac-2 binding protein 
NMR nuclear magnetic resonance 
PDB Protein Data Bank 
RPC reversed phase chromatography 
SEC size-exclusion chromatography 
SRCR scavenger receptor cysteine-rich 
WT wild type
Introduction
The attainment o f high protein concentrations is paramount in structural biology. 
Crystallisation trials require protein concentrations ranging from around 2 mg/ml to 20 
mg/ml. Multidimensional NMR experiments typically require protein concentrations o f 
at least 0.5 mM and preferentially greater that 1 mM, in order to detect signals in some o f 
the intrinsically insensitive experiments required for resonance assignment. Particularly 
for NMR, a considerable amount o f time is spent in optimising the solution composition 
to maximise protein solubility. Frequently, even at optimal solubility conditions, the 
required protein concentration cannot be achieved, and can become necessary to make 
modifications to the protein sequence in order to enhance solubility.
Amino acid substitution has proved to be a powerful technique for manipulating the
stability and solubility o f recombinant proteins. The technique has been used mainly to
reduce the formation o f inclusion bodies, but also to enhance the stability and/or
solubility o f purified proteins. The improvement o f the yield o f soluble protein in vivo
using random mutagenesis and an appropriate selection criterion has become a popular
technique in structural genomics initiatives. The solubility o f the mutant proteins is
assessed in vivo by means o f a gene fusion reporter system, such as the fluorescence
emitted by the green fluorescent protein1, the resistance to antibiotic conferred by the
choramphenicol acetyltransferase2 or the development o f blue colour as a result o f the
hydrolysis o f X-Gal (5-bromo-4-chloro-3-indolyl-|3-galactopyranoside) by J3-
galactosidase3. However, to set up a successful 'directed evolution' protocol often
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requires a considerable amount o f time and effort and may necessitate some degree of 
automation to attain a good mutation rate.
In small scale protein expression projects, the rational design of mutations may be a more 
efficient strategy to follow. A very useful approach has been to substitute solvent- 
exposed hydrophobic residues for hydrophilic amino acids. This approach has been 
successful in enhancing the yield o f correctly folded protein in vivo4'7 and in improving 
the solubility o f purified proteins8' 12. Even in the absence o f structural information to
evaluate solvent accessibility, groups have succeeded in using this approach by
£
exhaustively replacing hydrophobic residues . The construction o f large sets o f mutants 
has become a relatively straightforward task, because o f the availability o f efficient 
commercial site-directed mutagenesis kits that do not require the DNA of interest to be 
subcloned in specific vectors or necessitate the isolation o f single-stranded DNA. 
Nevertheless, to maximise the efficiency of this approach it is sensible to more precisely 
target the mutation sites by comparing the target protein amino acid sequence with 
orthologue sequences. The analysis o f a multiple sequence alignment highlights 
conserved hydrophobic residues, these are likely to be involved in the hydrophobic 
packing o f the core o f the protein and therefore are not appropriate for mutation to 
improve solubility. On the other hand, residues that are hydrophobic in the target 
sequence but hydrophilic in an orthologue are good candidates for mutation, as they have 
a high likelihood o f preserving the fold and enhancing solubility. This approach has been 
successfully applied for the catalytic domain o f p -1,4-galactosyltransferase l 10 and the 
adhesion domain o f CD588. If available, the analysis o f the 3D structure of a homologous 
fold can provide additional information about any particular residue's likely solvent 
accessibility and help identify residues with an important structural role that should not 
be altered7,8,11.
In the previous Chapter, I reported the expression, purification and optimisation o f the in 
vitro folding conditions for a construct o f the N-terminal scavenger receptor cysteine-rich 
domain o f human leukocyte receptor CD5 (7zCD5dl). However, the success o f this work 
was limited, because even the optimised folding yields were low overall and it was not 
possible to concentrate the folded /zCD5dl to higher than 0.3 mM, whereas a 
concentration around 1 mM is preferred to attempt structure determination. In this 
Chapter, I describe the improvement o f /zCD5dl solubility and in vitro folding yield
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using a directed mutagenesis approach. Some observations on the in vitro folding 
kinetics o f the enhanced solubility mutant are also presented.
Experimental procedures1
Design o fhC D 5dl mutants
In order to identify target residues for mutation, the amino acid sequence o f /zCD5dl was 
aligned with the orthologue sequences for other mammals using ClustalW13. Amino acid 
sequences were obtained from the SwissProt and Entrez protein sequence databases: 
mouse CD5 (SP, P13379), rat CD5 (SP, P51882), cow CD5 (SP, P19238) and sheep CD5 
(EP, 147074). The CD5dl sequences were manually aligned with the sequence for the 
scavenger receptor cysteine-rich (SRCR) domain o f Mac-2 binding protein14 (M2BP 
SRCR; PDB code lby2), the only homologous structure known at that time. Residue by 
residue side chain solvent accessibilities for the M2BP structure were calculated using 
the program NACCESS15.
Site-directed mutagenesis
Mutants o f the construct comprising residues 25 to 134 o f hCD5 (/zCD5dl) were made 
using the QuickChange Site-Directed Mutagenesis kit (Stratagene), following the 
manufacturer’s instructions. Oligonucleotides were purchased from MWG-Biotech AG 
(see Appendix B for sequences). E. coli XL 1-Blue cells were transformed with the 
mutagenesis products and plasmid DNA was isolated from 10 ml o f an overnight cell 
culture using the Qiaprep spin Miniprep kit (Qiagen). The presence o f the mutations was 
verified by automated DNA sequencing using dRhodamine dye-terminator chemistry 
(Applied Biosciences). The sequencing reaction products were run on an Abi Prism 377 
sequencer at the Ludwig Institute o f Cancer Research by Dr Athena Nikitopoulou.
1 Full details o f  the protocols are provided in Appendix A.
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Overexpression and purification ofhC D 5dl mutants
The methodology for the production o f mutant /zCD5dl protein products was the same as 
that described for the wild type protein in Chapter II. Briefly, each o f two 500 ml of LB 
medium with 50pg/ml carbenicillin in a 2-litre baffled flask was inoculated with 1 ml o f 
an overnight culture grown at room temperature with shaking. The cultures were 
incubated at 37 °C with vigorous shaking until the OD6 0 0  reached 1.0. Protein expression 
was then induced by addition o f IPTG to a final concentration o f 1 mM. Cells were 
harvested 4-12 hours after induction by centrifugation, resuspended, and lysed using a 
French pressure cell. The inclusion bodies were isolated by centrifugation, washed and 
solubilised in 6 M guanidine hydrochloride. The overexpression product was purified by 
immobilised metal ion affinity chromatography in denaturing conditions and elution was 
achieved by reducing the buffer pH to 4.5. The eluate was reduced with 0.1 M DTT. The 
/zCD5dl monomer was finally isolated by size-exclusion chromatography (SEC) under 
denaturing conditions.
For the production o f 15N-labelled samples, 1 ml of an 8-hour culture in LB with 50pg/ml 
carbenicillin was used to inoculate 100 ml of unlabelled M9 minimal medium with 
supplements and antibiotic. The cultures were incubated overnight at 30 °C with shaking. 
Cells were harvested by centrifugation and resuspended in fresh minimal medium. A 
volume equivalent to 10 ml o f the overnight culture was used to inoculate 500 ml of 15N- 
labelled minimal medium with 50 pg/ml carbenicillin. From this point, the same 
methodology used for the overexpression and purification o f un-labelled samples was 
followed.
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In vitro folding o f  mutants
The monomer-containing fractions (fractions 5 and 6; Figure III.3B) from SEC were 
concentrated to more than 10 mg/ml by centrifugal ultrafiltration (Vivaspin 20, 
Vivascience). Immediately after concentration, folding was performed at 4°C by rapid 
dilution of the concentrated protein sample into a 0.1 M Tris-HCl buffer pH 9 with 0.6 M 
arginine, 20% glycerol, 5 mM cysteine and 0.5 mM cystine (i.e. the best buffer found in 
the study o f the in vitro folding o f the wild type protein in Chapter II). Samples were 
incubated for 24 hours with gentle stirring and then clarified by centrifugation and 
dialysed against a 50 mM phosphate buffer pH 6.0 with 0.2 M NaCl, 1 mM EDTA and 
0.05% (w/v) sodium azide.
Kinetic observations
In vitro folding o f V88D/V97K ACD5dl was initiated as described above and 5 ml 
samples were taken at the desired time points. The disulphide bond formation reaction in 
the sample was immediately quenched with 50% (v/v) acetic acid, which lowered the pH 
below 2.0 (the oxidation reaction is no longer favourable under these conditions).
Reversed-phase HPLC
Acid-quenched and dialysed folding samples o f V88D/V97K /zCD5dl were analysed 
using a Sephasil Protein C4 (300 A, 5pm, 4.6 mm x 100 mm) RP-HPLC column 
connected to an Akta Purifier chromatography system (Amersham Biosciences). 
Detection was performed by measuring absorbance at 220 and 280 nm. Solvent A was 
5% (v/v) acetonitrile with 0.1% (v/v) trifluoroacetic acid (TFA) and solvent B was 95% 
acetonitrile 0.1% TFA.
For the in vitro folding screen o f /zCD5dl mutants, samples were eluted using a linear 
gradient from 0% to 45% B in 15 minutes with a flow rate o f 2 ml/min. For the kinetic 
observations o f V88D/V97K /zCD5dl folding a linear gradient from 28% to 40% B was 
run in 8 minutes with a flow rate o f 0.5 ml/min.
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Estimation o f  protein concentration
Protein concentration was estimated by measuring absorbance at 280 nm using the 
theoretical molar extinction coefficient calculated with the Gill and von Hippel 
equation16. This is 27880 M ^cm '1 for the majority o f the constructs, except for W28R 
for which the theoretical molar extinction coefficient is 22180 M ^cm '1.
NMR spectroscopy
The jH-15N HSQC spectra were acquired at 298 K on a Varian UnityPlus spectrometer 
operating at a nominal !H frequency of 600 MHz. The spectrum of V88D/V97K /iCD5dl 
was recorded with 1024 complex points and a spectral width o f 5 kHz in the ]H 
dimension and 256 complex points and a spectral width o f 1.7 kHz in the 15N dimension. 
The data for the /zCD5dl construct expressed in Pichia pastoris was provided by Dr 
Mark Pfuhl (Leicester University). The spectrum was recorded with 1600 complex points 
and a spectral width o f 5.5 kHz in the JH dimension and 256 complex points and a 
spectral width o f 2.0 kHz in the 15N dimension. Chemical shifts were indirectly 
referenced to sodium 2,2-dimethyl-2-silane-pentane-5-sulphonate (DSS) using absolute 
frequency ratios for the ]H signals17. All data were processed using 
NMRpipe/NMRDraw18. Figure III.7 was made with the Plot2 program of the AZARA 
suite19.
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Results
Design ofhC D 5dl mutants
The /*CD5dl amino acid sequence was aligned with the sequences from CD5 orthologues 
in order to find positions that were occupied by non-polar amino acids in the human 
protein and by polar amino acids in any o f the other sequences. There are nine positions 
that fulfil this criterion: L26, W28, M58, W71, V88, L96, V97, M124 and G129 (Figure 
III. 1). The amino acid sequence o f the M2BP SRCR domain was also aligned with the 
CD5dl sequences in order to derive some structural information for the mutation 
candidates. The SRCR domain o f M2BP shares 18% identity and 28% similarity to 
/*CD5dl. This is a low homology level and structural inferences from M2BP SRCR were 
taken with due caution. On the basis o f this analysis the residues selected for mutation 
were L26, W28, V88, V97, M l24 and G129. Residues M58 and L96 were not considered 
for mutation because the equivalent residues are buried in the M2BP SRCR structure. 
G lyl29 is also buried in the M2BP SRCR structure. Nevertheless, this residue was 
targeted for mutation because the accessibility of residues with larger side chains are not 
well predicted from the values reported for Gly. Trp71 was not chosen for mutation 
because it lies in an insertion not present in the M2BP SRCR the structure of which may 
have a particular biological significance.
A total o f eight single-site mutants of /zCD5dl were constructed: L26K, W28R, V88D, 
V88N, V97K, M124N, M124Q and G129S. O f these L26K was the only mutation to an 
amino acid type not present in an orthologue sequence. This N-terminal residue was not 
expected to be part o f the globular fold and a less conservative approach was taken to its 
mutation. It was reasoned that a change o f Leu to Lys as opposed to the Ser found in 
some o f the other sequences, would further enhance solubility o f the protein.
After evaluating the in vitro folding performance o f the single mutants as described 
below, the mutations with the best performance, were combined in a double mutant 
construct called V88D/V97K /iCD5dl.
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Figure III.1 Alignment of the amino acid sequences o f the N-terminal domain o f  CD5 (C D 5dl) o f 
different species and the SRCR domain o f Mac-2 binding protein (M2BP).
Arrows indicate residues selected for mutation in /?C D 5dl.
The accessibility values correspond to the side chain solvent accessibility as com puted by NACCESS for 
the SRCR domain o f M2BP. The scale runs from non-accessible(O) to very accessible (9).
The sequence o f  the sheep CD5d I appears truncated in the database.
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Expression and purification ofhC D 5dl mutants
The mutant constructs, each bearing an N-terminal hexa-histidine tag, were expressed in 
BL21 (DE3) cells using the IPTG-inducible T7 promoter system. Similarly to the WT 
protein, all mutants expressed in high yields as inclusion bodies (Figure III.2). Each 
mutant protein was solubilised using 6 M GdnHCl, purified by immobilised metal ion 
affinity chromatography, cysteines were reduced and the monomeric protein chains were 
isolated by SEC. As far as expression and purification are concerned, there were no 
significant differences among the mutants. Figure III.3 shows the results o f a typical 
protein purification procedure.
In vitro oxidative folding mutant screen
All mutants were set to fold separately by rapid dilution into the folding buffer at final 
protein concentrations o f 0.1 mg/ml and 0.2 mg/ml. Different mutants had different 
degrees o f immediate precipitation upon dilution, and the degree o f precipitation was 
qualitatively related to folding yield. The mutants with the best folding yield had no 
visible immediate precipitation at 0.2 mg/ml. On the other hand, the mutants that were 
found to produce no significant amount of folded protein underwent substantial 
precipitation immediately upon dilution to 0.1 mg/ml.
After incubating for 24 hours, samples were dialysed to remove the solubility enhancers. 
In each case, a fixed volume o f the dialysed protein solution was injected into the RP- 
HPLC system and eluted with an increasing gradient o f acetonitrile (Figure III.4). As 
previously found for WT /iCD5dl, there was more than one species distinguished by RP- 
HPLC in most o f the dialysed protein solutions. The native fold o f a protein is expected 
to minimise its hydrophobicity, consequently it is commonly assumed that the lowest 
retention volume peak in RP chromatography corresponds to the natively folded species. 
The results shown in Chapter II strongly support this supposition, as the buffer conditions 
which maximised the area for the lowest retention volume peak in RP-HPLC 
experiments, were also those that yielded a high proportion o f folded WT /*CD5dl as 
validated by NMR. It was assumed that this was the case for all /zCD5dl mutants and 
that the peak that eluted first was most likely to be the monomeric native folded species. 
The first peak for each o f the mutants eluted within a narrow range o f retention volumes 
and several clearly shown elution volumes lower than that o f the WT protein,
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Figure III.2 Non-reducing SDS-PAGE analysis o f the expression o f different single-residue mutants of 
hCD5dl in BL21(DE3) cells.
Lane M shows molecular weight markers (Mark 12, Invitrogen). There are three lanes for each mutant always 
in the same order: T total protein; S fraction o f protein soluble in 50 mM phosphate buffer pH 7.0;
IB fraction soluble in 8 M urea but insoluble in 50 mM phosphate buffer pH 7.0.
Groups o f three lanes: 1, L26K; 2, W28R; 3, V88D; 4, V88K; 5, V97K: 6, M124N; 7, M124Q; 8, G129S.
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Figure III.3 Expression and purification ofV88D/V97K /iCD 5dl.
(A) Reducing SDS-PAGE analysis o f expression at different time points.
Lane M: molecular weight markers (kDa). Lanes: 1-6 fractions soluble in 0.05 M potassium phosphate, 0.2 M NaCl, pH 7.0. Lanes 7-12: fractions soluble in 8 M urea, 0.1 M 
potassium phosphate, 0.01 M Tris,pH  8.0.
Lanes: 1 and 7,0 minutes after induction; 2 and 8,60 minutes; 3 and 9,120 minutes; 4 and 10,180 minutes; 5 and 11,240 minutes; 6 and 12,960 minutes after induction.
(B) Size exclusion chromatography (SEC) in denaturing conditions.
(C) Non-reducing SDS-PAGE analysis o f fractions from denaturing SEC. Lane M: molecular weight markers (kDa). Other lane numbers correspond to the fraction number in B.
(D) Size exclusion chromatography o f refolded protein.
(E) Reducing SDS-PAGE analysis o f fractions from SEC of refolded protein. Lane M: molecular weight markers (kDa). Other lane numbers correspond to the fraction number in D. 
The gel shows that the high molecular weight fractions (lanes 1 -5) correspond to multiples of the monomeric protein.
suggesting that they had the desired property o f increased hydrophilicity. The identity of 
the second peak could not be definitely established, and will be referred to hereafter as 
the 'non-native peak'. This peak did not represent insoluble aggregates, as the samples 
were dialysed to remove the folding enhancers that could solubilise aggregates prior to 
loading on the column. Furthermore, there was no correlation between the amount o f 
non-native protein present and the overall protein concentration (Table III.4). Perhaps 
this peak represents a mixture o f intermediates or soluble disulphide-bonded oligomers. 
The presence o f the latter is supported by the results o f the subsequent SEC purification 
step (Figure III.3D, E, and F).
The data from the RP-HPLC analysis o f the folding yield o f both the native and the non­
native peaks for each mutant o f /*CD5dlare given in Table III. 1. The average yields are 
given in Table III.2. The two-way analysis o f variance (ANOVA) o f the native peak data 
shows that there is a highly significant difference in yield due to mutations (Table III.3). 
The analysis also shows a significant difference in yield due to protein concentration, i.e. 
in general, working with lower protein concentration in the folding reaction resulted in 
higher yields o f native protein. There was no significant interaction between these two 
variables, indicating that all /zCD5dl mutants reacted similarly to the variation in protein 
concentration. On the other hand, with respect to the amount of non-native species 
formed, each mutant responded differently to the change in protein concentration, 
because the interaction between protein concentration and identity of the construct in the 
two-way ANOVA was significant (Table III.4). Four o f the eight single mutant hCD5dl 
constructs had notably better folding yields than the WT: L26K, V88D, V97K and 
M124Q (Figure III.5). The in vitro folding yield o f the V88D/V97K double mutant was 
more than 4 times higher than the WT protein at 0.1 mg/ml and more than 5 times higher 
at 0.2 mg/ml.
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F igure III.4  RP-HPLC elution profiles o f the hCD 5dl mutants after in vitro folding, at final protein 
concentrations o f 0.1 mg/ml and 0.2 mg/ml. The samples for V97K and V88D/V97K were diluted 
1.5 and 2-fold respectively prior to injection. Evidence indicates that the peak that elutes first may correspond 
to the folded species and the second to an un-identified species (herein refered to as the non-native peak).
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Table III.l Results for the in vitro folding analysis of h CD5dl mutants (1 of 2)
First RP-HPLC peak (native) Second RP-HPLC peak (non-native)
Protein Dialysis
dilution
Injected Retention Relative Retention Relative
Construct Replicate conc. volume volume Peak area yield volume Peak area yield
[mg/ml] [ml] [ml] [ml]
1 Wild type 1 0.10 1.29 2.00 21.43 8.96 57.13 22.24 10.71 68
2 Wild type 2 0.10 1.36 2.00 21.50 11.73 78.95 22.35 12.87 87
3 Wild type 3 0.10 1.33 2.00 21.53 7.77 51.19 22.38 6.51 43
4 Wild type 1 0.20 1.36 2.00 21.49 9.69 32.61 22.30 13.53 46
5 Wild type 2 0.20 1.36 2.00 21.52 11.07 37.25 22.32 12.88 43
6 Wild type 3 0.20 1.31 2.00 21.49 10.97 35.75 22.30 14.80 48
7 L26K 1 0.11 1.23 2.00 21.30 14.49 81.28 22.91 0.26 1
8 L26K 2 0.11 1.19 2.00 21.26 19.30 104.48 21.82 3.41 18
9 L26K 3 0.11 1.23 2.00 21.30 13.67 76.68 - 0.00 0
10 L26K 1 0.22 1.29 2.00 21.26 21.05 61.78 - 0.00 0
11 L26K 2 0.22 1.23 2.00 21.26 19.30 54.13 21.82 3.41 10
12 L26K 3 0.22 1.41 2.00 21.28 15.95 51.49 21.62 4.75 15
13 W 28R 1 0.11 1.31 2.00 21.46 1.56 11.88 - 0.00 0
14 W 28R 2 0.11 1.36 2.00 21.56 1.77 13.91 - 0.00 0
15 W 28R 3 0.11 1.30 2.00 21.62 0.58 4.37 22.38 0.17 1
16 W 28R 1 0.21 1.33 2.00 21.52 2.73 10.50 - 0.00 0
17 W 28R 2 0.21 1.36 2.00 21.56 2.14 8.41 - 0.00 0
18 W 28R 3 0.21 1.37 2.00 21.50 2.47 9.81 - 0.00 0
19 V88D 1 0.11 1.44 2.00 21.53 9.41 63.45 - 0.00 0
20 V88D 2 0.11 1.30 2.00 21.43 20.15 122.66 22.34 0.74 5
21 V88D 3 0.11 1.40 2.00 21.41 22.09 144.81 22.33 1.45 10
22 V88D 1 0.21 1.40 2.00 21.40 20.67 67.75 22.34 1.16 4
23 V88D 2 0.21 1.50 2.00 21.36 22.93 80.53 22.17 16.20 57
24 V88D 3 0.21 1.40 2.00 21.38 24.74 81.09 22.28 1.87 6
25 V88N 1 0.10 1.39 2.00 21.63 3.02 20.92 - 0.00 0
26 V88N 2 0.10 1.33 2.00 21.59 5.44 36.14 22.32 0.83 6
27 V88N 3 0.10 1.41 2.00 21.80 0.99 7.00 - 0.00 0
28 V88N 1 0.20 1.44 2.00 21.49 13.19 47.58 22.27 11.49 41
29 V88N 2 0.20 1.43 2.00 21.61 4.14 14.79 - 0.00 0
30 V88N 3 0.20 1.41 2.00 21.65 4.96 17.54 22.49 0.15 1
Table III.l Results for the in vitro folding analysis of h CD5dl mutants (2 of 2)
Construct Replicate
Protein
conc.
[mg/ml]
Dialysis
dilution
Injected
volume
[ml]
First peak RP-HPLC (native) Second peak RP-HPLC (non-native)
Retention
volume Peak area 
[ml]
Relative
yield
Retention
volume
[ml]
Peak area Relative
yield
1 V97K 1 0.10 1.25 0.67 21.10 10.48 188.54 22.06 0.91 16
2 V97K 2 0.10 1.38 0.67 21.10 10.59 209.57 22.02 0.90 18
3 V97K 3 0.10 1.23 0.67 21.15 12.02 213.37 22.09 1.13 20
4 V97K 1 0.21 1.31 0.67 21.11 15.43 145.74 22.11 2.24 21
5 V97K 2 0.21 1.38 0.67 21.12 15.00 148.42 22.13 1.94 19
6 V97K 3 0.21 1.36 0.67 21.12 13.91 136.39 22.11 1.56 15
7 M124N 1 0.10 1.36 2.00 - 0.00 0.00 - 0.00 0
8 M124N 2 0.10 1.34 2.00 - 0.00 0.00 - 0.00 0
9 M124N 3 0.10 1.29 2.00 - 0.00 0.00 - 0.00 0
10 M124N 1 0.20 1.36 2.00 - 0.00 0.00 - 0.00 0
11 M124N 2 0.20 1.37 2.00 - 0.00 0.00 - 0.00 0
12 M124N 3 0.20 1.34 2.00 - 0.00 0.00 - 0.00 0
43 M124Q 1 0.10 1.41 2.00 21.31 12.07 83.15 22.31 7.65 53
44 M124Q 2 0.10 1.36 2.00 21.26 12.42 82.11 22.22 9.59 63
45 M124Q 3 0.10 1.37 2.00 21.25 14.35 95.86 22.23 10.72 72
46 M124Q 1 0.21 1.31 2.00 21.24 17.04 54.55 22.19 18.72 60
47 M124Q 2 0.21 1.36 2.00 21.25 17.16 56.72 22.22 17.32 57
48 M124Q 3 0.21 1.33 2.00 21.25 17.01 55.04 22.22 18.03 58
49 G129S 1 0.11 1.34 2.00 - 0.00 0.00 22.21 8.41 53
50 G129S 2 0.11 1.36 2.00 - 0.00 0.00 - 0.00 0
51 G129S 3 0.11 1.37 2.00 21.85 0.07 0.45 - 0.00 0
52 G129S 1 0.21 1.39 2.00 21.74 0.62 2.01 - 0.00 0
53 G129S 2 0.21 1.37 2.00 - 0.00 0.00 22.48 0.06 0
54 G129S 3 0.21 1.39 2.00 - 0.00 0.00 - 0.00 0
55 V88D/V97K 1 0.10 1.37 0.50 21.07 13.13 359.54 21.96 1.95 53
56 V88D/V97K 2 0.10 1.17 0.50 21.06 19.45 454.67 21.88 0.69 16
57 V88D/V97K 3 0.10 1.42 0.50 21.13 9.38 266.25 21.89 1.89 54
58 V88D/V97K 1 0.20 1.42 0.50 21.03 19.24 273.07 21.88 0.51 7
59 V88D/V97K 2 0.20 1.42 0.50 21.08 21.28 302.02 21.91 0.75 11
60 V88D/V97K 3 0.20 1.42 0.50 21.11 20.66 293.22 21.93 0.52 7
Table III.2 Average results for the in vitro folding analysis o f h C D 5dl mutants
Construct
First peak RP-HPLC (native) Second peak RP-HPLC(non-native)
Protein conc. 
[mg/ml]
Average
yield
Fraction o f total 
soluble protein* 
(%)
Construct: WT
Average 
relative yield
Fraction o f total 
soluble protein* 
(%)
Wild type 0.1 62.4 49 1.00 65.9 51
Wild type 0.2 35.2 44 0.56 45.7 56
L26K 0.1 87.5 93 1.40 6.6 7
L26K 0.2 55.8 87 0.89 8.3 13
W28R 0.1 10.1 55 0.16 0.4 45
W28R 0.2 9.6 100 0.15 0.0 0
V88D 0.1 110.3 96 1.77 4.7 4
V88D 0.2 76.5 77 1.22 22.3 23
V88N 0.1 21.4 99 0.34 1.8 1
V88N 0.2 26.6 66 0.43 14.0 34
V97K 0.1 203.8 92 3.27 18.1 8
V97K 0.2 143.5 89 2.30 18.55 11
M124N 0.1 0.0 - 0.00 0.0 0
M124N 0.2 0.0 - 0.00 0.0 0
M124Q 0.1 87.0 58 1.39 62.6 42
M124Q 0.2 55.4 49 0.89 58.5 51
G129S 0.1 0.2 1 0.00 17.6 99
G129S 0.2 0.7 91 0.01 0.1 9
V88D/V97K 0.1 360.2 90 5.77 41.1 10
V88D/V97K 0.2 289.4 97 4.64 8.4 3
Table III.3 Analysis o f variance (ANOVA) for the in vitro folding analysis of h CD5dl mutants (native peak)
Source o f variation Degrees o f 
freedom
Sum o f 
squares
Mean
squares
F value p value Interpretation
Protein concentration 1 9379 9379 15.32 3.44x1 O'4 Significant
Construct 9 544579 60509 98.86 1.81x1 O'24 Significant
Interaction 9 9455 1051 1.72 0.12 Not significant
Residual 40 24482 612
Total 59 587896
Fisher's least significant difference (LSD) = 34.02 at 90% confidence interval
Table III.4 Analysis of variance (ANOVA) for the in vitro folding analysis of h CD5dl mutants (non-native peak)
Source o f variation Degrees o f 
freedom
Sum of 
squares
Mean
squares
F value p value Interpretation
Protein concentration 1 285 285 1.56 0.22 Not significant
Construct 9 256389 28488 155.99 2 .87xl0 '28 Significant
Interaction 9 769167.97 85463 467.97 1.27x10 '37 Significant
Residual 40 7305 183
Total 59 1033147
Fisher's least significant difference (LSD) -  18.60 at 90% confidence interval
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F igure III.5 Average yields o f  native and non-native protein after in vitro folding o f wild type and 
mutants o f ACD5dl. (A) Native peak (B) Non-native peak.
The error bars extend LSD/2 above and below the average to display uncertainty intervals. 
Least significant difference (LSD) was calculated using the F isher’s method, i. e.
LSD =t005(v) * [2/3 * MSE]17
W here t005(v) is the critical value for the t-distribution at an upper-tail probability o f  0.05 with v degrees o f 
freedom, v denotes the degrees o f freedom for the error in the ANOVA table (see Tables III.3 and III.4).
M SE is the mean square value for the error in the ANOVA table.
Mason RL, et al. (1989) Statistical Design and Analysis o f  Experiments, John Wiley & Sons.
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Kinetic observations on V88D/V97K hCD5dl
The high yield obtained for the double mutant allowed further characterisation o f the 
folding protocol. The in vitro folding of the double mutant /*CD5dl was monitored in 
order to investigate the time dependence o f the yield of folded protein (Figure III.6). 
During the initial phase o f folding the RP-HPLC trace progressively altered until -25  hrs 
after which it was essentially invariant. At this point and up to 36 hours there was still a 
broad shoulder in the native peak. After dialysis, the shoulder diminished and became 
more highly resolved and it does not appear at all in the RP-HPLC chromatogram of the 
monomeric species after purification by SEC. Thus, the non-native shoulder was 
apparently formed by disulphide-bonded soluble oligomers such as those seen in lanes 1 - 
3 of the non reducing SDS-PAGE of Figure III.3F. Non-reducing SDS-PAGE of the SEC 
fractions shown dimers, trimers and tetramers (Figure III.3F) that could be reduced with 
2-mercaptoethanol (Figure III.3E). The resolution of the RP-HPLC chromatogram was 
not sufficient to separate the intermediate species during the folding reaction. As the non­
native signal was very broad, many species must have been present during the folding 
process. One intermediate peak was sharper at 15 hours and it could represent a 
substantial population of a single stable intermediate.
NMR spectroscopy
V88D/V97K /iCD5dl could be concentrated to around of 1 mM without any significant 
precipitation in the same buffer previously used for WT /iCD5dl (50 mM potassium 
phosphate buffer pH 6.0, 0.2 M NaCl, 1 mM EDTA, 0.1% NaN3). Thus, the double 
mutant has both remarkably better solubility and higher folding yield than the WT. The 
HSQC spectrum of V88D/V97K /zCD5dl has shown that the sample had a high 
concentration o f a globular, folded component. Moreover, the distribution o f signals was 
very similar that observed for the WT hCD 5dl, suggesting that the mutations do not alter 
the overall fold o f the domain (Figure III.7).
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After SEC  
Dialysed
Retention volume (ml)
F ig u re  I I I .6  RP-H PLC elution profiles o f  the in vitro  fo ld ing  o f  V 88D /V 97K  ACD5dl 
at different time points. There is a progressive accumulation o f  the most hydrophilic species 
until 25 hours. This species is coincident with the protein monomer isolated by size-exclusion 
chromatography.
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Figure III.7  ‘H- 15N  HSQC spectra at 298 K  o f different constructs of/?CD5dl.
(A) Glycosylated /iCD5dl expressed in the yeast Pichia pastoris (Courtesy o f  Dr Mark Pfuhl).
(B) Unglycosylated /*CD5dl expressed in Escherichia coli.
(C) Unglycosylated V88D/V97K /*CD5dl expressed in Escherichia coli.
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Discussion
The N-terminal domain o f human CD5 expresses in eukaryotic systems with an N-linked 
glycan in residue N11620. The distribution of the signals in the ]H-15N HSQC spectrum 
of the glycosylated domain expressed in Pichia pastoris21 is very similar to that obtained 
for the unglycosylated version presented in this work (Figure III.7), indicating that the 
presence of the N-linked carbohydrate is not essential for the attainment o f the 
characteristic fold. However, the limited solubility o f WT /zCD5dl expressed in bacteria 
could be a consequence o f the lack of glycosylation.
It is generally accepted that one o f the effects o f the covalently bonded carbohydrates in 
proteins is to increase protein stability or solubility, or both, and to prevent aggregation. 
A statistical study o f the glycosylated proteins in the PDB has shown that the regions of 
the protein surface that are in contact with glycans are more hydrophobic than the rest of 
the protein surface22. This is in agreement with experimental work suggesting that 
complex carbohydrates improve solubility because they shield solvent-exposed 
hydrophobic patches23'26. Other experimental evidence indicates that the glycans increase 
protein solubility because o f their inherent polar properties, as there appears to be linear 
correlation between solubility and number of carbohydrate residues27.
Glycans tend to be chemically heterogeneous and seldom rigid, and as a consequence 
glycoproteins are generally difficult to crystallise28. The carbohydrate also increases the 
molecular weight, so glycoproteins are not often suitable for NMR spectroscopy. 
Because the three-dimensional structure o f a protein is not generally influenced by the
29glycan , it is common to circumvent these problems by removing most o f the
o 1 incarbohydrate by chemical or enzymatic digestion ’ ' , or by mutating the glycosylation 
site to Gin33,34.
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In general, bacterial expression systems are unable to produce glycosylated proteins. 
Nevertheless, because o f their many merits, and the complications o f working with 
glycosylated proteins, it is worth attempting the expression o f a glycan-free form of 
structural targets. Unglycosylated proteins expressed in E. coli are likely to be 
active8,10,35, however, they are often less soluble and prone to aggregation, a problem that 
has been solved in some instances by introducing mutations that decrease the 
hydrophobicity o f the protein surface810’36. In this Chapter it was shown that both the 
solubility and the in vitro folding yield o f the unglycosylated /zCD5dl could be enhanced 
by replacing non-conserved hydrophobic residues.
The influence o f the different mutations is difficult to interpret as they could have altered, 
at least, three different phenomena: (1) the solubility of the extended polypeptide chain; 
(2) the solubility o f the folded conformation; and (3) the stability o f intermediate folding 
states. There is also the possibility that some of the detrimental mutations prevented the 
protein from folding because they disturb the side chain packing. In order to assess 
whether there was any indication o f relationship between the properties o f the sequence 
and the folding yield, the Kyte-Doolittle hydrophobicity37, the Hopp-Woods 
hydrophilicity38, and the Rost and Sander predicted solvent accessibility39 were 
computed for the different positions o f the WT where mutations were introduced (Figure 
III.8A,B,C). No connection was found between the success o f a particular mutation and 
the predicted solvent accessibility or the Kyte-Doolittle hydrophobicity (Spearman 
correlation coefficients2, p, o f -0.09 and -0.03 respectively). The correlation score for the 
Hopp-Woods values was much higher (p = -0.59), this value indicating a significant 
correlation with a confidence level o f 80%. There was also no correlation between the 
calculated side-chain solvent accessibility15 for the equivalent residues in the M2BP 
SRCR structure (Figure III.8C). However, this may simply mean that the structural 
context o f these residues is different in the /jCD5dl and M2BP SRCR domains. Average 
values of hydropathy index (GRAVY) using the Kyte-Doolittle scores were calculated 
with ExPASy’s40 Protparam for each mutant. The Spearman value in this case was high 
(p =-0.72), pointing out a relationship between the GRAVY score and the folding yield
2 Spearman correlation coefficient (p) is a better indicator o f  the existence o f a relationship between two 
variables when this relationship is not linear. Like the least squares correlation coefficient, a p value o f  ±1 
indicates a perfect relationship, and a value o f  0 indicates no relationship.
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with a significance level o f 95%. GRAVY indices depend only on the amino acid 
sequence, not the 3D structure. If this correlation is real, it could mean that the unfolded 
WT /iCD5dl falls out o f solution because o f the intrinsic hydrophobicity o f the amino 
acid sequence, while the /zCD5dl mutants with very low or no folding yields precipitate 
in later intermediate states or are unable to fold because the three-dimensional structure 
has been disturbed.
Clearly, the strategy o f mutation o f potentially solvent-exposed residues has been 
successful in modifying the solubility o f /*CD5dl. However, the location of the mutations 
was not the only determinant for the dissimilar properties found for the mutants. For a 
given site substitution of different amino acids resulted in different behaviours. In the 
case of V88, replacement for Asp was very successful, but not for Asn. Perhaps the 
difference was just a consequence of Asp being more hydrophilic than Asn. In the case of 
M l24 the substitution for Asn prevented the protein from folding, while replacement for 
Gin resulted in a higher in vitro folding yield than WT. At a purely speculative level, this 
result could be a consequence o f the difference in side chain size. Perhaps the methylene 
group in the y position, present in Gin and Met but not in Asn, is important for adequate 
side chain packing.
For /zCD5dl, higher folding yields accompanied lower levels of precipitation during in 
vitro folding. Apparently the successful mutations were those that prevented aggregation 
o f the unfolded species and/or folding intermediates. While V88D/V97K /*CD5dl has 
improved solubility and in vitro folding yields, these two properties may not always be 
related. Studies with disulphide bonded proteins expressed in the bacterial periplasm 
have shown that in vivo folding yields correlate with aggregation rates but not with the 
solubility o f the purified protein41. Other studies have found a direct correlation between 
high thermodynamic stability o f the native structure and high in vivo folding yields42.
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F igure III.8  Comparison o f relative refolding yields o f  /zCD5dl variants with different physical parameters. 
(A) K yle-Doolittle hydrophobicity score for the position o f  the m utation in the wild type 
construct using a window size o f 9. The higher the score, the higher the hydrophobicity o f 
the position.(B ) Hopp-W oods hydrophilicity score for the position o f  the m utation in the 
wild type construct using a window size o f 7. The higher the score the higher the hydrophilicity 
o f the position. (C) Predicted solvent accessibility using the Rost and Sander algorithm and 
ca lcu lated  solvent accessib ility  o f  the corresponding  residue side chain  in M 2BP SRCR 
structure, if  available. (D) Grand average o f hydropathicity (GRAVY) for each o f the mutants.
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To summarise, two replacements of non-conserved, and presumably solvent exposed, 
hydrophobic residues for charged amino acids, have transformed a largely intractable 
unglycosylated version o f the N-terminal SRCR domain o f human CD5 into a construct 
that can be folded in vitro with high yield and that can be concentrated to a level that 
makes further structural characterisation possible. In order to find candidate mutations, 
no detailed structural information or exhaustive mutations were required. Rather, a 
simple comparison with orthologues was sufficient to select eight target residues and 
mutations at four o f these sites led to proteins with superior characteristics to the WT.
References
1. Pedelacq JD, Piltch E, Liong EC, Berendzen J, Kim CY, Rho BS, Park MS, Terwilliger TC & 
Waldo GS (2002) Engineering soluble proteins for structural genomics. N at Biotechnol. 20, 927- 
932.
2. fffaxwell KL, Mittermaier AK, Forman-Kay JD & Davidson AR (1999) A simple in vivo assay for 
increased protein solubility. Protein Sci. 8, 1908-1911.
3. Wigley WC, Stidham RD, Smith NM, Hunt JF & Thomas PJ (2001) Protein solubility and folding 
monitored in vivo by structural complementation o f a genetic marker protein. Nat Biotechnol. 19, 
131-136.
4. Schulze AJ, Degryse E, Speck D, Huber R & Bischoff R (1994) Expression o f a 1-proteinase 
inhibitor in Escherichia coli: Effects o f  single amino acid substitutions in the active site loop on 
aggregate formation. J  Biotechnol. 32, 231-238.
5. Dale GE, Broger C, Langen H, D'Arcy A & Stuber D (1994) Improving protein solubility through 
rationally designed amino acid replacements: solubilization o f the trimethoprim-resistant type SI 
dihydrofolate reductase. Protein Eng. 7, 933-939.
6. Jenkins TM, Hickman AB, Dyda F, Ghirlando R, Davies DR & Craigie R (1995) Catalytic domain 
o f human immunodeficiency virus type 1 integrase: identification o f  a soluble mutant by systematic 
replacement o f hydrophobic residues. Proc N atl A cad  Sci USA. 92, 6057-6061.
7. Daujotyte D, Vilkaitis G, Manelyte L, Skalicky J, Szyperski T & Klimasauskas S (2003) Solubility 
engineering o f the Hhal methyltransferase. Protein Eng. 16, 295-301.
8. Sun ZY, Dotsch V, Kim M, Li J, Reinherz EL & W agner G (1999) Functional glycan-free adhesion 
domain o f  human cell surface receptor CD58: design, production and N M R studies. EM BO J. 18, 
2941-2949.
9. M cElroy HE, Sisson GW, Schoettlin WE, Aust RM  & Villafranca JE (1992) Studies on engineering 
crystallizability by mutation o f surface residues o f  human thymidylate synthase. J  Cryst Growth. 
122, 265-272.
142
10. Malissard M & Berger EG (2001) Improving solubility o f  catalytic domain o f human beta-1,4- 
galactosyltransferase 1 through rationally designed amino acid replacements. Eur J  Biochem. 268, 
4352-4358.
11. Das D & Georgiadis MM (2001) A directed approach to improving the solubility o f Moloney 
murine leukemia virus reverse transcriptase. Protein Sci. 10, 1936-1941.
12. Mosavi LK & Peng ZY (2003) Structure-based substitutions for increased solubility o f  a designed 
protein. Protein Eng. 16, 739-745.
13. Thompson JD, Higgins DG & Gibson TJ (1994) CLUSTAL W: improving the sensitivity o f 
progressive multiple sequence alignment through sequence weighting, position-specific gap 
penalties and weight matrix choice. Nucleic Acids Res. 22, 4673-4680.
14. Hohenester E, Sasaki T & Timpl R (1999) Crystal structure o f  a scavenger receptor cysteine-rich 
domain sheds light on an ancient superfamily. Nat Struct Biol. 6, 228-232.
15. Hubbard, S. J. and Thornton, J. M. (1993) NACCESS (version 2.1.1) University College London.
16. Gill SC & von Hippel PH (1989) Calculation o f protein extinction coefficients from amino acid 
sequence data. Anal Biochem. 182, 319-326.
17. Wishart DS, Bigam CG, Yao J, Abildgaard F, Dyson HJ, Oldfield E, Markley JL & Sykes BD
(1995) 'H, i3C and 15N chemical shift referencing in biomolecular NMR. J  Biomol NMR. 6, 135- 
140.
18. Delaglio F, Grzesiek S, Vuister GW, Zhu G, Pfeifer J & Bax A (1995) NMRPipe: a 
multidimensional spectral processing system based on UNIX pipes. J  Biomol NMR. 6, 277-293.
19. Boucher, W (2002) AZARA suite for NM R data (version 2.7) Department o f Biochemistry, 
University o f Cambridge.
20. McAlister MS, Brown MH, Willis AC, Rudd PM, Harvey DJ, Aplin R, Shotton DM, Dwek RA, 
Barclay AN & Driscoll PC (1998) Structural analysis o f the CD5 antigen -expression, disulphide 
bond analysis and physical characterisation o f  CD5 scavenger receptor superfamily domain 1. Eur J  
Biochem. 257, 131-141.
21. McAlister MS, Davis B, Pfuhl M & Driscoll PC (1998) NM R analysis o f the N-terminal SRCR 
domain o f human CD5: engineering o f  a glycoprotein for superior characteristics in NM R 
experiments. Protein Eng. 11, 847-853.
22. Petrescu AJ, Milac AL, Petrescu SM, Dwek RA & W ormald M R (2004) Statistical analysis o f the 
protein environment o f N- glycosylation sites: implications for occupancy, structure, and folding. 
Glycobiology. 14, 103-114.
23. Toyoda T, Arakawa T & Yamaguchi H (2002) N-glycans stabilize human erythropoietin through 
hydrophobic interactions with the hydrophobic protein surface: studies by surface plasmon 
resonance analysis. J  Biochem (Tokyo). 131, 511-515.
24. Song Y, Azakami H, Hamasu M & Kato A (2001) In vivo glycosylation suppresses the aggregation 
o f amyloidogenic hen egg white lysozymes expressed in yeast. FEBS Lett. 491, 63-66.
25. Erbel PJ, Karimi-Nejad Y, van Kuik JA, Boelens R, Kamerling JP & Vliegenthart JF (2000) Effects 
o f  the N-linked glycans on the 3D structure o f  the free alpha-subunit o f human chorionic 
gonadotropin. Biochem. 39, 6012-6021.
26. Ioannou YA, Zeidner KM, Grace ME & Desnick RJ (1998) Human a-galactosidase A: 
glycosylation site 3 is essential for enzyme solubility. Biochem J. 332, 789-797.
143
27. Tams JW, Vind J & W elinder KG (1999) Adapting protein solubility by glycosylation. N- 
glycosylation mutants o f  Coprinus cinereus peroxidase in salt and organic solutions. Biochim  
Biophys Acta. 1432, 2 14-221.
28. Wormald M R & Dwek RA (1999) Glycoproteins: glycan presentation and protein-fold stability. 
Structure F oldD es. 7, R155-R160.
29. Helenius A & Aebi M (2001) Intracellular functions o f N-linked glycans. Science. 291 , 2364-2369.
30. Rydberg EH, Sidhu G, Vo HC, Hewitt J, Cote HC, Wang Y, Numao S, MacGillivray RT, Overall 
CM, Brayer GD & Withers SG (1999) Cloning, mutagenesis, and structural analysis o f  human 
pancreatic a-am ylase expressed in Pichiapastoris. Protein Sci. 8, 635-643.
31. Gordon K, Redelinghuys P, Schwager SL, Ehlers MR, Papageorgiou AC, Natesh R, Acharya KR & 
Sturrock ED (2003) Deglycosylation, processing and crystallization o f  human testis angiotensin- 
converting enzyme. Biochem J. 371, 437-442.
32. Avramopoulou V, Mamalaki A & Tzartos SJ (2004) Soluble, oligomeric and ligand-binding 
extracellular domain o f human alpha7 acetylcholine receptor expressed in yeast. Replacement o f the 
hydrophobic Cys-loop by the hydrophilic loop o f ACh-binding protein enhances protein solubility. J  
Biol Chem. 279, 38287-38293.
33. Bruinzeel W, Yon J, Giovannelli S & Masure S (2002) Recombinant insect cell expression and 
purification o f human a-secretase (BACE-1) for X-ray crystallography. Protein Expr Purif. 26, 139- 
MS.
34. Bowman KK, Clark J, Yu L, Mortara K, Radika K, Wang J & Zhan H (2000) Expression, 
purification, and characterization o f deglycosylated human pro-prostate-specific antigen. Protein 
Expr Purif. 20, 405-413.
35. Wenig K & Sondermann P (2003) Purification, crystallization and X-ray diffraction analysis o f the 
extracellular part o f the human Fc receptor for IgA, FcaRI (CD89). Acta Crystallogr D Biol 
Crystallogr. 59, 2247-2250.
36. Narhi LO, Arakawa T, Aoki K, W en J, Elliott S, Boone T & Cheetham J (2001) Asn to Lys 
mutations at three sites which are N-glycosylated in the mammalian protein decrease the 
aggregation o f Escherichia coli-derived erythropoietin. Protein Eng. 14, 135-140.
37. Kyte J & Doolittle RF (1982) A simple method for displaying the hydropathic character o f a protein. 
J  M ol Biol. 157, 105-132.
38. Hopp TP & Woods KR (1981) Prediction o f  protein antigenic determinants from amino acid 
sequences. Proc Natl Acad Sci USA. 78, 3824-3828.
39. Rost B & Sander C (1994) Conservation and prediction o f solvent accessibility in protein families. 
Proteins. 20, 216-226.
40. Gasteiger E, Gattiker A, Hoogland C, Ivanyi I, Appel RD & Bairoch A (2003) ExPASy: The 
proteomics server for in-depth protein knowledge and analysis. Nucleic Acids Res. 31, 3784-3788.
41. Nieba L, Honegger A, Krebber C & Pluckthun A (1997) Disrupting the hydrophobic patches at the 
antibody variable/constant domain interface: improved in vivo folding and physical characterization 
o f an engineered scFv fragment. Protein Eng. 10, 435-444.
42. Chan W, Helms LR, Brooks I, Lee G, N gola S, M cNulty D, M aleeff B, Hensley P & W etzel R
(1996) Mutational effects on inclusion body formation in the periplasmic expression o f the 
immunoglobulin VL domain REI. Fold Des. 1, 77-89.
___________________________ Chapter Four
The NMR solution structure of the N-terminal SRCR 
domain of human CD5
Abstract
The results of nuclear magnetic resonance (NMR) experiments performed on the N- 
terminal domain of human CD5 at 298 K revealed that regions of the structure are mobile 
on the microsecond to millisecond (intermediate) timescale, which is manifest as non- 
uniform peak broadening and irregular signal intensities in the ]H-15N heteronuclear single 
quantum coherence (HSQC) spectrum. Increasing the temperature above 298 K was found 
to greatly enhance the quality o f the JH -15N HSQC spectrum. Three-dimensional NMR 
experiments at 318 K enabled the assignment o f more than 95% of the main-chain and 
side chain resonances. The solution structure o f the N-terminal domain of human CD5 
was determined at 318 K using standard interproton distance and dihedral angle-restrained 
molecular dynamics protocols. Forty percent o f the residues were found to be in 
structurally well-defined regions, including all o f the regular secondary structure features 
found for other members of the scavenger receptor cysteine-rich (SRCR) superfamily. The 
remaining residues of the polypeptide appear to be distinctly less well ordered. 
Comparison with previous data obtained for a glycosylated form o f the CD5dl domain 
suggests that some o f the mobile residues are flexible because o f the absence o f the 
carbohydrate. However, some residues are mobile in both the glycosylated and the 
unglycosylated domains, suggesting that there is an inherent mobility in specific regions 
o f the domain that may have functional significance.
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Chapter abbreviations and acronyms 
/iC D 5dl N-terminal SRCR domain o f CD5 
ACD5dlm V88D/V97K hCD5dl
CD6d3 C-terminal SRCR domain o f  leukocyte receptor CD6
H SQ C  heteronuclear single quantum coherence
M2BP Mac-2 binding protein
N M R nuclear magnetic resonance
N O E nuclear Overhauser effect
PDB Protein Data Bank
ppm  parts per million
RM SD root mean square deviation
SR C R  scavenger receptor cysteine-rich
Introduction
The scavenger receptor cysteine-rich (SRCR) domain is a globular disulphide-bonded a  
and p fold o f around 110 residues. SRCR domains are almost exclusively found in 
secreted and/or membrane-anchored metazoan proteins and are usually glycosylated. A 
few SRCR domains have also been found in some members o f the Apicomplexa parasite 
family {Plasmodium and Toxoplasma genera)1’2, probably indicating a horizontal gene 
transfer event. Proteins with SRCR domains are expressed in a great variety of cell types, 
but predominantly in cells o f the immune system, epithelial cells, hepatocytes and 
neurones.
The SRCR domain superfamily was discovered during the analysis of the amino acid 
sequence of the mammalian type-II macrophage scavenger receptor type A (SR-A)3. SR- 
As are transmembrane glycoproteins that bind a broad range o f polyanions, including 
modified low density lipoproteins, phospholipids and polynucleotides. However, the 
SRCR domain of the SR-A does not appear to be involved in the polyanion recognition, as 
the absence o f this domain does not compromise ligand binding4.
The number o f cysteine residues in an SRCR domain varies from four to eight. When 
eight cysteines are present, the disulphide bond connectivity is C1-C4, C2-C7, C3-C8 and 
C5-C65 (where the numbering refers to the linear order o f occurrence o f the cysteine
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residues in the amino acid sequence of the protein), as has been confirmed experimentally 
for the N-terminal SRCR domain of CD56 and corroborated by the two solved structures 
from the superfamily7’8. Every known SRCR domain has at least two putative intradomain 
disulphide bonds, one of which is always equivalent to C3-C8. Traditionally, the 
superfamily had been divided in two groups, A and B, according to the number of 
cysteines present9. However, this criterion has now been found to be inadequate as new 
sequences with different numbers of cysteines have been incorporated into the family. A 
more robust classification divides group A and B according to their genomic organisation: 
Group A domains are encoded by two exons and group B members are encoded in a single 
exon10. The members of each group have varying numbers o f cysteines, but no group A 
member has been reported with a predicted C1-C4 disulphide bond.
The proteins of the superfamily are either formed by several tandem copies of the SRCR 
domain or are mosaic proteins (Figures IV. 1-3). So far, 25 different types of domain have 
been found together with SRCR domains. O f these associated domains, 22 are protein-, 
lipid- or carbohydrate- binding, and three have enzymatic activity (Table IV.4). SRCR 
domains of group B have only been found in association with six o f these domains (in the 
same protein), all of them implicated in protein- and/or sugar- binding. Group A SRCR 
domains are less exclusive and occur in association with 14 different domain types. In 
addition to protein-, lipid- and/or carbohydrate- binding domains, group A SRCR 
domains have also been found in association with enzymatic domains, namely tyrosine 
kinases, serine proteases and lysyl oxidases.
Some SRCR domains themselves are involved in protein-protein interactions. The only 
SRCR binding event that has been studied in any detail is the interaction o f the membrane- 
proximal SRCR domain of CD6 (CD6d3) with one o f the immunoglobulin C-type 
domains o f CD 166 (also known as the activated leukocyte-cell adhesion molecule, 
ALCAM). Other protein-protein interactions that probably involve SRCR domains, but 
have not been studied in detail, are CD 163 binding to the haptoglobin-haemoglobin 
complex11, gp340 binding to the C-lectin domains o f surfactant proteins A and D12’13, and 
the interaction o f gp340 with the sphingolipid binding m otif (V3 loop) o f g p l2 0 14 (a 
human immunodeficiency virus-1 surface envelope protein). Many other interactions of 
SRCR superfamily proteins have been mapped to regions outside the SRCR domain.
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Table IV.l Non-Chordata members of the scavenger receptor cysteine-rich superfamily group A
Name Uniprot entry
Number of SRCR 
domains Other domains*
Species and/or tissue distribution Function
Transmembrane 
or secreted Reference
SRCR Tyrosine Kinase* 097191
1 +
1 truncated TK (1)
Unknown T TrEMBL
Sponge aggregation receptor 
SRCR-SCR-Car
14 CCP (6) Marine sponge 
(G. cydonium )
Cell aggregation receptor T (15)
Putative gene SRCR Re 12 C C P (l)
Cell-cell interaction
T
SRCR-Mo 10 None S
SRCR_SD Q8SSX3 4 None Marine sponge (S.domuncula) Cell aggregation T (17)
SP85 / Receptor for sperm-activating peptide (Speract/SAP- 
I)
P 16264 Q 17064 
Q25111 4 None
Sea urchin spermatozoa flagella 
(A. punctulata, S.purpuratus 
H. pulclierrimus)
Binds decapeptide secreted by eggs for 
spermatozoa motility T (18)(19)
Scavenger receptor cysteine rich protein variant 1 
(SpSRCRl) 097378 4 TIL (4) S (20)
Scavenger receptor cysteine-rich protein variant 5 
(SpSRCR5) 097379 2 CUB (2) S (20)
Scavenger receptor cysteine-rich protein type 6 (SpSRCR6) Q9NC91 3 TIL (1) S (21)
Scavenger receptor cysteine-rich protein type 7.1 
(SpSRCR7.1) Q9NC90 7 EGF(3), CCP (1)
Sea urchin coelomocytes (S. purpuratus) Innate immune response T (21)
Scavenger receptor cysteine-rich protein type 7.2 
(SpSRCR7.2) Q9NC89 7 C C P (l)
T (21)
Scavenger receptor cysteine-rich protein type 12 
(SpSRCRl 2) 097375 20 None
S (21)
Scavenger receptor cysteine-rich protein type 20 
(SpSRCR20) Q9NC88 7 None
S (21)
c06b8.7*
017575
Q9VQV1
Q7PVZ0
2/3 PBH (20/21), C T L (l) C. elegans, Insecta - T
PFAM
SMART
SP22D / GRAAL* / Adhesive serine 
Tequila gene protease
Q9U1I2
Q9NJS5
2 CBD2 (2), LDL (2), SP (1) Insect immune-related cell types, hemolymph Innate immune response T/S (22)
products
GRAAL2* Q9B119 2 CBD2 (15), LDL (2), SP(1)
Upregulated in immune challenge
S
PFAM
SMART
|cg2105-pa* (Corin) Q9V4N6 1 FZ (1), LDL (2), S P(1) S (23)
Lysyl oxidase-like Q9V9X5 1 L O X L (l) - (24)
Lysyl oxidase-like 2
Q9N9Y8
Q7QBA0
2 L O X L (l) Insecta - -
PFAM,
SMART
PSLAP/PxSR Q8IM24 2 LH2 (1) LCCL(4) Plasmodium  spp. Toxoplasma spp. - s (1X2)
‘Hypothetical protein; t Please refer to Table IV.4 for information about these domains
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Figure IV.l Domain organisation o f  the non-Chordata protein members o f the scavenger receptor
cysteine-rich (SRCR) superfamily (refer to Tables IV.l and IV.4 for details and abbreviations).
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Table IV.2 Chordata members of the scavenger receptor cysteine-rich superfamily group A
Protein name Uniprot entry N- glycosylation Number o f SRCR 
domains Other domains*
Species or tissue distribution in 
mammals Function
Transmembrane 
or secreted Reference
Tunicate retinoic acid-inducible modular protease 
(TRAMP) Q9Y1V3 - 2 LDL (3), PA N (l) SP(1) T. misakiensis
Stimulation of cell differentiation and/or 
proliferation S (25)
Xesp-2 Q9DGR2 - 1 LDL(8), SP(1) Xenopus laevis Embryonic development T (26)
Scavenger receptor A I
SR-A gene
P21757 - 1 Coiled-coil (1), CL G (l) Macrophage
Innate immune response. Binds 
polyanions (LDL, LPS). T (3)
Scavenger receptor A III 060505 - 1 - Macrophage - T (27)
Macrophage receptor with collagenous structure 
(MARCO) Q9UEW3 - 1 CLG(l) Macrophage
Innate immune response. Binds bacteria 
and lipopolysacharides T (28)
LOXL-like 2 / WS914 Q9Y4K0 Amine oxidase
Cross-linking of extracellular matrix
(29)
LOXL-like 3 P58215 Potential 4 LOXL(l) Most tissues S (30)
LOXL-like 4 Q96JB6 Role in tumour suppression (31)
Neurotrypsin (motopsin, brain specific serine protease 
3 , leydin, PRSS-12) P56730 Potential 4 KR(1), SP(1). Neurones, lungs, Leydig ceils
Morphogenesis and development of neural 
tissue S (32)(33)
Hepsin serine protease P05981 Potential 1 SP(1) -
Cell growth and morphology. 
Overexpression promotes metastasis and 
cancer progression
S/T (8) (34)
Enterokinase P98073 Potential 1 SEA(l), LDL(2), CUB(2), 
M A N (l) , SP(1) Intestine
Activation of pancreatic proteolytic 
proenzymes S (35)
Epitheliasin (TMPRSS2) Q9JIQ8 Potential 1 LDL(l), SP(1)
Epithelia o f die gastrointestinal, 
urogenital, and respiratory tracts
Serine protease T (36)(37)
Tumour associated differentially-expressed gene-12 
protein serine protease (TMPRSS3) P57727 Potential 1 LDL(l), SP(1)
Wide. Inner ear tissue, diymus, 
stomach, testis
Serine protease. Possible substrates: Ion 
transporters & neurotrophins
T (38)
TMPRSS4 (CAP2, MP-SP2) Q9NRS4 Potential 1 LDL(l), SP(1)
Traquea, colon, small intestine, 
pancreas
Serine protease. Involved in metastasis 
formation and tumour invasion T (39)
Spinesin (TMPRSS5) Q9H3S3 Potential 1 SP(1) Neurones Serine protease T (40)
Heart specific serine protease (Corin) Q9Y5Q5 Potential 1 FZ (2), LDL(7), SP (1) Heart myocytes
Activation of die atrial natriuretic peptide 
for blood pressure regulation
T (41)
Complement Factor I (C3B/C4B inactivator) P05156 Yes 1 FIMAC (1), LDL(2),SP(1) Plasma, secreted by monocytes
Serine protease. Regulation of the 
complement cascade
S (42)
Mac2 Binding protein/ 90K/ gp90/ L3 Q08380 Yes 1 BTB(l), IVR(l) Ubiquitous
Promotes intergrin-mediated cell adhesion 
and aggregadon. Tumour cell 
embolisation
S (43)(44)
Cyclophilin C-associated protein /  MAMA 035649
070513 Yes
1 BTB(l) Macrophages Down modulation of endotoxin signal T/S (45)(46)(47)
t  Please refer to Table IV.4 for information about these domains
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— C
• O -  - i * _N
Hepsin
Enterokinase
-a - Epitheliasin / TM PRSS 2,3,4
Spinesin / TMPRSS5
- c > Corin
—  - Complement Factor I
a)oco
Cl
C/5
E 1C/> =
CO CD
1 1 Xo  hi
O " N 
0 _n
Mac-2 Binding protein
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F igure IV.2 Domain organisation of the Chordata protein members o f  the scavenger receptor
cysteine-rich (SRCR) superfamily group A (refer to Tables IV.2 and IV.4 for details and abbreviations).
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Table IV.3 Members of the scavenger receptor cysteine-rich superfamily group B
Nam e
Uniprot
entry
N- glycosylation
N um ber o f 
SRCR 
dom ains
Other domains*
Species or tissue distribution in 
m am m als Function
Transm em brane 
or secreted
Reference
M ultiadhesive protein Q967D 4 yes 1 FN3(2), C C P (l) M arine sponge (G. cyd o n iu m ) Cell aggregation T (48)
PEM A -SR CR Q 92098 potential 2 EG F(4), ZP(1) Sea lam prey (P .m a rin u s ) gut Imm une system T (49)
SIN FR U P000000137426 * - - IG(2) Fugu rubripes - T Ensembl Fugu
18-B Turpentine-induced protein (P1T54) Q98TD1 - 4 None Gallus gallus Antioxidant (50)
Sp-alpha/AIM 0 4 3 8 6 6 yes 3 None Lym phoid com partm ent 
Secreted by m acrophages
Developm ent & maintenance; inhibition o f  apoptosis; binds 
m onocytes and lym phocytes
S (51)
CD5 P06127 yes 3 None Lym phocytes M odulation o f activation and differentiation T -
CD 6 P30203 yes 3 None Lym phocytes and brain M odulation o f activation and differentiation T .
Scavenger receptor cysteine rich containing, group B 
4 dom ains (SRC RB-S4D ) Q 8W TU 2 no 4 None M ucosa Innate im m une response (?) S (52)
CD  163/M  130 Q 07898 yes 9 None
M acrophages
M onocytes
Hem oglobin scavenger receptor; anti-inflam m atory 
function; adhesion T/S (11)
M 160 Q 9N R16 yes 12 None
M acrophages
M onocytes -
T (53)
Scavenger receptor 2* Q 91Y K 7 1 IG-like(4) - - S TrEM BL
W C1/T19 P30205
Q9BDF1
yes 11 None Lym phocytes A ctivation o f differentiation; induction o f  growth arrest T (54)(55)
DMBT1 Q 96D U 4 yes 14 CUB (2), Z P (1 )
Respiratory and digestive systems. 
Tears
Epithelial differentiation; innate imm une system T (56)
G p340 Q 9U K J4 yes 14 CUB (2), Z P  (1)
M acrophage, respiratory m ucosa, 
small intestine
Binds a collectin fam ily m em ber; opsonin receptor; innate 
im m une response
T/S (1 3 )(5 7 )
Salivary agglutinin Q 9U K J4 yes 14 CUB (2), ZP (1) Saliva
Broad bacterial recognition and agglutination; binds IgA, 
IgG and other proteins
T/S (58)
CR P-D uctin  (mouse /  p ig) Q 60997 yes 8 CUB (5), Z P (1 ) Gastric, lug m ucosa
Epithelial differentiation; innate im m une defence; binds 
bacteria and som e proteins
T/S (59)(60)(61)
products M uclin (mouse) Q 9JH U 8 yes 8 CUB (5), ZP  (1) Pancreas Probable Golgi cargo receptor T (62)
V om eroglandin (mouse) Q 9JM J9 yes 7 CUB (5), Z P (1 ) Vom eronasal system Involved in pherom one perception (63)
Ebnerin (rat) Q 62827 yes 4 CUB (3), Z P  (1)
Liver, lung, heart, testis, von 
Ebner's salivary gland
Hepatic tissue repair and differentiation; regulation o f  taste 
sensation
T/S (64)(65)
Pancrin (rat) Q 6Q D 54 - 4 CUB (3), Z P (1 ) Pancreas - - TrEM BL
Hensin (rabbit) Q 95218 yes 8 CUB (2), Z P (1 ) Kidney, gastric m ucosa Induction o f  epithelial differentiation S (66)(67)
M ucin (cow) Q28908 yes - - Gall bladder epithelium  and pancreas Binds biliary lipids; prom otes cholesterol crystal nucleation s (68)
♦Hypothetical protein; $ Please refer to Table 1V.4 for information about these domains
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Figure I V.3 Domain organisation of the protein members o f the scavenger receptor cysteine-rich (SRCR)
superfamily group B (refer to Tables IV.3 and IV.4 for details and abbreviations).
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Table IV.4 Domains found in the same protein with SRCR domains
Size
(a.a .)
C A T H  or S C O P  entry
PD B
exam ple
O ccu rren ce  in hum an  pro teom e*
N am e O th er nam es A bbr. In terp ro  en try  Function S-S
C lass A rchitecture M atches # % R ank
R eferences
A pple  d ivergen t subfam ily
P lasm inogen, A pple, 
N em ato d e  (P A N ); apple-like
PA N IP R 003609 P ro te in  an d /o r sugar b inding 90 3 a  P 3-layer sw 1BH T 20 9 0.03 - (69)
B road-C om plex , T ram track  and  B ric-a-B rac
P oxvirus and  zinc finger 
(P O Z )
BTB IP R 000210 P ro te in  binding; o ligom erisation 100 0 a  P 2-layer sw 1BU O 5 26 209 0.63 37 (70)
C -type lectin
C arboh y d ra te -reco g n itio n  
dom ain  (C R D )
C T L IP R 001304 Sugar b inding 130 0 a p Roll 1IXX 413 103 0.31 79 (71)
C hitin  b ind ing  dom ain  type 2 Peritroph in -A C B D 2 IPR 002557 C hitin  b inding 70 3 M ainly  P C om plex 1D Q C 6 2 0.01 - (72)
C ollagen  trip le helix  rep ea t C LN IP R 0 0 8 160
Structural; trim erisation; 
carb o h y d ra te  b inding
50 0 N C N C 1Q 7D 861 111 0.33 73 In terp ro
C om plem ent su bcom ponen ts C lr/C ls, U eg f 
and  B one m orphogenic  p ro te in  1 C U B IP R 00859 P ro tein  an d /o r sugar b ind ing 110
2 M ainly  P Sw 1SPP 680 80 0.2 4 100 (73)(74)
D om ain  abundan t in  com plem ent con tro l 
pro teins
Short com plem ent like 
rep ea t (S C R ); sushi repea t
C C P IP R 000436 P ro te in  b inding 60 3 M ainly  P R ibbon 1QU B 1420 87 0.2 6 97 (75)
E piderm al g ro w th  facto r-like  p ro tein E G F IP R 006209 Protein  b inding 40 2 M ain ly  P R ibbon 1JL9 3740 604 1.82 6 (75)(76)
F ac to r I m em brane a ttack  com plex F IM A C LPR003884 Protein  binding; S P  inh ib ito r (?) 70 3 A lpha P* 2-layer sw* 1BUS* 3 2 0.01 - (77)
F ib ronectin  type III FN3 IPR 003961 P ro tein  and  su g ar b inding 100 2 M ainly  P Sw 2H FT 2930 244 0.73 28 (78)
F rizzled  cy ste in e-rich  dom ain FR I IP R 000024 Protein  b inding 120 5 A l l a 3 h elices; irregular 1UY 118 34 0 .1 0 - (79)
Im m unoglobulin-like IG IP R 0 0 7 1 10 P ro tein  b inding 100 1 M ainly  P Sw 1ETZ 7270 1142 3.44 1 (80)
K ringle KR IP R 000001
Protein  and  lipid binding; 
regu la tion  o f  S P /T K
90 3 M ainly  P B arrel 1TPK 4 93 28 0.08 - (81)
Lim ulus fac to r C , C o ch -5 b 2  and  L g ll L C C L IP R 004043 U nknow n 100 2 « P
M ainly  antiparalle l 
sheets; unusual
1JBI 30 9 0.03 - (82)
L ow -density  lipopro tein  recep to r c lass  A L D L IP R 002172 L ipopro tein  b inding 40 3 Little R S E Irregular 1F5Y 879 58 0.17 149 In terp ro
L ypoxygenase hom ology
Polycystin -1 , lipoxygenase, 
a lpha-tox in  (PLA T )
LH 2 IP R 001024 P ro tein  b ind ing 110 1 M ainly  P Sw 1BU 8 135 33 0 .1 0 - In te rp ro
L ysyl oxidase-like L O X L IPR 001695 O xida tive  deam ination 200 4 - - N one 65 8 0 .0 2 - In terp ro
M eprin , A 5, rec e p to r tyrosine p h osphatase  
mu
M A M IPR 000998 A dhesion 170 - - N one 163 23 0.07 - In terp ro
P arallel b eta-helix  repea ts PB H . - 20 0 M ain ly  P 3 Soleno ide 1QQ1 - - - - In terpro
S ea  urch in  sp e rm  pro tein , en te rok inase , 
an  grin
SEA IP R 000082 C arb o h y d ra te  b inding 130 0 a  P 2 -layer sw 1IVZ 184 26 0 .08 - In terp ro
T rypsin  Inhib itor-like  cyste ine-rich T IL DPR002919 - 60 5 M ain ly  P R ibbon 1CC V 83 19 0 .0 6 - In te rp ro
T rypsin -like  serine p ro tease S P IP R 0 0 1 2 5 4 P ep tidase 130 yes M ain ly  P B arrel 1FA X 651 166 0 .5 0 45 In terp ro
T yrosine  k inase T K IP R 001245 P ho sp h o tran sferase 100 0 a  P 2 -lay er sw 1R1W 937 236 0.71 33 In terp ro
Z ona  pellucida Z P IP R 001507 O ligom erisation 260 4 - - N one 129 23 0.07 - (83)
* In tegr8  B ro w ser @ w w w .eb i.ac .u k /in teg r8 ; + S truc tu re  o f  the h om ologous fo ld  K azal
S -S , disu lphide b onds; a .a .  am ino ac id s ; #  N u m b er o f  p ro te in s; %  percen tag e  o f  the genom e; S P , serine  p h o sp h atase ; T K  tyrosine k inase; sw , sandw ich ; N C , not c lass ified ; R S E  reg u la r  seco n d ary  structu re
These interactions include the Mac-2 binding protein (M2BP) binding to galectin-3, 
collagen, fibronectin and nidogen43, cyclophilin C-associated protein (CyCAP) binding to 
cyclophilin C44, and SR-A binding to polyanions84. SRCR domains are also involved in 
cell binding to bacteria, probably via interactions with saccharide moieties on the bacterial 
surface. Trimeric constructs o f the macrophage scavenger receptor MARCO containing 
only the first 19 residues o f its SRCR domain bind bacteria with high affinity. The motifs 
in the SRCR domain Arg-Gly-Arg and/or Arg-Val-Arg are essential for the binding85. A
peptide corresponding to residues 11-26 o f the N-terminal SRCR domain o f gp340, with
86the motif Gln-Gly-Arg has also been reported to bind bacteria . These RGR and QGR 
sequence motifs are moderately conserved throughout the SRCR superfamily in the 
second P-strand o f the domain (Figure IV.9).
In this Chapter, I present the first structure of a group B SRCR domain, the doubly 
substituted (V88D/V97K) N-terminal domain of human CD5 (hereafter referred to as 
/iCD5dlm). The sequence identity between /zCD5dlm and the two previously solved 
group A domains is lower than 20%. However, the distribution of regular secondary 
structural elements is shown to be similar in the three structures, but these regions 
account for less than 35% of the 110 residues of the domain. The remainder o f the fold 
comprises long loops that appear to be mobile in /zCD5dlm. The presence of the 
additional C1-C4 disulphide-bond in /*CD5dlm, which occurs only in group B members 
o f the SRCR superfamily, does not significantly impact in the overall conformation of 
the molecule. The low sequence identity among members o f the superfamily suggests 
that this fold is a stable scaffold that tolerates great sequence variation in its potentially 
exposed (long) loop regions, probably allowing substantial variations in ligand 
specificity across the superfamily.
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Experimental procedures
The experimental work presented in this Chapter was a collective effort o f Dr Richard Harris (RH), Dr 
Diego Esposito (DE) and m yself (AG). The initials o f the person that performed each part o f  the 
experimental work are written after the title o f the section. The NM R resonance and assignment data from 
the glycosylated /zCD5dl construct were kindly provided by Dr Mark Pfuhl.
Sample preparation (AG)
Samples of V88D/V97K /zCD5dl labelled with 15N or with 13C and 15N were prepared as 
described in previous chapters. Labelling was achieved by growing the cells in 
supplemented minimal medium using C-glucose and/or ( N H ^SC L  as the sole sources 
for carbon and nitrogen respectively. The purified protein was dissolved in 90% 50 mM 
phosphate pH 5.0, 200 mM NaCl, ImM EDTA, 0.01% (w/v) NaN 3 / 10% D2O at a protein 
concentration in the region o f 1 mM. Both standard Imperial grade 5mm NMR tubes 
(Wilmad) and susceptibility matched tubes (Shigemi) were used to contain the samples.
NMR spectroscopy (RH)
All experiments were recorded on either Varian Unity INOVA or Varian UnityPLUS 
spectrometers, operating at nominal !H frequencies o f  600 MHz and 500 MHz 
respectively. Both spectrometers are equipped with a 5mm indirect detection, triple 
resonance (]H/13C/15N) probe and have a Z-axis pulsed field gradient capability. Chemical 
shifts were indirectly referenced to sodium 2,2-dimethyl-2-silane-pentane-5-sulphonate 
(DSS) using absolute frequency ratio to the ]H signals87.
Sequential backbone and  Cp resonance assignment at 298 K  and 318 K  (AG & RH)
Sequence specific resonance assignments o f  H 15N, 15NH, 13C a  and also 13Cp nuclei were 
obtained from the triple resonance correlation spectra HNCA88, HNCACB89, and 
CBCA(CO)NH90. The HNCA and HNCACB experiments provide cross-peaks between 
the Cp and/or C a of the current (/) and the preceding residues (M ), and the N and NH of 
residue /. The CBCA(CO)NH spectrum correlates the C a  and Cp o f the i-\ residue with
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the N and NH of residue i. Typically, 1024 complex data points were collected in the 
proton dimension and 64 and 34 complex points in the 13C and 15N dimension respectively 
(Please refer to Appendix C for a list o f all experimental details). Carbonyl carbons and 
H a signals were assigned only at 318K using the 3D HNCO88 and the HA(CACO)NH91 
experiments, respectively.
Side chain and NOE resonance assignments at 318 K  (RH)
Resonances o f aliphatic side chains were assigned using the 15N-separated TOCSY- 
HSQC92 and the HCCH-TOCSY93 experiments, each recorded with a mixing time o f 20
13ms. In an ideal case, the latter spectrum allows the correlation of C a, H a  with all 
aliphatic side chain protons and carbon nuclei within a given residue, provided there is 
appropriate H-C-C-H connectivity. The 15N-separated TOCSY-HSQC correlates side 
chain protons with the amide proton and amide nitrogen. Proton and carbon resonances 
within aromatic rings were identified with an 'aromatic' HCCH-TOCSY recorded with a 
,3C mixing time of 12 ms. Interproton NOEs arising from through-space dipolar 
interactions were identified by recording 15N and 13C-edited NOESY-HSQC spectra with a 
]H mixing time of 100 ms.
NMR data processing and analysis (RH & AG)
All spectra were processed and displayed with the program NMRpipe/NMRDraw94. Plot2 
from AZARA95 was used to plot all ID and 2D NMR spectra for Figures IV.4-7. Spectra 
were analysed using ANSIG 3.396.
A typical processing scheme used to obtain 3D NMR spectra from the free induction 
decay (FID) data set consisted o f the following steps:
*H dimension
1. Subtraction of the water signal from the FID by polynomial fitting by application 
o f a high-pass digital filter.
2. Correlation o f the FID with a window function (apodisation) to generate a signal 
with a smooth decay in order to avoid data truncation artefacts.
3. Doubling the data size by addition o f null data to the FID (zero filling) in order to 
increase digital resolution and signal to noise ratio o f the transformed spectrum
4. Application of the Fourier transform to obtain intensity vs. frequency data
5. Manual correction of the phase o f the spectrum.
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13C and 15N dimensions
The interferogram was first extrapolated using linear prediction in order to enhance 
resolution and then the strategy outlined for the *H dimension was followed, with 
exception o f the water signal subtraction.
Structure calculation (DE)
1 1 3Interproton distance restraints were obtained from the analysis o f the 3D H- C NOESY- 
HSQC and *H-15N NOESY-HSQC spectra. Cross peaks were assigned manually, classified 
into four categories according to their relative peak intensity, and associated with an 
interproton distance restraint limit as follows: strong peaks (1.8-2.5 A), medium peaks 
(1.8-3.0 A), weak peaks (1.8-3.5 A) and very weak peaks (1.8-4.0 A). For NOEs involving 
methyl groups, 0.5 A was added to the upper limit to account for the 3-fold degeneracy 
and narrow linewidth o f these signals. Only unambiguously assigned cross peaks and 
distance restraints were used in the calculations. Ambiguous distance restraints were 
filtered out based upon the coordinates of the ensemble in early calculations. Backbone cj)
1 13 13 13and \\f torsion angle restraints were derived from the pattern o f H a, C a, Cp, C' and 
15NH chemical shifts using the database searching program TALOS97. Dihedral angle 
restraints were assigned an error range o f ±20°. The presence of the four disulphide bonds, 
Cys44-Cys86, Cys60-Cysl25, Cys81-Cysl32 and Cysl07-Cysl 17, were predefined in the 
topology file for structure calculations, but covalent terms corresponding to these bonds 
were only turned on after the torsion dynamics step.
Structures of /zCD5dlm were calculated from the experimental restraints using the CNS- 
solve program98 employing the PARALLHDGv5.3 force field parameters99’100, with the 
non-bonded energy function o f PROLSQ. To induce the proper conformation of prochiral 
centres (methylene and isopropyl groups), protocols were modified to allow floating 
stereospecific assignments and active atom swapping101,102. The dynamic simulated 
annealing protocol consisted o f two stages: high temperature (10,000 K) torsion angle 
molecular dynamics for 2200 steps o f 45 fs each, and Cartesian dynamics while cooling 
from 2,000 K to 50 K in 20,000 steps o f 5 fs each. After the simulated annealing each 
structure was energy minimised with 200 steps o f Powell minimisation and an ensemble 
o f 100 conformers was calculated. In order to improve the structure quality, all structures 
generated in the torsion dynamics protocol were used as starting points for restraint
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refinement in explicit solvent100. The final ensemble consisted o f the 20 lowest energy 
conformers from the refinement.
Results
Sequence-specific backbone and  C[3 resonance assignment o f  hCDSdlm at the typical 
operational temperature o f  25° C (298 K)
The ]H-15N HSQC spectra of both wild-type /*CD5dl and /zCD5dlm consisted of peaks 
o f different intensities and shapes. Some peaks were strong and symmetric while others 
were weak and broad; additionally there were fewer signals than expected from the 
amino acid sequence. This variable peak appearance suggested that a subset o f nuclei 
were experiencing chemical exchange processes on an intermediate timescale, i.e. 
between 10'6 to 10 3 seconds103. Such extensive exchange suggests that a substantial 
proportion of the protein has conformational flexibility. The sequence specific 
assignment of NH, C a and Cp resonances was attempted but the presence o f exchange 
broadening made the assignment of peaks very difficult. Many peaks showed strong 
overlapping and low intensity, and only 53% of the backbone amide N-H resonances 
could be unambiguously assigned in the ]H -15N HSQC spectrum (Figure IV.4).
The NMR behaviour ofhC D 5dlm  improves with increasing temperature
The intensity and line width o f the NMR signals in the spectra for /zCD5dlm was greatly 
affected by changes in temperature (Figures IV.5-6). Very few signals were present in the 
*H-15N HSQC spectrum at 278 K. As the temperature was increased progressively, more 
peaks were detected and peaks became more intense and symmetric. It was not until 318 
K that the intensities of the peaks in the spectrum became fairly even and the vast majority 
o f the expected peaks became visible. This behaviour must be consequence of either of 
two phenomena: (i) a progressive increase in the rate o f the exchange among different 
conformations; (ii) the stabilisation o f a single conformer with the increase in temperature. 
Whatever the case may be, the /zCD5dlm samples could be kept at 318 K for several days 
without denaturation or other changes becoming apparent in the NMR spectra. This high 
thermal stability, probably due to the presence o f multiple disulphide bonds, permitted the 
full sequence specific backbone resonance assignment o f the ^ - ^ N  HSQC spectrum and
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allowed us to proceed with side chain and interproton NOE assignments and finally with 
the calculation o f the 3D solution structure.
Resonance assignment and calculation o f a preliminary structure ofhC D Sdlm  at 318 K
The backbone amide NH resonances for almost all residues within the sequence o f the 
/zCD5dl domain, with the exception o f Asn41, Cys44, Serl03 and Hisl26, could be 
located in the ]H-15N HSQC spectrum at 318 K (Figure IV.7). The first 10 residues of the 
construct, which are part o f the affinity tag, were not visible in any spectra, indicating 
that they are highly mobile. The remaining nine residues o f the tag were assigned in the 
]H-15N HSQC spectrum. Ninety-five percent o f the side chain resonances were assigned. 
A total of 1088 unambiguous interproton distance restraints and 94 backbone dihedral 
angle restraints obtained from the analysis of the spectra were used for the structure 
calculation. The statistics for the 20 conformers with the lowest total energy after 
refinement in explicit water are presented in Table IV.5 (Figure IV.8A). The average 
global root mean square deviation (RMSD) o f the best-fit ensemble was 1.59±0.26 A for 
the backbone and 2.74±0.37 A for all heavy atoms. The backbone atoms o f 61% o f the 
residues (26-30, 33-40, 42, 44-52, 55-64, 76-95, 104-107, 113-114, 117-119, 128-133), 
including all elements o f regular secondary structure and some turns and loops, were 
better defined within the ensemble and superimposed with an average global backbone 
RMSD of 1.04±0.14 A. The positions o f the remaining residues were less well defined. 
These 'disordered' residues are mainly found in three long loops. One loop comprises 
residues 65 to 75 which correspond to an insert in the amino acid sequence o f the CD5dl 
domains that is not present in any other SRCR domain (Figure IV.9); the second loop 
consists of residues 96 to 103; and the last loop connects residues 120 and 128.
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Figure IV.4 (A) 'H-ISN HSQC spectrum of /zCD5dlm at 298K and pH 6 showing the assignment o f the backbone amide resonances. Under these conditions only 40% o f the expected 
backbone HN signals could be assigned. (B) Two views (rotated 180° with respect to each other) o f the solvent accessible surface o f the final structure o f ACD5d 1 m at 318K and pH 5 (see 
below). Residues whose backbone HN resonance could beassigned at 298K (green) cluster at one side o f the N-glycosylation site (blue). Prolines are in yellow.
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Figure IV.5 'H -I5N HSQC spectra o f /iCD 5dlm  at different temperatures. The construct experiences chemical exchange processes, on a timescale between 106 to 103 seconds, that causes 
severe line broadening and loss o f peak intensity. The increase in temperature speeds up the exchange rates to a point where only the averaged conformation is fully represented by 
backbone NH cross peaks.
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F igure  IV.6 ID  cross section traces through the 'H -I5N  HSQC spectra o f  (A) /iCD 5dlm  and (B) human 
ubiquitin, at several temperatures.
/zCD5dlm experiences chemical exchange on an intermediate timescale (10 6 to 103 second)below 298 K, 
temperatures above 298 K shift the exchange to a fast timescale (< 106 second) improving the appearance o f 
the spectra. In the case o f ubiquitin, temperature has only a minor effect in peak intensity or shape.
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Figure IV.7 'H-15N HSQC spectrum o f /zCD5dlm at 318 K and pH 5 showing the assignment o f the 
backbone amide resonaces.
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AB
F i g u r e  I V . 8 N M R  s o l u t i o n  s t r u c t u r e  o f  / i C D 5 d l m  a t  p H  5 a n d  3 1 8  K.
(A) Backbone atoms o f the ensemble o f the 20 lowest energy conformers obtained after restrained 
refinement in explicit water.
(B) Two orthogonal views of a ribbon representation o f the structure o f the lowest energy conformer o f the 
ensemble (P-strands, blue; a-helix, green; disulphide bonds, yellow). The p-strands are named 
according to the number of their corresponding P-sheet (before the point) and P-strand number within 
that sheet (after the point).
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Table IV.5 Restraints and structural statistics of the h CD5dlm ensemble
E n se m b le  (n = 2 0 ) L o w es t e n e rg y  c o n fo rm er
N u m b e r  o f  e x p er im e n ta l r e s tra in ts
In te r -p ro to n  d is ta n c es
A ll 1088
In tra -re s id u e 391
S eq u en tia l (| i - j  =  1) 291
S h o rt (1 <  | i - j  | <  5) 93
L o n g  ( | i - j  | >  5) 313
D ih ed ra l an g le s 94
D isu lp h id e  b o n d s 4
R o o t m e a n  sq u a r e  d e v ia tio n  f r o m  e x p er im e n ta l d a ta  (C N S)
In te r -p ro to n  d is ta n c es  (A )
A ll 0 .0 4 2 ± 0 .004 0.043
In tra -re s id u e 0 .0 1 8 ± 0 .002 0 .0 1 8
S e q u e n tia l (| i - j  | =  1) 0 .0 2 8 ± 0 .0 0 5 0 .0 3
S h o rt (1 <  | i - j  | <  5) 0 .0 7 2 ± 0 .0 1 1 0 .0 8
L o n g  ( | i - j  | >  5) 0 .0 6 5 ± 0 .0 1 0 0 .0 5 4
D ih ed ra l a n g le s  ( ° ) 1.2±0.1 0 .8 9
R e s tra in t v io la tio n s  (C N S)
N O E  v io la tio n s  >  0 .5  A 0 .95± 0 .51 1
D ih ed ra l an g le  v io la tio n s  >5° 0 .2 ± 0 .4 0
N o n  -b o n d e d  e n e rg y  v a lu e s  (kca l/m o l)  (C N S)
v an  d e r  W a a ls  e n e rg y  (L e n n ard -Jo n es) -8 9 .0 ± 4 3 .4 -69 .7
E le c tro sta tic  e n e rg y -6 9 1 ,7 ± 1 0 7 .9 -601.1
A v e ra g e  ro o t m e a n  sq u a re  d e v ia tio n  to  th e  m e a n  s tr u c tu re  (A) (M O L M O L )
B ack b o n e  a to m s ( re s id u e s  2 5 -1 3 4 ) 1 .1 2 ± 0 .1 7 1.2
H eav y  a to m s ( re s id u e s  2 5 -1 3 4 ) 1 .9 4 ± 0 .2 0 1.95
R e g u la r  ec o n d a ry  s tru c tu re  b a c k b o n e  a to m s (32  re s id u e s* ) 0 .5 8 ±  0 .1 2 0 .7 4
R e g u la r  s e co n d a ry  s tru c tu re  h eav y  a to m s (32  re s id u e s* ) 1.14 ± 0 .10 1.28
W ell d e fin e d  b a c k b o n e  a to m s (68  res id u e s* * ) 0.71 ±0.11 0.65
W ell d e fin e d  h e a v y  a to m s (68  res id u es* * ) 1 .2 2 ± 0 .1 0 1.10
R o o t m e a n  sq u a r e  d ev ia tio n  f r o m  id e a lise d  c o v a le n t g e o m e try
B o n d s ( A ) 0 .0 0 4 7 ± 0 .0 0 0 3 0 .0 0 4 6
A n g le s  (°) 0 .6 6 ± 0 .0 3 0.65
Im p ro p e r  d ih ed ra ls  (°) 2 ±  0 .2 1.9
R a m a ch a n d ra n  p lo t  s ta tis tic s  (P R O C H E C K )
R e s id u es  in  m o s t  fa v o u re d  reg io n s  (% ) 6 3 .2 65.3
R e s id u es  in  a d d itio n a lly  a llo w e d  reg io n s  (% ) 25 .3 26.3
R e s id u es  in  g e n e ro u s ly  a llo w ed  reg io n s  (% ) 5.3 2.1
R e s id u es  in  d isa llo w e d  reg io n s(% ) 6.3 6.3
♦ R e s id u e s  fo rm in g  re g u la r  s eco n d ary  s truc tu re : 3 5 -3 7 ,4 5 -5 0 ,  5 7 -5 8 , 7 8 -8 4 , 9 1 -9 4 , 1 0 5 -1 0 7 ,1 1 7 -1 1 9  a n d  128-131
166
Description o f  the structure
/zCD5dlm forms a globular domain of approximately 109 residues, between Arg25 and 
Glul34. The first residue that is involved in long-range interactions is Leu26, which is 
seven residues before the nominal N-terminal boundary o f the domain deduced from 
consensus sequence alignment and the two known 3D structures o f SRCR domains. These 
seven residues are not conserved in other species, and possibly this is not a general feature 
o f other group B SRCR domains. The structure consists o f a short a-helix, three anti­
parallel p-sheets and several extensive loops. As one traverses the polypeptide chain from 
the N-terminus to the C-terminus, the chain firstly forms four p-strands up to residue 
Cys60. After a further 19 residues without regular secondary structure the a-helix comes 
next, followed by a six-residue turn preceding the fifth P-strand. A 10-residue loop 
follows, then the sixth and the seventh P-strands separated by a further 9-residue loop. 
After a 6-residue loop, the eighth p-strand is formed at the end o f the polypeptide chain. 
Thus, the regular secondary structural elements of the fold are in sequential order p 1.1 
(A)-P2.1 (B l)-p l.2  (B2)-pi.3 (C)-a-p2.2 (D)-P3.1 (E)-p3.2 (E>p2.3 (F), where the first 
number indicates the p-sheet number, and the second number indicates the strand number 
within the p-sheet (Figure IV.8B).
Traversing in the conventional direction from the N-terminus towards the C-terminus, the 
first disulphide bond in the structure, Cys44 -Cys86, bridges the p l.l/p2.1 loop to the 
a/p2.2 loop (this is the C1-C4 disulphide bond that is the distinguishing feature o f group 
B SRCR domains). The second disulphide bond, Cys60-Cysl25, corresponding to the 
generic C2-C7 bond in SRCR domains, connects the p i.3 /a  and p3.2/p2.3 loops. The 
disulphide bond between Cys81-Cysl32 corresponds to the generic C3-C8 bond, the only 
disulphide found in all SRCR domains; this disulphide connects the a-helix with the end 
o f strand p2.3, at the C-terminus o f the fold. Finally, the disulphide bond between Cysl07 
and Cysl 17 (the generic C5-C6 bond) links strand p3.1 with strand p3.2.
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Figure IV.9 Structure-based multiple sequence aligment o f selected members o f the SRCR domain 
superfamily. The regular secondary structure elements o f the available structures are represented at the top: 
P-strands (blue arrows), a-helices (green ribbons) and 3, helices (pink ribbons). The alignment was computed 
with 3D-Coffee using both pairwise sequence aligments and pairwise structure comparisons. Residue colour 
coding: red, positive; purple, negative; blue, hydrophobic; green, aliphatic & polar; cyan, aromatic & polar; 
pink, cysteine; yellow, proline; orange, glycine.
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Fourteen o f the residues that form the hydrophobic core o f the /zCD5dlm structure are 
well conserved among the SRCR superfamily. These residues are: Ala35, Leu37, Leu48, 
Val50, Leu52, Val59, Trp64, Ala77, Val80, Leu90, Leu92, P hell4 , Leul28, and 
Leul30. Three non-conserved residues, Trp28, Phe33 and L e u l l l ,  are also part o f the 
hydrophobic core. There are five exposed aromatic resides scattered over the surface of 
the structure: Tyr29, Tyr51, Trp56, Trp71, and Tyrl08. These residues could interact 
with the N-linked carbohydrate in the glycosylated form. In /*CD5dlm, the only 
conserved or semi-conserved residues apparently involved in side chain to main chain or 
side chain to side chain hydrogen bonds are Gln47, Trp64 and Arg83. Non-conserved 
residues that potentially form structurally important side chain hydrogen bonds include 
Asp30, Gln34, Arg66, Thr38, Gln62, Gln76 and Thr98. The domain is unusually rich in 
Ser (16% of all residues); most of these residues are located in the extended loops and 
many of the side chains appear to make hydrogen bonds with the backbone in the final 
structure ensemble.
A curious feature o f the ’H -^N HSQG spectrum of /zCD5dl is a cross peak located around 
3.0 ppm in the dimension. This value is extremely unusual for a backbone amide 
group, and implies that this particular amide group is strongly shielded from the magnetic 
field generated by the spectrometer (Bo). The signal corresponds to G ly ll2  backbone 
amide, which is in spatial proximity to the aromatic rings o f Trp28, Trp64 and P h e ll4  
(Figure IV. 10C). Consequently it seems that the HN of G ly ll2  encounters an effective 
magnetic field that has been diminished by the magnetic fields generated by the 
7i electrons of Trp28, Trp64 and/or P h e ll4 . As the frequency of resonance is directly 
proportional to the effective magnetic field, the chemical shift o f the HN nucleus moves to 
a lower frequency in the spectrum. The dramatic shift o f more that -5 ppm from the coiled 
coil value suggests that the HN of G ly ll2  is located perpendicularly to one o f these 
aromatic rings, because it is at this position that maximum shielding occurs (Figure 
IV .l OB). Unfortunately, in our ensemble o f structures this is not the case. The calculated 
contributions to the shift (using the Haigh-Mallion method as implemented in MOLMOL 
104,105) o f the HN nucleus of Glyl 12 are o f roughly -1.0 ppm for Trp28 and -0.5 for Trp64, 
and the contribution o f P h e ll4  is either null or slightly positive (deshielding) in all 
members of the ensemble. Most likely, the precise conformation o f the aromatic rings or 
the position o f this particular HN is not well defined by the experimental constraints.
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Figure IV.10 (A) 'H-I5N HSQC spectrum of /?CD5dlm showing the position of the highly shifted cross peak of the backbone amide group of Gly 112. The precession 
frequency of the HN of Gly 112 is dramatically decreased from the random coil value. Such a large shift usually indicates that the proton is shielded from the external 
magnetic field by neighbouring aromatic rings, this is called a ring-current shift. As shown in (B), the induced magnetic field generated by the n electrons of an 
aromatic ring decreases the local field of nuclei situated perpendicular to the ring and increases the local field of nuclei situated in the plane of the ring. Thus, the HN 
group of Gly 112 is predicted to be perpendicular to an aromatic ring. However, the ensemble of calculated structures of /zCD5dl does not correspond to this 
prediction. According to our preliminary ensemble of structures, the aromatic rings that influence the local field of the HN group of Glyl 12 are Trp28, Trp64 and 
Phel 14 (C). The spatial arrangement of these residues in respect to the HN of Glyl 12 does not explain the dramatic shift. The ring-current shift for the HN of Glyl 12 
calculated from this structure is only ~1 ppm, while the observed shift is of—5.5 ppm
Discussion
Flexibility ofhC D 5dl
Chemical exchange effects in NMR spectra can arise from a number of sources, including 
exchange o f labile protons with those o f the solvent, an oligomerisation equilibrium or 
conformational variation. In the case o f /*CD5dlm, the strong temperature dependence of 
the linewidths in the spectra, together with the marked differences in the behaviour of 
different regions o f the structure suggests that the dominant exchange processes involve 
complex conformational variations. The severity o f the temperature dependence is 
reminiscent of that which has been observed for the molten globule states of a -  
lactalbumin106,107 and apomyoglobin108. Both /zCD5dlm and molten globule states 
experience a dramatic improvement on the quality of the NMR spectra as a result of an 
increase in temperature. Although /zCD5dlm is not a classical molten globule (many side 
chain and backbone fixed tertiary interactions are evident in the NMR data), analogous 
exchange processes may be occurring. In the case o f the molten globule state, and most 
likely also for /*CD5dlm, the change from very broad lines to intense narrow lines with 
increasing the temperature can be explained as arising from an increase in the rate at 
which the different conformations are sampled107. The severe line broadening observed in 
the spectra is probably the result o f multiple interacting conformational exchange 
processes occurring as the domain switches between several energetically similar 
conformations. At high temperature a single chemical shift corresponding to its averaged 
environment is observed for each amide. In the case o f /*CD5dlm, the differential effect of 
temperature on the two sides o f the structure is presumably a result o f differences in the 
temperature dependence o f local structural stability. It seems that on the structured face of 
the domain one particular conformation becomes more stable than the others above 298 K. 
Consequently, exchange effects are diminished by that conformation becoming highly 
populated and hence dominating the spectrum. The disordered face o f the molecule, 
however, remains in conformational exchange and its peaks only become visible through 
the increase in exchange rate at higher temperatures.
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It is yet to be determined whether the dynamic features o f /?CD5dlm are an intrinsic 
property of the domain, or a result of the deliberate experimental manipulations o f the 
protein, e.g. the isolation of the domain from the rest o f the protein, the mutations and/or 
the absence o f N-linked carbohydrate. The possibility that the two mutations introduced to 
improve protein solubility are the cause o f this behaviour can be discarded, because the 
NMR spectra of the wild type construct and the double mutant both exhibit the same line 
broadening. On the other hand, there is strong evidence to support that at least part o f this 
flexibility is due to the absence of the N-linked carbohydrate.
Covalently-bonded glycans play a variety o f different roles in proteins. Glycans often 
provide recognition sites for receptors109, control o f maturation in the endoplasmic 
reticulum110, or serve as protein chaperones. It is thought that the glycans in leukocyte co­
receptors such as CD5 are involved in preventing non-specific interactions111, modulating 
protein organisation within the cell surface112, protecting the receptors from proteases, 
providing rigidity to the molecule so that it can extend away from the surface, and 
increasing conformational stability112. Most o f the N-H cross peaks in the !H-15N HSQC 
spectrum of an N-linked glycosylated form of CD5dl expressed in Pichia pastoris (Mark 
Pfhul, personal communication) do not experience line broadening at 298 K, suggesting 
that the observed mobility o f some /zCD5dlm residues is a consequence o f the absence of 
the N-linked carbohydrate. The fact that above 298 K all o f the mobile residues of the 
unglycosylated domain are clustered on the same face o f the fold to one side of the N- 
glycosylation site (Figure IV.4) supports this explanation. Thus, it appears that the 
covalently bonded carbohydrate in /zCD5dl confers additional rigidity to an extensive 
region of the structure.
The P. pastoris N-glycosylated /zCD5dl spectrum exhibits more moderate exchange- 
derived features that appear to be limited to a group o f 10 residues (Ser61, Gln62, Gln70- 
Glu73, Phe95, and Aspl23-Cysl25). The cross peaks o f these residues are absent in both 
the N-glycosylated and the unglycosylated ^ - ^ N  HSQC spectra at 298 K. These residues 
may have an inherent conformational mobility. The residues Ser61, Gln62, Aspl23, 
Met 124, and Cysl25 are located close to the disulphide bond between Cys60 and Cysl25. 
It is possible that the motions o f these residues are caused by the isomerisation o f this 
disulphide bond. Another disulphide bond that might be experiencing isomerisation is 
Cys44, whose cross peak could not be found in any o f the NMR spectra. A disulphide 
bond isomerisation resulting from a 180° rotation o f the %1 dihedral angle o f one o f the
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involved cystines has been comprehensively studied in basic pancreatic trypsin inhibitor 
(BPTI)113' 115. In BPTI the interconversion between the two rotamers o f the each o f the two 
cystines forming the disulphide bond occurs in a microsecond to millisecond timescale 
resulting in line broadening o f the backbone amide cross peaks o f the two cysteines and of 
their neighbouring (7+1) residues113,116. Disulphide bond isomerisation has also been 
reported to contribute to chemical-exchange line broadening in other proteins, such as 
another Kunitz (BPTI-like) domain117 and two epidermal growth factor-like 
domains118,119.
Another possibility is that the flexibility in the yeast construct arises as a consequence of 
the non-native nature o f the N-linked glycan expressed in P. pastoris. The glycoproteins 
expressed by P. pastoris do not contain some o f the residues found in mammalian glycans, 
such as fucose, galactose and sialic acid120. These three monosaccharides are known to be 
components o f the N-linked glycans attached to /zCD5dl when expressed in mammalian 
cell lines121.
Whilst the increase in temperature to 45 °C made possible the calculation o f the structure 
o f /zCD5dlm, it is important to keep in mind that the values o f chemical shifts and NOE 
intensities detected under these conditions in many cases reflect an average over the 
ensemble of distinct conformations that exist in solution. In order to characterise the 
dynamic processes involved and make a direct assessment of the amplitude and timescale 
o f these motions, it would be necessary to perform a detailed NMR spin relaxation 
analysis.
Comparison with the other SRCR domains
The only 3D structures o f SRCR domains that have been reported to date are the SRCR 
domain o f the tumour associated and matrix protein Mac-2 binding protein (M2BP)122 
(PDB code, lby2) and the SRCR domain o f  the serine-protease hepsin123 (PDB code, 
lp57). Both structures were obtained by X-ray diffraction and both belong to group A of 
the SRCR superfamily, i.e. these domains are encoded by two exons and do not have the 
C1-C4 disulphide bond. At the amino acid sequence level, /zCD5dlm shares 20% 
sequence identity and 33% similarity with M2BP SRCR, and 14% identity and 25% 
similarity with hepsin SRCR. Similarly to /zCD5dlm, the group A SRCR domains consist 
o f long loops, an a-helix and several (3-strands (Figure IV. 11). Overall, the group A
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structures are more similar to each other (backbone atom RMSD 0.95 A) than to 
/*CD5dlm, although /?CD5dlm differs less from the M2BP SRCR domain (backbone 
atom RMSD 1.52 A) than from the hepsin SRCR domain (backbone atom RMSD of 1.83 
A). In the first 25 residues o f the fold, which includes both elements o f regular secondary 
structure and loops, the structure of M2BP SRCR is categorically more similar to 
/zCD5dlm than to hepsin SRCR (backbone atom RMSD 1.24 A and 7.14 A, respectively), 
and this could have some functional significance.
The architecture o f the SRCR domains is unusually subtle and irregular, and the automatic 
analysis of the topology of the three structures gives conflicting results. The Kabsch and 
Sander (DSSP) algorithm, defines secondary structure elements based on hydrogen bond 
patterns and it is the most widely used method to assign secondary structure124. The 
algorithm attributes a different organisation to the p-strands in each of the group A SRCR 
domain structures: A single six-stranded [3-sheet in M2BP SRCR and seven p-strands 
forming two p-sheets in the case o f the hepsin SRCR. The M2BP SRCR domain was the 
first o f the structures to be solved and the six p-strands were denoted A through F (Figure 
IV.9); the same nomenclature will be adopted hereafter for consistency. For the region o f 
the structure corresponding to strand B in the M2BP SRCR domain, DSSP assigns two 
separate p-strands in /zCD5dl, here labelled B1 and B2. An additional strand found in the 
hepsin SRCR domain and /*CD5dlm, here referred to as E', runs between strands E and F. 
In the hepsin SRCR domain, strands A, B, C, E and E' are assigned to one p-sheet and 
strands D and F to the other. In /zCD5dlm, strands A, B2 and C are assigned to one p- 
sheet, strands B l, D and F to a second, and strands E and E' to a third sheet. Strands A-D 
and F, that are supposedly part o f different elements o f secondary structure in each case, 
are the best conserved among the three structures and superimpose with an average global 
backbone atom RMSD o f 1.43±0.45 A. Several other regions o f the structure 
superimpose well if  considered independently from the rest o f the structure (Table IV.6), 
which suggests that some parts o f the fold form rigid structural motifs with hinges 
between them.
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Despite the variability in automatically attributed p-sheet organisation, the tertiary 
contacts established in the three structures are very similar, as can be seen in their C a-C a 
contact maps (Figure IV. 13). There are contacts in all the three structures linking strands 
A to B, B to C, B to F, C to E, C to F, D to F. There are also contacts between the 
sequence segment corresponding to strands E and E' in the three structures, regardless of 
the fact that the M2BP SRCR domain lacks a specifically defined E' strand. This 
connectivity pattern suggests that all the three structures form a very irregular curved six 
or seven-stranded mixed p-sheet, similar to that originally described for the M2BP SRCR 
domain.
Prior to the solution of the /zCD5dlm 3D structure, it was expected that the C1-C4 
disulphide would play a major role in shaping the fold, because it is the only consistent 
difference -a t the amino acid sequence level- between Group A and Group B SRCR 
domains. However this does not turn out to be the case. At this point is not evident from 
the /zCD5dlm structure what the significance o f this disulphide bond is to the overall 
properties o f the fold. Cys44 (C l) of /zCD5dlm is located in the AB loop. This loop has a 
very similar conformation in both M2BP SRCR and /zCD5dlm (backbone atom RMSD 
0.88 A), implying that its shape is not a consequence o f the presence o f the disulphide. 
However, it does appear that the C1-C4 disulphide bond is reinforcing C3-C8 in its role to 
maintain the a-helix in position with respect to strands F and D. In the group A structures, 
the a-helix lies between strands D and F on one side and the EE' loop on the other. In the 
/zCD5dlm structure the a-helix also packs against the D and F strands, but it does not 
interact with the EE' loop. Instead, side chains from the a-helix establish hydrophobic 
interactions with the N-terminal region, prior to strand A, which is not a part o f the fold in 
the group A structures. As was noticed above, this unexpected contribution o f the N- 
terminus to the structure is not likely to be conserved in other group B SRCR domains, 
and its functional significance, if  any, remains to be established.
The only disulphide bond that maintains a consistent position in the three SRCR domain 
structures is C3-C8, which joins the a-helix with the domain C-terminus. This is the single 
disulphide bond shared by all SRCR domains, and presumably it is essential for the 
formation o f the overall fold. The M2BP SRCR domain and the hepsin SRCR domain 
share the position o f the C2-C7 disulphide, and the equivalent disulphide in /zCD5dlm is 
only 4 A away. The C5-C6 disulphide is in a similar position in /*CD5dlm and the hepsin
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SRCR domain, but the C5-C6 disulphide in M2BP SRCR domain is 13 A away. This 
difference was quite unanticipated, because it is intuitively expected that the conservation 
o f the pattern of cysteines at the amino acid sequence level would be reflected in a similar 
distribution o f the disulphide bonds in space.
A very interesting feature o f the hepsin SRCR 3D structure is that it was solved together 
with the hepsin serine-protease domain, giving the first glimpse o f the potential, 
quaternary organisation o f SRCR domains. The interdomain interface lies roughly 
perpendicular to the SRCR domain a-helix and corresponds to the area formed by the C- 
terminus of the a-helix and the aD  turn the middle part of the EE' loop, and both the N 
and C-termini of the domain. The most prominent residues in the contact area are those 
of the aD  turn, whose positions are very well conserved in the three SRCR structures 
(backbone atom RMSD 0.4 ±0 .16  A). This region is also where the C1-C4 disulphide 
bond is located in the /zCD5dlm structure. Perhaps this zone is optimised to be the 
interface with different domains in SRCR group A, while in group B the presence o f the 
disulphide and the significantly shorter EE' loop facilitate the stacking of several SRCR 
domains. This would explain why group B SRCR domains form tandem arrays whilst the 
Chordate group A SRCR domains are mostly found in mosaic proteins.
Ligand binding
The only detailed protein-protein interaction studies involving an SRCR domain are 
those of the C-terminal SRCR domain o f CD6 (CD6d3) with the N-terminal Ig C-like 
domain o f CD166125’127. Mutagenesis and modelling studies have established that the 
binding site o f CD6d3 comprises residues Glu293, Tyr327, Ser329, Phe344, Arg346, 
Arg348, Gln352 and Ser3 53128. According to sequence alignment with the known SRCR 
3D structures (Figure IV.9), most o f these residues are in the E'F loop o f the fold, except 
for Glu293 which is in the C a loop and Tyr327 and Ser329 which are at the beginning of 
the EE' loop. The conservation o f the loop length and amino acid composition o f the EE' 
and E'F loops is very poor among members o f the SRCR superfamily, so perhaps 
variability in these loops modifies the ligand specificity. These two loops lie on the 
opposite side o f the hepsin SRCR domain interface with its correspondent serine protease 
domain, lending support to the hypothesis that these two separate faces of the domain 
could be consensus ligand binding and intra-protein interaction zones.
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ftCD5d1 m (A) M2BP SRCR (B) Hepsin SRCR (C)
Figure IV .ll Orthogonal views o f a ribbon representation o f the three known structures o f scavenger receptor cysteine-rich (SRCR) domains.
The (3-strands (in blue) are labelled sequentially A-B-C-(a helix)-D-E-E’-F; a-helices are in green and 3 ,0helices are in pink.
(A) The NMR solution structure o f /jCD5dlm
(B) The crystal structure o f the SRCR domain o f the tumor-associated antigen and matrix protein Mac-2 binding protein (PDB code: lby2)
(C) The crystal structure o f the SRCR domain o f the extracellular serine protease hepsin (PDB code: lp57)
Table IV.6 Structural alignments of the SRCR domains
R ig id  body alignm ents o f  hom ologous tertiary structures
Structure feature 
included in the 
alignm ent
~ C D 5dl 
(I)
Total
residues
R esidues in the segm ent 
M 2BP Total 
(II) residues
H epsin
(III)
Total
residues
Backbone atom  RM SD  (A )
I vs II I vs III II vs III A verage
Strand A 3 4 -3 8 5 -9 8-1 2
S trand B 4 6 -5 2 17-23 16-22
Strand  C 5 6 -5 9 r 24 2 7 -3 0 L 24 28-31 r 24 1.52 1.83 0.95 1.43±0.45
Strand D 9 1 -93 54 -5 6 5 5 -5 7
Strand  F 128-132 101-105 J VI©T©
Related structure Residues in the segm ent
feature included in the C D 5dl Total M 2BP Total H epsin Total
alignm ent (I) residues (II) residues (H I) residues
Strand A 34-38 A 5 -9  ^ 8 -1 2  A
Strand B 4 6 -5 2 17-23 16-22
Strand C 5 6 -6 0 27-31 2 8 -3 2
Helix2 7 8 -8 9 4 1 -5 2 4 2 -5 3
Strand D 9 0 -93
( 51
53 -56
1 51
5 4 -5 7
(  51Strand E 104-108 6 6 -7 0 7 0 -7 4
Loop EE ' (1) 109-112 7 1 -7 4 75 -78
S trand E' 117-120 9 2 -9 5 9 3 -9 6
S trand F 127-132 100-105 100-105
B ackbone atom  R M SD  (A )
I vs II I vs III II vs III A verge
3.25 3.50 1.79 2.85±0.92
A lignm ent o f  hom ologous segm ents o f  the s tructure
Related structure 
feature
R esidues in the segm ent
C D 5dl
(I)
Total
residues
M 2BP
(II)
Total
residues
H epsin
(H I)
Total
residues
B ackbone atom  RM SD (A )
1 vs II I VS III II vs III Average
Strand A 3 4 -38 5 5 -9 5 8 -1 2 5 0.59 0.93 0.83 0 .7 8 ± 0 .18
L oop A B 3 9 -4 5 7 10-16 7 13-15 3 0.88 - - -
S trand B 4 6 -5 2 7 17-23 7 16-22 7 0.33 0.73 0.67 0.58±0.21
Loop BC 53 -5 5 3 2 4 -2 6 3 2 3 -2 7 7 0.71 - - -
S trand C 5 6 -6 0 4 27-31 4 2 8 -3 2 4 0.76 0.68 0.40 0.61 ±0.19
Loop C a 6 1 -7 7 15 3 2 -3 5 4 33,34 ,36 ,37 4 - - 1.08 -
H elix l - 3 7 -4 0 4 38-41 5 - - 0.10 -
Helix2 7 8 -8 9 12 4 1 -5 2 12 4 2 -5 3 12 0.65 0.64 0.22 0.51±0.25
Strand D 90 -93 4 5 3 -5 6 4 5 4 -5 7 4 0.84 0.98 0.52 0.98±0.24
L oop DE 94-1 0 3 9 5 7 -65 8 5 8 -6 9 11 - - - -
Strand E 104-108 5 6 6 -7 0 5 7 0 -7 4 5 1.23 0.94 1.08 1.0 8 ± 0 .13
Loop EE ' (1) 109-112 4 7 1 -7 4 4 7 5 -7 8 4 1.11 1.00 1.12 1.08±0.06
Loop EE ' (2) 113-116 4 75-91 17 7 9 -9 2 14 - - - -
S trand E' 117-120 4 9 2 -9 5 4 9 3 -9 6 4 1.04 0.89 1.28 1.07±0.20
L oop E 'F 121-126 6 9 6 -9 9 4 9 7 -9 9 3 - - - -
Strand F 127-132 6 100-105 6 100-105 6 0.59 0.66 0.48 0.55±0.10
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Figure IV.12 Struc tu re -b ased  am in o  acid  seq u en ce  a lig n m en t o f  /7C D 5dlm , M 2B P  and  hep sin  SR C R  dom ains. S haded  reg io n s in d ica te  the  m o re  h ig h ly  c o n se rv ed  seg m en ts  o f  the struc tu res. 
R esidues are  show n  in bo ld  w h en  there  is an accep tab le  deg ree  o f  s truc tu ra l sim ilarity . T he seco n d ary  stru c tu re  a ssig n m en t is from  D S SP : a -h e l ix  (h), 3, ()he lix  (g), h e lix -tu m  (t), ex ten d ed  p* 
sheet (e), P -b ridge  (b) and b en d  (s). S ide  chain  so lven t accessib ility  va lu es w ere  co m p u ted  w ith  N A C C E S S  and  th en  co n v erted  to a sca le  from  0 (0 -1 0 %  re la tiv e  so lven t acces ib ility ) to  9 (90- 
100%  re la tiv e  so lven t accessib ility ).
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Figure IV.13 (A ) C a-C a  co n tac t m ap  (d is tan ce  b e tw een  a to m s <  6 A) fo r the  th ree  k n o w n  S R C R  d o m ain  s truc tu res. T h e  n a tu re  o f  the  co n tac ts  a m o n g  th e  stran d s is very  s im ila r  in the 
th ree  struc tu res. T h ere  are  an tip a ra lle l co n tac ts  (bands p e rp en d icu la r  to  the m ain  d iag o n a l) b e tw een  P -s trands (o r seq u en ce  e lem en ts eq u iv a len t to ) A  and  B , B and  C, C  and  F, D  and  F, 
and  E and  E ’ (N o te  that the  E ’ s tran d  is n o t p ro p e rly  defin ed  in  M 2 B P  SR C R  d o m ain  struc tu re). T he  co n tac ts  b e tw een  strands C and  E are  o f  a p a ra lle l n a tu re  (b an d  p a ra lle l to  the  
m ain  d iagonal). (B ) S chem atic  illu stra tio n  o f  the  co m m o n  to p o lo g y  o f  the  th ree  k n o w n  SR C R  dom ain s, rep re sen tin g  the  in te rac tio n  am o n g  th e  P -s tran d s d e riv ed  from  the  co n tact 
m aps. T he th ree  stru c tu res fo rm  a h ig h ly  d is to rted  six  (o r seven) s tran d  m ix ed  p -sheet.
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In this chapter, I have presented the results o f the NMR study of an unglycosylated 
double residue mutant o f the N-terminal domain o f CD5dl (/zCD5dlm) and discussed 
their implications. Some regions of this protein construct experience mobility in the 
microsecond to millisecond timescale that causes substantial line-broadening and cross 
peak intensity loss. The recording of good quality spectra to enable the complete peak 
assignment and 3D solution structure calculation was only possible through acceleration 
o f the conformational exchange processes by elevation o f  the temperature to 318 K. The 
main reason o f this mobility is most probably the absence of the N-linked carbohydrate. 
The structure of /*CD5dlm presented here closely resembles that o f the other published 
SRCR domains, and it is the first solved structure of a group B SRCR domain. The SRCR 
fold has extensive loops that account for at least 50% of the residues in the domain. Some 
o f these loops vary significantly among the structures, both in sequence and in position, 
and are the most probable regions for ligand binding and inter-domain interactions. Other 
regions in the fold are well conserved in structure despite low sequence conservation. For 
example, there is a structurally conserved turn, flanked by the a-helix and the fourth (3- 
strand that is the main contact site between the SRCR and the serine protease domains in 
the hepsin structure. The high degree of structure conservation suggests that this feature is 
also important for the inter-domain interactions of CD5dl and M2BP. The nature of the 
SRCR fold makes it difficult to generalise about the features o f the whole superfamily. 
Hopefully, more structures will come to light in the near future, bringing us closer to full 
comprehension o f the structure-function relationships o f SRCR domains.
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General conclusions and perspectives
Chapter Five
A systematic screen fo r  suitable folding conditions makes in vitro protein folding a highly 
effective tool fo r  successful recombinant protein production
Recombinant proteins that express in inclusion bodies are a common occurrence in 
structural biology projects. In large scale projects, around 30-40% of the targets that 
express well in Escherichia coli. accumulate in inclusion bodies; a similar percentage has 
been reported for single-domain cytoplasmic yeast proteins1, human protein domains2 
and non-membrane proteins from thermophilic archaebacteria3.
Considerable effort has been expended in trying to reduce or avoid inclusion body 
formation and produce protein in a soluble form. A variety o f strategies have been 
developed including: directed evolution to create soluble mutants4, direction o f the 
recombinant protein to the periplasmic space of E. coli, co-expression with chaperones5 
and use o f cell-free expression systems6. A recent publication has compared the utility of 
three different methods, in respect to their ability to produce soluble protein, using 20 
different proteins that expressed in inclusion bodies under standard conditions1. The 
authors concluded that none o f the studied methods (chaperone co-expression, cell-free 
expression and protein in vitro folding) had a superior performance over the others and 
that the best method for a given protein cannot be predicted. These different methods 
should be regarded as complementary and not competing techniques.
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In vitro protein folding is the only strategy for obtaining folded protein that takes 
advantage o f the benefits of inclusion body expression instead of trying to avoid their 
formation. These advantages include: high expression yield, reduced toxicity for the 
expression host and reduced degradation during expression and purification. In vitro 
folding is also well suited for the preparation of proteins that require co-factors, 
prosthetic groups, metals or protein partners to attain their 3D structure, and it is 
compatible with the use of protein chaperones in order to further improve yields.
The major disadvantage o f in vitro protein folding is the difficulty of finding suitable 
folding conditions given that optimal conditions vary from one protein to another. 
However, the development of efficient methods to identify the optimal folding conditions 
for any particular protein will make in vitro folding amenable to implementation on 
projects of all scales. The fractional factorial screen for in vitro protein folding presented 
in this project, and similar screens published previously, provide strong evidence of the 
merits o f this technique in finding optimal folding conditions. Fractional factorial screens 
are systematic, easy to implement, readily modifiable to suit particular circumstances, 
fast, and suitable for small and large scale projects.
The in vitro oxidative protein folding screen developed in this project succeeded in 
identifying suitable conditions to fold RNAse A, lysozyme, and two of the SRCR 
domains of CD5. However, the general efficacy of the screen needs to be further 
demonstrated by assessing a larger number o f proteins. In an immediate future, the 
obvious candidates within our laboratory are the remaining SRCR domain o f CD5 
(CD5d2) and a protein construct comprising both CD5d2 and CD5d3 (CD5d2+3). I have 
subcloned CD5d2+3 and CD5d2 into bacterial expression vectors. While CD5d2+3 
expresses in good yield in inclusion bodies, the current CD5d2 construct does not show 
any expression. New constructs o f CD5d2 need to be made in order to overcome this 
problem, and it is possible that expression can be attained by changing the expression 
vector or by modifying the length o f the construct. Our initial interest in creating 
CD5d2+d3 arose because CD5d2 and CD5d3 do not have a clear linker region between 
them (such as the stalk region between CD5dl and CD5d2) and it seemed possible that 
they might require each other to attain their native fold. At this time, the !H-15N HSQC 
spectrum of CD5d3 (Figure 11.13) strongly suggests that CD5d3 does not require CD5d2 
for attainment o f its 3D structure. However, tandem SRCR domains are a very common 
feature of the members of the superfamiliy (Figures IV. 1-3) and a CD5d2+3 structure
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would be the first example of an arrangement o f tandem SRCR domains, and would 
perhaps provide information about how SRCR domains interact with each other.
Another imminent target with which to test the utility o f the in vitro folding screen is the 
Ly-6 domain o f the GPI anchored protein Prodl. Structural studies of Prodl are an 
ongoing collaboration with Prof Jeremy Brockes at the Department o f Biochemistry of 
UCL. Prodl is a single-domain glycosylated cell surface protein implicated in cellular 
interactions during newt limb regeneration. Ly-6 domains are mainly beta folds of ca. 
100 residue-long and contain five conserved disulphide bonds. Efforts are being made in 
order to express the folded domain in vivo using the thioredoxin reductase and 
glutathione reductase suppressor strain Origami, which it is known to enhance disulphide 
bond formation in the cytoplasm7. However, although some soluble protein does 
accumulate, most of the expressed protein is in inclusion bodies, making the Ly-6 
domain o f Prodl another case for the application of the in vitro folding screen.
The oxidative folding screen presented here would benefit from further improvements in 
the methodology, particularly in order to reduce sample handling. A disadvantage of the 
current implementation is that it includes a dialysis step that requires extensive sample 
manipulation and relatively large volumes (of the order of a few millilitres). This dialysis 
step is performed in order to remove guanidine HC1 and arginine, which might otherwise 
enhance the solubility o f protein aggregates. However, it would be worth investigating 
whether this step is essential for successful determination o f suitable folding conditions. 
It may be that determining folding yield in the presence o f arginine or guanidine HC1 
gives similar results and the dialysis is only required for preparative purposes.
The implementation of hydrophobic interaction chromatography (HIC), instead of 
reversed-phase chromatography, for quantifying folding yields may have several 
advantages. Folding yield quantification by HIC would make the screen suitable for non 
disulphide-bonded proteins and would avoid the generation o f organic solvent waste. 
Another approach that requires consideration is whether a measurement o f protein 
solubility, instead o f folding yield, would be sufficient to determine optimal folding 
conditions, as this would save a considerate amount o f time and effort. Turbidity 
measurements (determination o f absorbance at 390 or 340 nm) have recently been found 
to be a suitable method to evaluate in vitro folding conditions in high throughput 
screens1,8.
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Orthologue sequence comparison is an efficient and straightforward strategy fo r  the 
design o f  mutations in order to improve solubility and stability
Low solubility o f proteins is a common problem in structural biology, as studies often 
require protein concentrations o f the order o f 1 mM. Approaches that have been used to 
generate versions o f proteins with higher solubility include directed evolution4 and the 
use of solubility enhancing tags9. However, the approach utilised here was to make 
rational replacements o f a limited number o f apparently solvent exposed residues, 
replacing apolar with polar residues. Since a folded protein is always in equilibrium with 
its unfolded or partially unfolded forms, improved behaviour of the protein as a result of 
mutation may arise either from a reduction in aggregation o f the folded protein or its 
(partially) unfolded forms, or via an increase in the stability o f the soluble folded form 
(which would diminish the proportion of any aggregation prone unfolded form present in 
solution). Given this variety of ways in which mutation may alter solubility, it is not 
always an easy task to locate good candidate residues for mutation.
Enhancement of the stability o f the folded form o f the protein is one route to improving 
yield of soluble protein. It is usually the case that the largest contribution to stability 
arises from burial o f hydrophobic residues in the protein core. Unfortunately, it is 
difficult to make stability improving mutations in the well-packed and probably 
evolutionarily optimised protein interior. However, it has been observed that the surface 
of thermophilic proteins comprises more charged amino acid residues than in their 
mesophilic orthologues10 and has a larger fractional polar content11. The increased 
stability of many thermophilic proteins has been found to be a consequence o f a small 
number of differences in the solvent-exposed residues between the thermophile and its 
mesophilic orthologues12. It is hypothesised that short and long-range electrostatic 
interactions between solvent-exposed charged amino acids residues make an important 
contribution to this stability13' 17 by destabilising the unfolded state and by stabilising the 
folded state18 12,19. This suggests that apolar-to-polar and especially apolar-to-charged 
amino acid mutations o f solvent-exposed residues are likely to be successful in 
improving solubility (and protein yield) by improving stability.
193
In a recent high throughput study on prokaryote proteins, it was estimated that the
probability o f obtaining one sample suitable for structural studies using three orthologue
20sequences instead o f the sequence from a single organism rises from 70% to 96% . 
Mutation o f one or two exposed amino acid residues has been proved to be sufficient to 
significantly enhance the stability of several proteins21. Thus, exploiting the subtle 
sequence variation among orthologues in selecting mutations is sufficient to alter the 
stability and solubility o f proteins. In this project, I have provided new evidence to 
support the use o f a multiple sequence alignment with orthologue proteins as basis for 
selecting mutations that are likely to improve the protein’s behaviour. In the case of 
/iCD5dl, this strategy was successful in engineering proteins with superior properties for 
structural studies in four out o f eight attempts. A posteriori analysis o f these mutations in 
light of the solved structure showed that the successful mutations V97K, L26K, V88D, 
and M124Q all correspond to solvent-exposed residues that do not seem to have a critical 
structural role. On the other hand, residues W28 and G129, whose mutants did not yield 
folded protein, are buried residues whose alteration probably disturbs the three 
dimensional structure. More intriguing are the mutations V88N and M124N, which 
despite being apolar to polar substitutions o f solvent exposed residues gave a lower yield 
o f soluble folded protein than the wild type. It is tempting to conclude that the difference 
in behaviour between the V88D and V88N mutants is due to the negative charge in Asp, 
which makes V88D more hydrophilic than V88N, and able to establish the charge-charge 
interactions common in stabilising mutations.
It has been proposed that relatively simple theoretical calculations can be used to make a 
rational design of mutations to increase stability12, and the implementation o f one of such 
methodologies has proved successful21. Adopting such calculations as a criterion for 
selecting mutations may help to improve folding yields or make proteins more amenable 
for structural studies. It would also provide evidence to address the question o f whether 
there is a correlation between improvement o f folding yields and enhancement of 
stability o f proteins.
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The N-terminal SRCR domain o f CD5 is an interesting target fo r  dynamic studies using 
NMR
NMR is a powerful technique to characterise molecular dynamics at atomic resolution. 
Using NMR it is possible not only to identify the regions o f the structure that are 
exchanging between different conformations, but to measure the rate constant o f the 
exchange process and the relative populations o f the conformations. Techniques to 
characterise chemical exchange processes in the microsecond to millisecond timescale, 
namely the experiments based on the Carr-Purcell-Meibbom-Gill (CPMG) and the R jp 
relaxation dispersion methods22’23, are not as well-established as are the experimental 
methods for the investigation of faster motions. The development of methods to study 
microsecond to millisecond timescale dynamics remains an area o f active research22'24 
and the complex nature of the dynamics o f /zCD5dl may provide an opportunity to 
establish and experiment with these state-of-the-art methodologies within the group.
An in-depth analysis o f the residues undergoing conformational exchange and the 
estimation of the timescales for their motions would provide evidence to determine the 
nature of the mechanism o f improvement of the quality o f the NMR spectra with 
increasing temperature, i.e. whether it is a consequence of an increase in the rate o f the 
exchange among different conformations or of the stabilisation o f a single conformer. 
Furthermore, it may be possible to use knowledge o f the chemical shift changes with 
temperature, in conjunction with such exchange analysis, to provide additional 
information about the structural origin o f the mobility. Chemical shift changes have been 
previously correlated with structural changes (such as disulphide bond rotation) using 
data from chemical shift databases25’26, or by measuring the relaxation o f more than one 
nucleus27.
The fact that /zCD5dl expresses in eukaryotic systems with very poor yields, mean that it 
is unlikely that we will be able to further compare the dynamics o f the mammalian, yeast 
and bacterial versions in order to determine the role o f different glycans in restricting 
flexibility. However, a technique to produce O-glycosylated proteins in E. coli has been 
recently reported28’29, and perhaps the bacterial expression o f N-glycosylated proteins 
will become a reality in the near future.
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The C-terminal SRCR domain o f  CD5 is a promising target fo r  ligand binding 
experiments
The peaks in the !H -15N HSQC of the C-terminal SRCR domain of CD5 (CD5d3), are 
well dispersed and have a uniform intensity, as was shown in Chapter II. This result 
suggests that the CD5d3 polypeptide is folded and is not experiencing significant 
conformational exchange. Consequently, its structure should be determined in the near 
future and it is anticipated that it will be of higher ‘quality’ than that of CD5dl. 
Furthermore, CD5d3 does not have any putative N-glycosylation sites, which means that 
study o f CD5d3 will not be complicated by issues with respect to the functional 
relevance o f the structure arising from the presence/absence of glycan.
The extracellular region of CD5 has been proposed to bind the framework sequences or
TOthe variable immunoglobulin domains o f many antibodies . In this case, the interaction
31was mapped to the intermediate SRCR domain (CD5d2) . The only well characterised 
protein-protein interaction of an SRCR domain involves the C-terminal SRCR domain of 
CD6 (CD6d3) and the N-terminal immunoglobulin domain o f CD16632. As CD5 and 
CD6 are closely related and have a very similar domain organisation, it is feasible that 
CD5d3 also binds an immunoglobulin domain Studying the putative antibody and 
immunoglobulin binding properties of CD5 using different constructs comprising one or 
two o f the SRCR domains o f CD5, would be possible with the recombinant protein 
produced using methods created in this study. This could be achieved by immobilising 
antibodies to beads and attempting binding o f the CD5 constructs to them. The opposite 
strategy, immobilising the CD5 constructs to the beads, might prove valuable in a general 
search for CD5 ligands. The CD5 construct-coated beads could be used to attempt the 
isolation of molecules from, for example, lymphocyte cell lysates.
Also, having implemented a strategy to produce SRCR domains o f CD5 suitable for 
structural characterisation using a bacterial expression system, the recombinant 
expression o f the SRCR domains o f CD6 is not likely to present a major challenge. 
Availability o f 15N-labelled CD6d3 would open the doors for the characterisation o f the 
known CD6-CD166 interaction using NMR.
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And finally
The increased availability o f automated techniques and apparatus and the success of 
high-throughput methodologies are fundamentally changing the way of conducting 
research. Nowadays, much research must be done rapidly and cost-effectively to generate 
results in the short-term. What recalcitrant proteins like the SRCR domains o f CD5 have 
to offer in this environment, is a challenge to current methods and a motivation to 
develop new strategies for future wider application. The lessons that have been learnt 
with CD5 will certainly be useful in rapidly and efficiently overcoming similar problems 
in future projects.
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Experimental protocols
Appendix A
Culture media
M9 minimal medium with supplements
- M9 salts (1 OX): 60 g/1 Na2H P04, 30 g/1 KH2P 0 4, 5 g/1 NaCl, H20  to 1000 ml
■ Nitrogen source (10X): 10 g/1 (NH4)2S 0 4 (use 15N ammonium sulphate for 15N- 
labelling)
■ 0.1 M CaCl2
■ 1 M MgCl2
■ 0.01 M FeS04(make fresh)
■ Filter-sterilised 20% (w/v) D-glucose (use 13C glucose for 13C-labelling)
■ Micronutrient stock (10,000X): 0.4 M H3BO3, 30 mM CoCl2, 10 mM C uS04, 8 mM 
MnCl2, 10 mM Z nS04, 3mM (NH4)6Mo70 24
■ Vitamin stock (1000X): 0.4 g/1 choline chloride, 0.5g/l folic acid, 0.5 g/1 pantothenic 
acid, 0.5g/l nicotinamide, 1 g/1 myo-inositol, 0.5 g/1 pyridoxal HC1, 0.5 g/1 thiamine 
HC1, 0.05 g/1 riboflavin, 1 g/1 biotin
Instructions are given to make 1000 ml o f culture, scale as appropriate.
1. Mix 100 ml o f 10X M9 salts, 100 ml o f 10X nitrogen source add F120  up to 1000 ml 
and adjust pH to 7.0-7.4. Pour buffer into two 2-litre baffled flasks (500 ml o f buffer 
each). Sterilise by autoclaving for 15 minutes.
2 0 0
2. Mix 2 ml o f 1M MgCl2, 1 ml of 0.1M CaCl2, 1 ml o f 0.01 M FeS04, 1 ml o f vitamin
stock, 0.1 ml o f micronutrient stock and 25 ml o f 20% glucose (10 ml only if  using
13C-labelled glucose). Sterilise by filtration and add half o f the mixture into each of
the 2-litre baffled flasks with sterile buffer.
Luria-Bertani (LB) medium
■ 10 g/1 tryptone
■ 5 g/1 yeast extract
■ 5 g/1 NaCl
■ Distilled H20  up to 1 litre
Adjust pH to 7.5 using 5 M NaOH and sterilise by autoclaving.
LB Agar plates
9 10 g/1 tryptone
■ 5 g/1 yeast extract
■ 10 g/1 NaCl
■ 15 g/1 agar
■ Distilled H20  up to 1 litre
Adjust pH to 7.5 using 5 M NaOH and sterilise by autoclaving. Allow to cool to ~50°C, 
add antibiotic, mix thoroughly by swirling and pour into Petri dishes.
SOC medium (100 ml)
■ 2 g tryptone
■ 0.5 g yeast extract
■ 0.06 g NaCl (or 1ml o f 1 M NaCl)
■ 0.02 g KC1 (or 250 pi o f 1 M KC1)
■ Distilled H20  up to 90 ml
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Adjust pH to 7.5 using 5 M NaOH and sterilise by autoclaving. Allow to cool and add a
filter-sterilised solution of the following:
■ 1 ml o f 1 M MgCl2
■ 1 ml of 1 M MgS0 4
■ 2 ml o f 20% (w/v) glucose
Add sterile distilled H20  up to 100 ml and make 10-ml aliquots. Store at 20°C. 
Preparation of competent E. coli cells
1. Streak cells from a glycerol stock on an LB agar plate and incubate overnight at 
37°C.
2. Select a well-isolated colony from the plate and inoculate 100 ml of sterile LB 
medium in a 250-ml baffled-flask.
3. Incubate at 37°C with vigorous shaking until the absorbance at 600 nm reaches 0.4.
4. Transfer the culture into 2 sterile disposable 50-ml conical centrifuge tubes and cool
on ice for 10 minutes.
5. Centrifuge at 4000 rpm at 4°C for 10 minutes.
6. Decant the medium and invert the tubes for 1 minute to remove as much medium as
possible.
7. Resuspend each o f the two pellets in 10 ml o f sterile ice-cold 0.1 M CaCl2 and 
incubate on ice for 10 minutes.
8. Centrifuge at 2500 rpm at 4°C for 5 minutes and decant the medium.
9. Repeat steps 7 and 8 twice (for a total o f 3 incubations in CaCl2).
10. Resuspend each of the two pellets in 2 ml o f ice-cold sterile 0.1 M CaCl2.
11. Add 0.5 ml o f 50% (w/v) glycerol to each 2-ml suspension (to achieve a final
concentration o f -10%  glycerol).
12. Prepare 200-pl aliquots in sterile screw-cap vials and store at -80°C.
2 0 2
Transformation of competent is. coli cells
1. Remove the vials with competent cells from the ultrafreezer and allow them to thaw 
by leaving them on-ice.
2. Transfer 100-pl o f the competent cell suspension into a cold sterile 1.5 ml 
microcentrifuge tube.
3. Add 5 pi (or less) of the plasmid DNA to be transformed into the cells and mix 
carefully by tapping the tube.
4. Keep on ice for 30 minutes.
5. Transfer the tube to a 42°C water bath for 90 seconds.
6. Return the tube to the ice for 2 minutes.
7. Add 900 pi of LB or SOC medium and incubate the cells for 1 hour at 37°C with 
occasional manual shaking.
8. Plate out 50 ml o f the culture on LB agar plates containing the appropriate antibiotic 
and incubate overnight at 37°C.
Preparation of E. coli glycerol stocks
1. Select a well-isolated bacterial colony from a freshly-streaked plate to inoculate 20 
ml o f sterile LB medium with the appropriate antibiotic in a sterile disposable 50-ml 
conical centrifuge tube (Falcon tube).
2. Incubate at 37°C with vigorous shaking until the Abs 600 nm reaches 0.6 (6-8 hrs).
3. Add 0.3 ml o f 50% (w/v) glycerol to a 2 ml screw-cap vial and sterilise by 
autoclaving.
4. Add 0.7 ml o f the log-phase E. coli culture to the screw-cap vial and vortrex 
vigorously.
5. Store at-80°C.
D Use frozen by scraping some flakes from the surface o f the stock with an 
inoculating loop, avoid thawing.
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DNA electrophoresis in agarose gels
■ Tris-acetate-EDTA (TAE) buffer (50X): 121 g of Tris base (2 M), 29 ml o f acetic acid 
(1 M), 9.3 g Na2EDTA (0.05 M), add distilled H20  to 500 ml, (pH -8.5).
■ Sample loading solution (6X): 30% (w/v) glycerol with a tiny amount of bromophenol 
blue (suitable for fragments less that 1 kb long) or xylene cyanol FF (suitable for 
fragments o f more than 4 kb).
1. Prepare the agarose slurry by mixing the appropriate amount o f solid agarose and 100 
ml o f IX TAE in a 250 ml autoclavable glass bottle with a screw cap. Use 1% (w/v) 
agarose for plasmid DNA (>4 kb) and 2% (w/v) agarose gels for PCR products (<1 
kb).
2. Heat the agarose slurry in the microwave (with the cap loose) until the agarose is 
dissolved.
3. Cool the agarose to ~60°C and pour the solution onto the gel tray, insert the comb and 
let the gel to set.
4. Transfer the gel to the electrophoresis tank and fill the tank with just enough IX TAE 
to cover the gel.
5. Mix DNA samples with the sample loading solution and load into the gel.
6. Run at 50-100 V until the dye reaches the bottom of the gel.
7. Stain by immersing the gel in 100 ml of a 2 pg/ml solution o f ethidium bromide in 
water.
8. Rinse the gel with water before visualisation.
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In vitro amplification of DNA by polymerase chain reaction (PCR)
Amplification o f  DNA fragments
D DNA fragments for cloning should be amplified using a high-fidelity polymerase, 
such as Pyrococcus furiosus DNA polymerase Pfu (Stratagene).
1. Program the following cycling parameters in the thermal cycler:
01. Lid on 110°C
02. 94°C for 5 minutes
03. Loop 30x (
04. 95°C for 30 seconds
05. 55°C for 45 seconds
06. 72°C for 2 minutes
07. )  Loop
08. 72°C for 5 minutes
09. Lid off
10. Ramp4°C 1.0 °C/s
11. 4°C Forever
2. Prepare the reaction mixture in an ice-chilled thin-walled PCR tube, add the 
components in the following order:
■ Distilled H20  64.5 pi
■ Pfu buffer (1 OX) 10 pi
■ dNTPs mix (10 mM each) 2 pi
■ DNA template (-40 ng/pl) 2.5 pi
■ Forward primer (10 mM) 10 pi
■ Reverse primer (10 mM) 10 pi
3. Put the reaction mixture in the thermal cycler and start the program.
4. Add 1 pi o f Pfu polymerase after step 02 (5 minutes at 94°C).
5. Allow the program to proceed.
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6. If the PCR product is going to be used for restriction digestion, proceed to purify the 
DNA by isopropanol precipitation or use the QIAquick PCR purification kit 
(Qiagen). Resuspend the purified DNA in 30 pi o f sterile distilled H2O.
Colony screening
° PCR can be used to screen for cells containing a desired DNA fragment without 
prior plasmid purification. If  possible, use a forward primer that anneals with the 
vector and a reverse primer that anneals with the end of the inserted DNA 
fragment (or vice versa).
1. Prepare and label 1.5 ml microcentrifuge tubes with 20 pi of sterile LB medium (as 
many tubes as colonies needed to screen, ri).
2. Transfer each colony into the corresponding tube with LB medium and resuspend the 
cells thoroughly.
3. Transfer 10 pi o f each cell suspension into an empty labelled PCR tube.
4. Lyse the cells in the PCR tubes by heating for 10 minutes at 95°C.
5. Prepare a bulk PCR reaction mixture for (n+2) PCR reactions. Add per reaction:
■ Distilled H 2 0 13 pi
■ PCR buffer (10X) 2 pi
■ dNTPs mix (10 mM each) 0.4 pi
■ Forward primer (10 mM) 2 pi
■ Backward primer (10 mM) 2 pi
■ Taq polymerase (or other DNA polymerase) 0.2pl
6. Aliquot 20 pi o f the bulk PCR reaction mixture into n PCR tubes and label them.
7. Add 1-2 pi o f the lysed cells to the corresponding PCR tube with reaction mixture.
8. Amplify with the standard PCR cycling program described above.
9. Load 5 pi o f the PCR reaction into a 2% agarose gel to analyse the PCR products.
10. Use the remaining 10 pi o f living cells to inoculate cell cultures.
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Isopropanol precipitation of DNA
1. Add 0.1 volumes o f 3 M sodium acetate pH 5.2 to the solution containing the DNA.
2. Add 0.7 volumes o f isopropanol.
3. Centrifuge the sample at 13000 rpm for 15 minutes at 4°C.
4. Decant the supernatant.
5. Wash the pellet with 1 ml o f 70% ethanol.
6. Centrifuge the sample at 13000 rpm for 10 minutes at 4°C.
7. Decant the supernatant.
8. Air-dry the pellet at 37°C and redissolve the DNA in the desired buffer or in sterile 
distilled H 2O.
Small scale purification of low-copy plasmid DNA using the QIAprep 
miniprep kit (Qiagen).
D This is a slightly altered protocol from the one provided by the manufacturer.
1. Select a well-isolated bacterial colony from a freshly-streaked plate to inoculate 10- 
15 ml o f sterile LB medium with the appropriate antibiotic in a sterile disposable 50- 
ml conical centrifuge tube (Falcon tube).
2. Incubate overnight at 37°C with vigorous shaking.
3. Harvest the cells by centrifugation at 4000-4500 rpm for 15 minutes at 4°C.
4. Decant the medium and invert the tube for 1 minute to remove as much medium as 
possible.
5. Resuspend the pellet in 500 pi o f Tris-EDTA buffer with RNase A (buffer P I) and 
transfer the resulting suspension to two 1.5 ml microcentrifuge tubes (each with half 
the amount o f the cell suspension).
6. Lyse the resuspended cells by adding 250 pi o f the NaOH/SDS solution (buffer P2) 
to each o f the tubes and mix gently.
7. Precipitate proteins, chromosomal DNA and cellular debris by adding 300 pi o f the 
acidic potassium acetate solution (buffer N3) to each o f the tubes and mix gently.
8. Centrifuge tubes for 10 minutes at 13000 rpm.
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9. Load the supernatants from one of the tubes into a QIAprep spin column by 
decanting.
10. Centrifuge the spin column for 1 minute at 13000 rpm and decant the flow-through.
11. Load the supernatant from the second tube into the same QIAprep spin column by 
decanting.
12. Centrifuge the spin column for 1 minute at 13000 rpm and decant the flow-through.
13. Wash remaining enzymes from the column-bound plasmid DNA by loading 0.5 ml of 
binding buffer (PB) into the column. Centrifuge for 1 minute at 13000 rpm and 
decant the flow-through.
14. Wash remaining salts from the column-bound plasmid DNA by loading 0.75 ml of 
ethanol wash buffer (PE) into the column, centrifuge for 1 minute at 13000 rpm and 
decant the flow-through.
15. Remove the remains of buffer PE by an additional 1 minute centrifugation at 13000 
rpm.
16. Place the column in a clean lidless 1.5 microcentrifuge tube (cut the lid with scissors 
and set aside).
17. Elute the plasmid DNA by loading 50 pi o f sterile distilled H2O to the centre of the 
column. Let stand for 1 minute and centrifuge for 1 minute at 13000 rpm.
Restriction endonuclease DNA digestion
n The quantities given here are for digestion o f 30 pi of a 50pl-plasmid miniprep 
(see the small scale purification o f low-copy plasmid DNA protocol) or for the 
digestion o f the DNA obtained from a 100 pl-PCR reaction, purified and 
resuspeded in 30 pi o f H2 O (see amplification o f DNA fragments protocol).
1. Set up the restriction reactions in ice-chilled 1.5 ml microcentrifuge tubes as follows:
■ H20  20 pi
■ Enzyme buffer (10X) 6 pi
■ 30 pi o f DNA
■ Restriction enzyme 3 pi
■ BSA (if required by the enzyme) 0.6 pi
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Mix well but gently. If  setting up a double digest, add 3 pi o f the second restriction 
enzyme and only 17.4 pi of H2O. For restriction enzyme compatibility refer to 
New England Biolabs catalogue.
2. Incubate for 2 hours at 37°C. If digesting with Ndel add 1.5 pi of enzyme at the 
beginning and 1.5 pi o f enzyme at 20 minutes and do not let the reaction proceed for 
more that 40 minutes.
3. If  the restriction enzymes used generate blunt ends, it is better to remove the 5'- 
phosphates o f the vector to prevent recircularisation. Calf intestinal phosphatase 
(CIP) and shrimp alkaline phosphatase (SAP) are compatible with most restriction 
enzyme buffers. Add 1 unit o f phosphatase to the vector digest (0.2 units per pmol of 
DNA) and incubate at 37°C for another 30 minutes.
Purification of digested DNA by agarose gel electrophoresis
1. Prepare a 1% agarose gel for the purification of plasmid DNA and a 2% agarose gel 
for the purification o f PCR amplification products. Join individual wells with self- 
adhesive tape in order to make a single large well -1-1.5 cm wide. Transfer the gel to 
the electrophoresis apparatus and load the running buffer.
2. Mix the DNA from the digestion reactions with the appropriate amount of sample 
loading solution and load the large well. Include some uncut vector in a parallel 
(small) well to see the difference between the linearised and the undigested plasmid.
3. Run the gels at 50 V until the dye is 1 cm from the bottom of the gel.
4. Stain the gel with ethidium bromide.
5. Follow the instructions provided by the manufacturer in the QIAquick gel extraction 
kit (Qiagen).
6. Elute the DNA from the columns with 30 pi o f distilled sterile H2O.
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Ligation of plasmid DNA
1. Estimate the concentration of DNA by running an agarose gel with a DNA mass 
ladder o f the appropriate molecular weight.
2. Mix the appropriate amounts of digested vector and insert in a PCR tube and heat for 
5 minutes at 65°C. Cool the tube down on ice and centrifuge for 1 minute at 13 000 
rpm.
D The rule o f thumb is to set up ligation reactions with -0.015-0.03 pmols of vector 
(50-100 ng of a 5 kbp plasmid) and -0.2-0.3 pmols o f insert (50-75 ng of a 500 bp 
insert). This is usually around -10  pi o f vector and -2  pi o f insert in a 20 pi 
reaction. Set up several reactions with 100 ng o f vector and different amounts of 
insert (e.g. 0 pmol, 0.1 pmol, 0.2 pmol, 0.3 pmol).
3. Add the appropriate amount of ligation buffer according to the manufacturer's 
instructions (usually 2 pi) and distilled H2O up to 19 pi. If  using blunt-ended 
fragments or DNA digested with Ndel , add PEG to achieve a final concentration of 
15%.
D Make aliquots o f the ligase buffer provided with the enzyme. The buffer contains 
ATP and it is very sensitive to repeated freezing and thawing cycles.
4. Add 1 pi o f DNA ligase (3-5 units), mix well by pipetting up and down and incubate 
overnight at 14-16°C.
5. Transform 50 pi D H5a subcloning efficiency competent cells (Invitrogen) with 10 pi 
o f ligation reaction following the manufacturer's instructions. After transformation 
and incubation for one hour, harvest the cells by centrifugation at 3000 rpm for 10 
minutes. Decant most o f the supernatant and plate all the cells in one or two Petri 
dishes with LB agar and the appropriate antibiotic.
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DNA Sequencing
D Use the Abi Prism dRhodamine (Applied Biosciences) or the Dyenamic ET 
(Amersham Biosciences) Terminator Cycle Sequencing Kit.
1. Estimate the concentration o f DNA by running an agarose gel with a DNA mass 
ladder o f the appropriate molecular weight.
2. Assemble each sequencing reaction in a PCR tube as instructed by the manufacturer. 
Each reaction consists of:
■ Template DNA
■ Sequencing primer (5 pmol)
■ Sequencing reagents mix (8 pi)
■ Distilled H2 O to a total volume of 20 pi
3. Mix the contents o f the tube well by pipetting up and down and centrifuge the tubes 
briefly.
4. Place the tube in the thermal cycler and run the sequencing program recommended by 
the manufacturer.
5. Use the DyeEx spin kit (Qiagen) to remove the excess o f dye.
6. Air-dry the eluate from the DyEx column or use a centrifugal vacuum concentrator.
7. Take the sample for automated sequencing.
D Sequencing was done by Dr Athena Nikitopoulou at the Ludwig Institute of 
Cancer Research using an Abi Prism 377 automated DNA sequencer.
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Tricine denaturing polyacrylamide gel eletrophoresis for proteins
Materials
■ 50% (w/v) glycerol
■ 40% (w/v) acrylamide / 5% (w/v) bisacrylamide (40%T, 5% C)
■ N,N,N’N ’-tetramethy-ethylenediamine (TEMED)
■ 20% (w/v) ammonium persulphate (APS) freshly prepared
■ Gel buffer: 3 M Tris base, 0.3% SDS
■ Sample buffer (3X): 50 mM Tris base pH 6.8, 12% glycerol, 4% SDS, 2% 2- 
mercaptoethanol, 0.01% bromophenol blue
■ Cathode buffer (10X): 1 M Tris base, 1 M tricine, 1% SDS. Do not correct pH (should 
be around 8.25)
■ Anode buffer (10X): 2 M Tris base, pH 8.9
■ 1% (w/v) SDS
■ Coomassie staining solution: 40% methanol, 10% glacial acetic acid, 0.05% (v/w) 
Coomassie Brilliant blue G-250. Leave stirring overnight and filter.
■ Coomassie destaining solution: 40% methanol, 10% glacial acetic acid.
1. Assemble two 0.75 mm-thick gel cassettes.
2. Insert the comb and make a mark on the glass 5 mm below the end o f the comb wells.
3. Prepare 12% separating gel by mixing 2.15 g o f  50% glycerol, 2.66 ml gel buffer, 2.4 
ml o f acrylamide/bis (40%T, 5%C), 0.8 ml H 20, 10 pi TEMED and 20 pi o f APS. 
Mix well by inversion.
4. Pour the separating gel mixture into the gel cassettes up to the 5 mm-mark.
5. Overlay the separator gel mixture with 1% SDS and leave to polymerise (15-20 
minutes).
6. Decant the 1% SDS from the gel cassettes.
7. Prepare the stacking gel by mixing 0.75 ml o f gel buffer, 0.3 ml o f acrylamide/bis
(40%T, 5%C), 2 ml H2 O, 10 pi TEMED and 30 pi o f APS. Mix well by inversion.
8. Pour the stacking gel into the gel cassettes and insert the combs and leave to
polymerise.
9. Dilute one part o f sample buffer with 2 parts o f protein sample. Heat the samples at 
95°C for 10 minutes.
10. Remove the combs from the gel cassettes and assemble the electrophoresis module.
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11. Fill the anode and cathode chambers with the appropriate IX buffer.
12. Load the samples into the gel wells.
13. Run the gels at 40 mA per gel for around 120 minutes.
14. Remove the gel cassettes from the electrophoresis module and the gels from the 
cassettes and stain.
Native polyacrylamide gel electrophoresis for basic proteins
(Adapted from Goldenberg D.P. Analysis o f protein conformation by gel electrophoresis
in Protein Structure, a practical approach)
Materials
■ Acrylamide/ bisacrylamide (30%T, 0.8%C)
■ Acrylamide/ bisacrylamide (40%T, 5%C)
■ 20% ammonium persulphate freshly prepared
■ Separating gel buffer (8X): 12.8 ml acetic acid, 30 ml o f H2O, 1 ml TEMED, 1 M 
KOH to pH 4.0 (around 35 ml), add H2O to 100 ml
■ Stacking gel buffer (8X): 4.3 ml acetic acid, 30 ml o f H2O, 0.46 ml TEMED, 1 M 
KOH to pH 5.0 (around 50 ml), add H2 O to 100 ml
■ Electrode buffer (4X): 14.2 g {3-alanine, 800 ml of H20 , acetic acid to pH 4.0, add 
H 2 O to 1000 ml
■ Tracking solution (5X): 50% (m/v) glycerol, 0.2% (m/v) methyl green
1. Assemble a 1.5mm-thick gel cassette.
2. Prepare the resolving gel solution by mixing in a vacuum flask 4.5ml of H2 O, 6ml 
30%T, 0.8%C Acrylamide/Bis and 1.5 ml o f resolving gel buffer. Put a bung in the 
flask and connect to vacuum pump for 10 minutes. Add 30 pi o f APS 20% and fill 
the gel cassette to a level 1 cm below the bottom of the comb wells. Overlay with 
20% ethanol and leave to polymerise for 60 minutes.
3. Prepare the stacking gel solution by mixing in a vacuum flask 6.5 ml o f H2 O, 0.5 ml 
o f  acrylamide 40% and 1 ml o f stacking gel buffer. Put a bung in the flask and 
connect to vacuum pump for 10 minutes. Add 80 pi o f APS 20%. Rinse the top o f the 
separating gel with H2O and then with stacking gel solution.
4. Fill the gel cassette with the stacking gel solution and insert the comb. Allow to 
polymerise for 1-2 hrs.
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5. Assemble the gel in the electrophoresis chamber, remove the comb and fill the 
chamber with IX electrode buffer.
6. Pre-run the gel for 2 hrs at 30 mA per minigel.
7. Prepare the samples and load the gel.
8. Run at 10 mA per minigel for 180 minutes.
Immuno (Western) blot
■ Wet transfer apparatus (Xcell II blot module, Invitrogen)
■ Filter paper
■ Transfer buffer (25X): 0.3 M Tris base, 2.4 M glycine. Do not adjust pH (Should be 
-8.3)
■ Transfer buffer (IX): 40 ml o f 25X transfer buffer, 200 ml methanol, distilled H2O to 
1 litre.
■ TBS (10X): 0.1 M Tris base, 1.5 M NaCl. Adjust pH to 7.5
■ TBSTT (5X): 0.1 M Tris base, 2.5 M NaCl, 0.25% Tween-20, 1% Triton X-100
■ Blocking solution: 10% skimmed milk power, 0.1% Tween-20 in TBS IX
■ First (mouse pentahistidine) antibody dilution: Use a 1:1000 dilution of antibody 
solution prepared following the instructions of the manufacturer in TBS IX with 1% 
casein or 3% BSA
■ Second (goat anti-mouse alkaline phosphatase conjugate) antibody dilution: Use a 
1:5000 dilution o f antibody solution prepared following the instructions of the 
manufacturer in blocking buffer
■ Alkaline phosphatase (AP) colorimetric detection kit (Novagen)
Transfer o f proteins from the SDS-PAGE gel to the membrane
° It is a good idea to run the SDS-PAGE gel with pre-stained markers to monitor the 
transfer o f proteins to the membrane.
1. Cut the protein transfer membrane (PVDF) and two pieces o f filter paper to the size 
o f the gel.
2. Immerse the membrane in methanol and leave for 1 minute, then immerse the 
membrane in transfer buffer and leave until needed.
3. Soak five blotting pads in 500 ml o f transfer buffer and squeeze then to remove the 
air bubbles with a glass pipette.
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4. Remove the gel from the glass plates, briefly soak it in transfer buffer and position 
the transfer membrane over the gel, remove air bubbles.
5. Soak the filter papers in transfer buffer and place one of them on top of the 
membrane and another on top of the gel, remove air bubbles.
6. Place two soaked blotting pads in the cathode core o f the XCell blot module then 
place the assemble o f gel and membrane with the gel facing the cathode (down).
7. Place three soaked blotting pads over the membrane (or enough pads to rise 0.5 cm 
over the cathode core) and put the anode core at the top.
8. Insert the blot module into the electrophoresis tank.
9. Fill the blot module with just enough transfer buffer to cover the blotting pads.
10. Fill the outer buffer chamber with distilled H2O to serve as a coolant.
11. Place the lid and connect the unit to the power supply.
12. Run at 25 V for 1-2 hrs (expected current 100 mA), until the pre-stain markers appear 
on the membrane.
Membrane blocking
1. Place the membrane in a shallow tray.
2. Wash membrane with TBS for 10 minutes, twice.
3. Incubate membrane for 1 hour in blocking solution (Can be left overnight in blocking 
solution).
4. Wash membrane with TBSTT for 10 minutes, twice.
5. Wash membrane with TBS for 10 minutes.
Antibody binding
1. Incubate membrane in first antibody dilution for 1 hour.
2. Wash membrane with TBSTT for 10 minutes twice.
3. Wash membrane with TBS for 10 minutes.
4. Incubate membrane in second antibody dilution for 1 hour.
5. Wash with TBSTT for 10 minutes 5 times.
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Colorimetric detection
1. Prepare developing solution by adding 60 pi o f NBT (nitro blue tetrazolium chloride) 
and 60 pi o f BCIP (5-bromo-4-chloro-3-indolyl phosphate) solution to 15 ml of IX 
AP buffer.
2. Place the membrane in a clean tray and add the developing solution.
3. Incubate the membrane until colour develops (2-10 minutes).
4. Wash thoroughly with distilled H 20 to stop the reaction and let the membrane to dry.
D Store at room temperature wrapped in plastic.
Large scale expression of CD5dl in minimal medium
Protocol is given to prepare one litre o f culture.
Growth o f initial culture for inoculation.
1. Select a well-isolated bacterial colony from a freshly-streaked plate and inoculate 10 
ml o f sterile LB medium with 50 pg/ml carbenicillin in a sterile disposable 50-ml 
conical centrifuge tube (Falcon tube).
2. Incubate for around 8 hrs at 37°C with shaking.
3. Harvest the cells by centrifugation at 3,000 rpm for 10 minutes.
4. Pour the supernatant and resuspend the pellet in some sterile minimal medium.
5. Inoculate the resuspended pellet into 100 ml o f minimal medium with 50 pg/ml 
carbenicillin.
6. Incubate overnight at 37°C with shaking.
Inoculation o f culture and induction o f expression.
1. Prepare 1 litres o f minimal medium in two 2-litre baffled flasks.
2. Harvest the overnight culture by centrifugation at 3,000 rpm for 20 minutes.
3. Decant the supernatant and resuspend the bacterial pellet in 10 ml o f sterile minimal 
medium.
4. Inoculate each one o f the 2 flasks with 5 ml o f the resuspended cells.
5. Incubate at 37°C at 180 rpm until the absorbance at 600 nm reaches 0.9-1.0 (around 6 
hrs).
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6. Induce recombinant protein expression with 500 pi of 1 M IPTG (ImM  final 
concentration).
7. Leave expression to proceed for 4 hrs (Expression can be left overnight with a mild 
decrease in yield).
8. Harvest the cells by centrifugation at 6,000 rpm for 15 minutes.
Large-scale expression of CD5dl in LB medium
Protocol is given to prepare one litre o f culture.
1. Select a well-isolated bacterial colony from a freshly-streaked plate and resuspend in 
1 ml o f sterile LB.
2. Use 500 pi o f the cell suspension to inoculate each o f two 2-litre baffled flasks with 
500 ml o f sterile LB and 50 pg/ml carbenicillin.
3. Incubate at 37°C and 180 rpm until the absorbance at 600 nm reaches 0.8-1.0 (7-8 
hrs).
4. Induce recombinant protein expression with 500 pi of 1 M IPTG (1 mM final 
concentration).
5. Leave expression to continue overnight.
6. Harvest the cells by centrifugation at 6,000 rpm for 15 minutes.
Purification of CD5dl from inclusion bodies
Buffers
■ Buffer A: 50 mM KH2PO4 and 100 mM NaCl. Adjust pH to 7.0 with 5 M NaOH
■ Buffer C: 50 mM KH2PO4, 100 mM NaCl and 2 M urea. Adjust pH to 7.0 with 5 M 
NaOH
■ Buffer E: 6 M GdnHCl or 8 M urea, 0.1 M NaH 2 P0 4 , 0.01 M Tris base. Adjust pH to 
8.0 with 5 M NaOH
■ Buffer F: 6 M GdnHCl or 8 M urea, 0.1 M NaH 2P0 4 , 0.01 M Tris base. Adjust pH to 
6.3 with 5 M NaOH in using GdnHCl. Buffer pH should be 6.3 without adjusting if 
using urea.
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■ Buffer G: 6 M GdnHCl or 8 M urea, 0.1 M NaH2P 0 4, 0.01 M Tris base. Adjust pH to 
4.5 with 5 M NaOH in using urea. Buffer pH should be 4.5 without adjusting if using 
GdnHCl.
Preparation o f solubilised inclusion bodies.
1. Resuspend the cell pellet in Buffer A. Use 1/50 of the original culture volume.
2. Lyse the cells using the French Pressure Cell three times.
3. Centrifuge the cell suspension for 30 minutes at 20,000 rpm.
4. Decant the supernatant and resuspend the pellet in Buffer C using the homogenizer. 
Use 1/100 o f the original culture volume.
5. Centrifuge for 40 minutes at 20,000 rpm.
6. Decant the supernatant and resuspend the pellet in buffer E using the homogenizer. 
Use 1/100 o f the original culture volume.
7. Incubate for two hours at RT (Gdn HC1) or 30°C (urea).
8. Centrifuge for 60 minutes at 20,000 rpm.
9. Decant the supernatant and adjust the pH to 8.0 if necessary.
10. Repeat twice if  the sample is isotope-labelled.
Gravity-driven immobilised metal ion affinity chromatography.
1. Use 5 ml o f Ni-IDA agarose resin (His Bind resin, Novagen) in a 30-ml or bigger 
gravity-driven chromatographic column.
2. Equilibrate with 5 CV of Buffer E.
3. Load 3 CV o f solubilised inclusion bodies.
4. Wash with 5-10 CV of Buffer F or until the Bradford assay (RioRad) is negative for 
50pl o f flow-through.
5. Elute with 5 CV of Buffer E or until the Bradford assay in negative for 50fil o f flow­
through.
6. Regenerate the column by washing with 3 CV of strip buffer, 5 CV of H20 , 5 CV 50 
mM o f N iS 04 and 10 CV of H20 .
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Concentration and reduction.
1. Concentrate the eluate from the metal ion affinity chromatography by centrifugal 
ultrafiltration (Vivaspin 20) until the protein concentration is around 20 mg/ml as 
measured with the Bradford assay (BioRad).
2. Set the pH to 8.0 with diluted NaOH and add enough solid DTT to achieve a final 
concentration o f 100 mM.
3. Leave overnight at RT with gentle mixing.
Size-exclusion chromatography.
1. Run a SEC with the following specifications:
Matrix: Superdex 75 (Amersham Biosciences)
Column: XK16 
Mobile phase: Buffer G 
Flow rate: 0.5 ml/min
Injection: ~ 20 mg of protein or less than 2 ml 
Fractions: 2.5 ml fractions between 0.3 and 0.60 CV
D Proteins start to elute around 0.32 CV. The peak corresponding to monomeric
CD5dl should elute between 0.40 and 0.55 CV. Low molecular weight
components elute between 0.89 and 1.2 CV.
2. Pool the fractions of monomeric CD5dl and concentrate to more than 10 mg/ml 
using centrifugal ultrafiltration (Vivaspin). The samples at this point are ready for in 
vitro folding.
D Samples should never be stored in 8 M urea. If  it is not possible to fold
immediately, the buffer has to be changed to GdnHCl or 0.1% TFA for storage.
In vitro oxidative folding of CD5dl
■ Folding buffer: 0.1 M Tris base, 0.6 M arginine, 20% glycerol, pH 9.0 Filter and 
degas by stirring the buffer while connected to the water-driven vacuum. Equilibrate 
at 4°C.
■ Cysteine (100X): 0.5 M cysteine
■ Cystine (100X): 0.05 M cystine. In order to dissolve add a few drops o f 5 M NaOH
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■ Buffer B: 50 mM KH2P 0 4 and 200 mM NaCl, 1 mM EDTA, 0.1% Sodium azide. 
Adjust pH to 5.0 with 5 M NaOH
1. Add the necessary amount of cysteine and cystine to the folding buffer.
2. Measure protein concentration of the unfolded monomeric sample by absorbance at 
280 nm. The theoretical extinction coefficient for reduced CD5dl is 27880 M 'em  1 
and the molecular weight is 14721 g/mol. The concentration has to be above 10 
mg/ml.
3. While gently mixing the in vitro folding buffer with a stirring magnet, add enough 
protein to achieve a final concentration o f 0.5 mg/ml. If  time allows, add smaller 
aliquots every hour.
4. Incubate at 4°C for 24 hrs with gentle stirring.
5. Remove the precipitate by centrifugation at 4500 rpm for 15 minutes followed by 
syringe-driven filtration.
6. Concentrate the folded protein solution to ~30 ml using a stirred ultrafiltration cell 
(Amicon).
7. Dialyse the concentrate against Buffer B for 24 hours with 3-4 buffer changes.
8. Concentrate using a stirred ultrafiltration cell and/or centrifugal ultrafiltration units.
9. Purify by size-exclusion chromatography with the following specifications:
Matrix: Superdex 75 (Amersham Biosciences)
Column: XK16 
Mobile phase: Buffer B 
Flow rate: 0.5 ml/min
Injection: 2 ml of in vitro folding concentrate 
Fractions: 2.5 ml fractions
10. Concentrate using centrifugal ultrafiltration units.
In vitro folding screen for mutants
n Enough protein to screen a mutation is obtained by growing 500 ml o f cells in LB. 
D Proceed to solubilise and purify the inclusion bodies as explained for CD 5dl.
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n Load all the GdnHCl solubilised protein (should be 10-15 ml) into 5ml of Ni-IDA 
resin and elute as described for the purification of CD5dl.
1. Add diluted NaOH to the eluate to set the pH to 8.5. Concentrate to less than 2 ml by 
centrifugal ultrafiltration (Vivaspin 20). The final concentration should be above 10 
mg/ml, as measured with the Bradford assay.
2. Add solid DTT to achieve a final concentration of 0.1 M and incubate with gentle 
stirring overnight at room temperature.
3. Size-exclusion chromatography.
• Specifications
Column: Superdex 75. XK16 
Mobile phase: Buffer G
Flow rate: 0.5 ml/min 0 to 0.6 CV; 1.0 ml/min from 0.6 to 1.2 CV 
Injection: ~ 20 mg of protein or less than 2 ml 
Fractions: 2.5 ml fractions between 0.3 and 0.60 CV
Pool fractions between 0.4 and 0.45 CV.
D Using the 55cm XK16 column this corresponds to 45 to 50 ml (fractions A5 and 
A6) Concentrate until the protein concentration is above 10 mg/ml. This is usually 
a lOx or more concentration. Measure protein concentration using the Bradford 
assay.
4. Prepare six universal tubes with 5-10 ml o f a degassed solution of 0.6 M arginine, 
20% glycerol and 0.1 M Tris at pH 9.0. The chosen volume depends on the amount 
o f purified protein obtained. A 5ml screen requires 5 mg o f protein. Equilibrate at 
4°C.
5. Prepare 5 ml o f stock solutions of cysteine and cystine and add to the folding buffer.
6. Add the reduced protein to the folding buffer to achieve a final concentration of
0.1 mg/ml in three o f them and 0.2 mg/ml in the other three. For the 0.2 mg/ml 
samples, add the protein in two steps, allowing some time in between the additions.
7. Incubate at 4°C for 24 hrs with gentle stirring.
8. Dialyse all the samples overnight against Buffer B.
9. Run RP-HPLC
• Specifications
Column: C4 100 mm
Mobile phase A: 5% acetonitrile, 0.1% TFA
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Mobile phase B: 95% acetonitrile, 0.1% TFA 
Flow rate: 2 ml/min
Injection: 2 ml o f in vitro folded protein 
Gradient: 0-45% B in 15 minutes
Folding screen for model proteins
1. Denaturation and reduction o f disulphide bonds.
Prepare 3 ml o f a 10 mg/ml protein solution in buffer E using GdnHCl.
Determine protein concentration by measuring absorbance at 280 nm.
Take a 60 pi aliquot and store at 4°C.
Add solid DTT to the rest o f the protein solution to achieve a final concentration of 100 
mM DTT.
Incubate overnight at 4°C with gentle mixing.
Take a 60 pi aliquot and store at 4°C.
Extinction coefficients of oxidised species at 280 nm:
Lysozyme 38460 M '1cm"1. Molecular weight 14.3 kg/mol 
Ribonuclease A 8160 M ^cm '1. Molecular weight 13.7 kg/mol
2. Refolding.
Prepare the in vitro folding buffers as indicated in the table.
Pour 5 ml o f each buffer in a separate 30ml universal tube. Add 100 pi o f 0.5 M cysteine 
and 100 pi o f 0.05 M cystine. Place the 4°C buffers in the fridge and wait for them to 
equilibrate.
Dilute the protein solution in each o f the in vitro folding buffers at the appropriate 
concentration.
Incubate at the indicated temperature with gentle mixing for 24-36 hrs.
3. Dialysis.
Centrifuge the tubes at 4000 rpm for 10 minutes.
Dialyse 4 ml o f each run against 100 volumes o f Buffer B at 4°C overnight.
Use -1 5  cm o f narrow dialysis tubing (23 mm width, Spectra/Por 1) for each one.
2 2 2
4. RP-HPLC analysis.
Record the final volume o f each dialysed sample.
Dilute 30 pi o f the oxidised sample into 3 ml o f buffer B.
Dilute 30 pi o f the reduced sample into 3 ml o f buffer E or 5%AcCN/0.1% TFA.
Run the ten samples using a 1 ml loop and injecting 2.5-3 ml.
I f  the amount o f soluble protein in the buffers with initial protein concentration of 0.5 
mg/ml is too high, dilute 1:5 with buffer B.
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Materials
Amersham Biosciences (GE Healthcare) 
Hybond P (PVDF) protein transfer 
membrane
Superdex 75 prep grade SEC medium
BDH AnalaR
NaCl
NaH2P 0 4
NaOH
KH2 PO4
Urea
D(+)-Glucose
Calcium chloride (1 M) solution 
Sodium dodecyl sulphate 
2-mercaptoethanol
BD H  Electran 
Acrylogel 5 solution
Biorad
Protein assay (Bradford)
Invitrogen
M ark-12 Molecular weight standard 
Subcloning efficiency DH 5a competent 
cells
Low and high DNA mass ladders.
M elford Labs Ltd.
Dithiothreitol (DTT)
Isopropyl-p-D-thiogalactopyranoside 
Carbenicillin, disodium salt 
Kanamycin, monosulphate 
Guanidine hydrochloride 99%
New England Biolabs
Endonucleases
T4 DNA ligase
Calf intestine phosphatase
Taq polymerase
lkb DNA ladder
100 bp DNA ladder
Novagen 
HisBind resin
Goat anti-mouse IgG AP conjugate 
AP detection reagent kit
Promega 
Pfu polymerase
Qiagen
QIAquick Gel Extraction kit 
QIAquick PCR purification kit 
QIAprep Spin Miniprep Kit 
DyeEx 2.0 Spin kit 
HisTag Monoclonal Antibody
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Sigma/Aldrich/Fluka 
Acetonitrile (99.93%) HPLC grade 
(Aldrich)
Ammonium persulphate 
Bovine serum albumin (98%)
Cysteine 
Cystine (Fluka)
Glycerol
Guanidine hydrochloride (98 and 99%) 
L-Arginine Hydrochloride (98%) 
N,N,N’N ’-tetramethy-ethylenediamine 
Nickel Sulfate • 6 H2O 
Tricine
Trifluoroacetic acid HPLC grade (Fluka) 
Trizma-Base
Spectrum
Spectra/Por 1 membrane 
MWCO 6-8000 
Spectra/Por 3 membrane 
MWCO 3000
Stratagene
QuickChange site-directed mutagenesis 
kit
Vivascience
Vivaspin concentrators (6 and 20 ml) 
3000 and 5000 MWCO
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Equipment
American Instrument Company 
French Pressure Cell Press
Amersham Biosciences (GE Healthcare) 
X K 16/70 empty chromatography 
column
Akta purifier chromatography system 
BioRad
Disposable chromatography columns 
Mini Protean II electrophoresis system 
Mini Protean III electrophoresis system 
PowerPac 3000 power supply 
Bio-Silect SEC 125-5 Column
Eppendorf 
Centrifuge 581 OR
Heraeus 
Labofuge 400R
Invitrogen
Xcell II blot module
Xcell SureLock mini-cell
Millipore
Amicon stirred cell for ultrafiltration 
Amicon YM ultrafiltration discs 3 kDa
MWG-Biotech 
Primus thermocycler
Perceptive BioSystems 
Biocad chromatography system
Sanyo
Ultrasonic disintegrator Soniprep 150 
with exponential probe lOmicrons 
amplitude
Sorvall
Superspeed centrifuge 5RB 
SLA-3000 rotor 
SS-34 rotor
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Oligonucleotide sequences
Appendix B
CD5d3 expression vector
CD5D3_FOR_NdeI
5 ’-GAT GAT GAT GAT CAT ATG GGT TTC CAG CCC AAG GTG-3’
C D 5 D 3 R E  V_stop_XhoI
5 ’-GAT GAT GAT GAT CTC GAG CTA GCC TGC GGG GTT TGG ATC-3’
Site-directed mutagenesis
L26K
5'-CCG CGC GGC AGC CAT ATG CGG AAA AGC TGG TAT GAC CCA GAT TTC-3’ 
5-G A A  ATC TGG GTC ATA CCA GCT TTT CCG CAT ATG GCT GCC GCG CGG-3'
W28R
5-G G C  AGC CAT ATG CGG CTC AGC CGT TAT GAC CCA GAT TTC CAG GC-3' 
5'-GC CTG GAA ATC TGG GTC ATA ACG GCT GAG CCG CAT ATG GCT GCC-3'
V88N
5'-GC CAG CGG CTG AAC TGT GGG AAC CCC TTA AGC CTT GGC CCC TTC-3' 
5 -G A A  GGG GCC AAG GCT TAA GGG TGG CCC ACA GTT CAG CCG CTG GC-3’
V88D
5'-GC CAG CGG CTG AAC TGT GGG GAT CCC TTA AGC CTT GGC CCC TTC-3' 
5 -G A A  GGG GCC AAG GCT TAA GGG ATC CCC ACA GTT CAG CCG CTG GC-3'
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V97K
5-G C C  TTG GCC CCT TCC TTA AAA CCT ACA CAC CTC A G A G C T C A A T C -3 ' 
5'-GAT TGA GCT CTG AGG TGT GTA GGT TTT AAG GAA GGG GCC AAG GC-3'
M124Q
5'-GC AGC CAC AGC AGA AAT GAC CAA TGT CAC TCT CTG GGC CTG ACC-3' 
5'-GGT CAG GCC CAG AGA GTG ACA TTG GTC ATT TCT GCT GTG GCT GC-3'
M 124N
5'-GC AGC CAC AGC AGA AAT GAC AAC TGT CAC TCT CTG GGC CTG ACC-3’ 
5'-GGT CAG GCC CAG AGA GTG ACA GTT GTC ATT TCT GCT GTG GCT GC-3'
G129S
5'-GAC ATG TGT CAC TCT CTG TCC CTG ACC TGC TTA GAA TAG GG-3'
5'-CC CTA TTC TAA GCA GGT CAG GGA CAG AGA GTG ACA CAT GTC-3’
2 2 8
________________________________ Appendix C
Experimental details of NMR experiments
13C/I5N V88D/V97K ACD5dl NMR experiments at 25°C
*H 13C 15N
Experiment Points SweepWidth Points
Sweep
Width Points
Sweep
Width Transients
HSQC 1024(102ms) 5000 256
1700
(150ms) 16
HNCA 1024(102ms) 5000
64
(16ms) 4050 32
1700
(19ms) 16
HNCACB 1024(102ms) 5000
64
(6ms) 10200 32
1700
(19ms) 24
CBCA(CO)NH 1024(102ms) 5000
70 
(7 ms) 10200 34
1700
(19ms) 16
H(CCO)NH-TOCSY 
(12ms mixing time)
1024
(98ms) 5200
64
(17ms) 3800 32
1700
(19ms) 8
Experiments run at 600 MHz except HCCONH run at 500MHz
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13C/15N V88D/V97K /iCD5dl NMR experiments at 35°C
'H ,3c / 'h 15n
Experiment Points Sweep Width Points SweepWidth Points
Sweep
Width Transients
HSQC 1024(102ms) 5000
256
(150ms) 1700
16
HNCA 1024(120ms) 4200
70
(17ms) 4050
32
(19ms)
1700) 16
HNCACB 1024(102ms) 5000
64 
(8 ms) 10200 32 1700
32
(H)C(CO)NH-TOCSY
(12ms)
1024
(102ms) 5000 80 10200 32 1700 16
HA(CA)NH 1024 5000 40 1700 32 1700 16
HA(CACO)NH 1024 5000 40 1700 32 1700 16
Experiments run at 600 MHz
uC/15N V88D/V97K ACD5dl NMR experiments at 45°C pH 5
Experiment
'H 13C l5N
TransientsPoints SweepWidth Points
Sweep
Width Points
Sweep
Width
HSQC 1024 5000 256 1700 8
HNCO 1024 4200 64 1600 32 1700 8
HNCA 1024 4200 66 4050 32 1700 12
HNCACB 1024 5000 57 8200 32 1500 24
CBCA(CO)NH 1024 5000 57 8200 32 1500 26
HA(CACO)NH 1024 4200 64 1800 32 1700 8
Experiments run at 600 MHz except CBCACONH/HNCACB run at 500MHz
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13C/15N V88D/V97K ACD5dl NMR experiments in D20  at 45°C pH 5
'H 13C 'H
Experim ent Points SweepWidth Points
Sweep
Width Points
Sweep
Width Transients
HSQC
CT-HSQC
HCCHTOCSY (20ms) 
NOESY (100ms)
1024
1024
1024
1560
5500
5500
5500
7800
150
256
96
58
9900
9900
10000
6040
64
100
3800
7800
16
48
8
8
Experiments run at 600 MHz except NOESY run at 800 MHz
UC/1SN V88D/V97K ACD5dl NMR aromatic experiments in D20  at
45°C and pH 5
'H l3C 'H
Experiment Points SweepWidth Points
Sweep
Width Points
Sweep
Width Transients
HSQC
CT-HSQC
HCCHTOCSY (12ms) 
NOESY
2048
2048
2048
512
8000
8000
8000
3200
40
128
32
32
4200
4200
4200
4200
48
86
2400
6400
16
32
8
16
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,5N V88D/V97K /i€D5dl NMR experiments at 45"C and pH 5
'H   1SN 'H
Experim ent Points Sweep Width Points Sweep W idth Points Sweep Width Transients
HSQC 1024 5000 128 1250 4
TOCSY 1024 5000 32 1250 100 5100 8
NOESY 1024 5000 32 1500 128 6800 16
HNHA 1600 6400 36 1250 128 3600 8
HNHB-2D 1024 6400 64 1250 16
HNHB-3D 1024 6400 32 1250 64 5200 16
T1 1024 6400 100 1250 32
T2 1024 6400 100 1250 32
NOE 1024 6400 100 1250 80
Relaxation times:
T1 10, 10, 151, 302, 453, 603, 603, 905, 905 ms; T2 16, 16, 80, 143, 207, 239, 239 ms 
NOE: 0, 3sec
Experiments run at 500 MHz except NOESY-HSQC run at 600MHz________________
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